milrinone has been researched along with Heart Failure in 375 studies
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Milrinone exerts positive inotropic and dose-dependent vasodilatory effects that promote haemodynamic improvement after intravenous administration to patients with heart failure." | 10.16 | Acute effects of intravenous milrinone in heart failure. ( Rettig, GF; Schieffer, HJ, 1989) |
| "Clinical evaluation of oral milrinone in moderate to severe heart failure has demonstrated pronounced beneficial effects." | 10.16 | Clinical results with oral milrinone in heart failure. ( DiBianco, R, 1989) |
| "This study aims to evaluate the difference between dobutamine and milrinone in patients presenting with acute decompensated heart failure (AHF)." | 9.41 | Meta-analysis Comparing the Efficacy of Dobutamine Versus Milrinone in Acute Decompensated Heart Failure and Cardiogenic Shock. ( Bandyopadhyay, D; Biswas, S; Briasoulis, A; Fonarow, GC; Goel, A; Gupta, R; Lanier, GM; Malik, AH; Naidu, SS, 2023) |
| " In this study Olprinone, milrinone, PDE inhibitors, cardiac failure, and HF were selected as the search terms to retrieve articles published between January 1999 and March 2022." | 9.41 | Systematic review and meta-analysis of the efficacy of olprinone and MEFV gene in treating heart failure. ( Fu, Y; Pan, Y; Wang, X; Zhang, H, 2023) |
| "Two authors searched MEDLINE, PubMed, Embase, Science Direct, Cochrane Central Register of Controlled Trials, the Cochrane Library, Wanfang database, Chinese Biomedical Literature Database, China National Knowledge Infrastructure (CNKI) for randomized controlled trials (RCTs) about the application of milrinone in the treatment of heart failure caused by severe pneumonia in children with CHD in children up to December 10, 2022." | 9.41 | Milrinone for the treatment of heart failure caused by severe Pneumonia in children with congenital heart disease: a meta-analysis. ( Cai, L; Diao, S; Shao, W; Zhou, L, 2023) |
| "In end-stage congestive cardiac failure, intravenous milrinone and sildenafil both cause similar reductions in systemic and pulmonary vascular resistance; however, milrinone has more cardiac selective effects on left ventricular filling and heart rate." | 9.14 | Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. ( Botha, P; Dark, JH; Macgowan, GA; Parry, G, 2009) |
| "The Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study randomized 949 patients with systolic dysfunction hospitalized for worsening heart failure to receive 48 to 72 hours of intravenous milrinone or placebo in addition to standard therapy." | 9.11 | Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) s ( Adams, KF; Califf, RM; Felker, GM; Gattis-Stough, W; Gheorghiade, M; Klein, L; Leimberger, JD; O'Connor, CM; Piña, IL, 2005) |
| "The goal of this study was to assess the interaction between heart failure (HF) etiology and response to milrinone in decompensated HF." | 9.10 | Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. ( Benza, RL; Califf, RM; Chandler, AB; Cuffe, MS; Felker, GM; Gheorghiade, M; Leimberger, JD; O'Connor, CM, 2003) |
| "To prospectively test whether a strategy that includes short-term use of milrinone in addition to standard therapy can improve clinical outcomes of patients hospitalized with an exacerbation of chronic heart failure." | 9.10 | Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. ( Adams, KF; Benza, R; Bourge, R; Califf, RM; Colucci, WS; Cuffe, MS; Gheorghiade, M; Massie, BM; O'Connor, CM; Pina, I; Quigg, R; Silver, MA, 2002) |
| "The objective of this study was to examine the efficacy of milrinone in chronic congestive heart failure." | 9.09 | [Response to milrinone treatment in patients with chronic congestive heart failure]. ( Fang, Y; Huang, D; Liu, X; Wen, S; Zeng, H, 2000) |
| "To characterize the effect of the phosphodiesterase inhibitor (PDEI) milrinone in adult patients with a non-hyperdynamic condition during the course of the systemic inflammatory response syndrome (SIRS) or sepsis when compared with patients with congestive heart failure (CHF)." | 9.09 | IV milrinone for cardiac output increase and maintenance: comparison in nonhyperdynamic SIRS/sepsis and congestive heart failure. ( Delle Karth, G; Frossard, M; Geppert, A; Gschwandtner, ME; Heinz, G; Neunteufl, T; Reinelt, P; Siostrzonek, P; Zauner, C, 1999) |
| "To assess the hemodynamic and vasodilating effects of milrinone lactate (ML) in patients with dilated cardiomyopathy (DCM) and New York Heart Association (NYHA) class III and IV heart failure." | 9.09 | Assessment of inotropic and vasodilating effects of milrinone lactate in patients with dilated cardiomyopathy and severe heart failure. ( Bregagnollo, EA; Cicogna, AC; Fortes, AH, 1999) |
| "The OPTIME CHF (Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure) trial is an ongoing multicenter, randomized, placebo-controlled trial of a treatment strategy for patients with acute exacerbations of CHF." | 9.09 | Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. ( Adams, KF; Bourge, RC; Califf, RM; Colucci, W; Cuffe, MS; Gheorghiade, M; Leimberger, JD; Massie, B; O'Connor, CM; Pina, I; Quigg, R; Robinson, LA; Silver, M, 2000) |
| "Treatment with the PDE-III inhibitor milrinone improves hemodynamics in patients with heart failure." | 9.09 | Milrinone therapy in catecholamine-dependent critically ill patients with heart failure. ( Delle-Karth, G; Haumer, M; Heinz, G; Koller-Strametz, J; Koreny, M; Siostrzonek, P, 2000) |
| "Hemodynamic benefits of milrinone administration are accompanied by adverse effects on arterial oxygenation in mechanically ventilated patients with end-stage heart failure." | 9.09 | Effects of milrinone on pulmonary gas exchange in catecholamine-dependent heart failure. ( Delle Karth, G; Geppert, A; Heinz, G; Koreny, M; Siostrzonek, P; Wutte, M, 2000) |
| "Carvedilol has been shown to improve morbidity and mortality in patients with congestive heart failure (CHF)." | 9.09 | Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. ( Antonio, C; Choudhary, G; Heaney, L; Jain, A; Just, V; Kumar, A; Papp, MA, 2001) |
| "5, 5, or 10 mg) of milrinone in 31 patients with acute or decompensated heart failure." | 9.08 | Hemodynamic effects and pharmacokinetics of oral milrinone for short-term support in acute heart failure. ( Hayakawa, H; Kamishima, G; Kanmatsuse, K; Motomiya, T; Murata, M; Saitoh, S; Saitoh, T; Seino, Y; Takano, T; Watanabe, K, 1995) |
| "To assess the hemodynamic effects of milrinone in a 48h intravenous infusion in patients with severe congestive heart failure (CHF) (NYHA class III or IV)." | 9.08 | [Value of the use of milrinone in the treatment of acute crisis in patients with congestive heart failure]. ( Bianco, AC; Freire, RB; Gun, C; Piegas, LS; Ramos, RF; Timerman, A, 1995) |
| "This study was designed to test a proposed dose modification for intravenous milrinone in congestive heart failure patients (CHF, NYHA I-II) with either moderate or severe renal impairment." | 9.08 | Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure. ( Fox, PA; Greenslade, D; Hegbrant, J; Lasher, K; Lendrem, DW; Lockwood, GF; Rogers, J; Thysell, H; Woolfrey, SG, 1995) |
| "In this multicenter, randomized, double-blind, cross-over, placebo-controlled trial, hemodynamic effects of domestic milrinone were studied in 57 patients with functional class III or IV chronic congestive heart failure." | 9.08 | [Hemodynamic effects of milrinone on patients with chronic congestive heart failure: a multicenter study. Cooperative Group for Phase II Clinical Trial of Milrinone]. ( , 1995) |
| "The purpose of this study was to compare the hemodynamic and clinical effects of milrinone, a vasodilating and positive inotropic agent, with those of dobutamine in patients with congestive heart failure (CHF) following acute myocardial infarction (AMI)." | 9.08 | Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group. ( Berk, MR; DeMaria, AN; DeWood, MA; Karlsberg, RP; Lasher, KP, 1996) |
| " Metoprolol treatment restores the blunted inotropic response to milrinone in patients with heart failure, indicating that postreceptor events (e." | 9.08 | Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. ( Böhm, M; Deutsch, HJ; Hartmann, D; Rosée, KL; Stäblein, A, 1997) |
| "To evaluate the clinical effects of milrinone in patients with severe heart failure, heart function and clinical observations were performed on 25 patients with severe congestive heart failure treated with domestic intravenous milrinone for 15 days." | 9.08 | [Heart function and clinical observations of patients with severe congestive heart failure treated with milrinone]. ( Lu, G; Zhang, L; Zheng, Z, 1998) |
| "We have analysed the hemodynamic effects of milrinone in 13 patients (11 men, 2 women, mean age 55 +/- 12 years) with advanced heart failure resistant to dopamine, dobutamine and/or nitroprusside." | 9.07 | [The hemodynamic effects of the combination of milrinone in heart failure refractory to treatment with dopamine, dobutamine and/or nitroprusside]. ( Domínguez de Rozas, JM; Guindo Soldevila, J; Martínez Vílchez, R; Rodríguez Font, E, 1994) |
| "We describe the results of two placebo-controlled trials (MIL-1077 and MIL-1078) designed to evaluate the clinical efficacy of oral milrinone administered together with converting enzyme inhibitors to patients with congestive heart failure." | 9.07 | Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The Milrinone Multicenter Trials Investigators. ( Adams, KF; Berk, M; Brozena, SC; Colucci, WS; Cowley, AJ; Grabicki, JM; Kubo, SA; LeJemtel, T; Littler, WA; Sonnenblick, EH, 1993) |
| "The hemodynamic effects of milrinone (Mil) were studied in 11 patients with congestive heart failure (CHF) and New York Heart Association (NYHA) functional class II-IV before and after a 2-week treatment." | 9.07 | Hemodynamic effects of milrinone in patients with congestive heart failure--short- and long-term follow up studies. ( Fukuoka, Y; Maeda, T; Nanimatsu, H; Saikawa, T; Takaki, R, 1993) |
| "The hemodynamic effects and safety of milrinone, a phosphodiesterase inhibitor, were studied in 57 patients in the acute phase of cardiac failure." | 9.07 | [Efficacy of intravenous milrinone in the treatment of acute congestive cardiac failure. Results of a French multicenter study]. ( Bory, M; Brochier, M; Dubois-Randé, JL; Guérot, C; Jan, F; Lambert, H; Le Bloc'h, Y; Pony, JC; Sacrez, A; Vacheron, A, 1993) |
| "To assess the inotropic, vasodilator, and after-load-reducing effects of intravenous milrinone in patients with severe congestive heart failure, a simple noninvasive echocardiographic study coupled with a right catheterization was performed in 12 patients." | 9.07 | Physiologic assessment of milrinone therapy in severe heart failure patients. ( Brun, P; Castaigne, A; Deleuze, P; Dubois-Randé, JL; Dupouy, P; Duval-Moulin, AM; Lellouche, D; Loisance, D; Merlet, P; Saal, JP, 1991) |
| "High levels of endogenous plasma catecholamines in patients with severe congestive heart failure induce a down-regulation of the myocardial beta-adrenoreceptors and thus cause adrenoreceptor agonists, such as dobutamine, to be less effective in the treatment of these patients." | 9.07 | Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure. ( Hilger, HH; Höpp, HW; Klocke, RK; Kux, A; Mager, G, 1991) |
| "Milrinone, a phosphodiesterase inhibitor, enhances cardiac contractility by increasing intracellular levels of cyclic AMP, but the long-term effect of this type of positive inotropic agent on the survival of patients with chronic heart failure has not been determined." | 9.07 | Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. ( Bommer, WJ; Carver, JR; DiBianco, R; Elkayam, U; Hendrix, GH; Ivanhoe, RJ; Kukin, ML; Packer, M; Rodeheffer, RJ; Zeldis, SM, 1991) |
| "The response of patients with chronic severe heart failure to extended infusions (greater than or equal to 48 hours) of milrinone was evaluated in a multicenter, baseline-controlled, phase III efficacy and safety trial in 189 patients in the United States." | 9.07 | Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States. ( Anderson, JL, 1991) |
| "The systemic and pulmonary arterial hemodynamics of 40 patients with severe congestive heart failure were determined during a 24-hour infusion of milrinone (0." | 9.07 | Effects of a twenty-four-hour milrinone infusion in patients with severe heart failure and cardiogenic shock as a function of the hemodynamic initial condition. ( Hilger, HH; Höpp, HW; Klocke, RK; Kux, A; Mager, G, 1991) |
| "We randomly assigned 230 patients in sinus rhythm with moderately severe heart failure to treatment with digoxin, milrinone, both, or placebo." | 9.06 | A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. ( DiBianco, R; Kostuk, W; Moran, J; Schlant, RC; Shabetai, R; Wright, R, 1989) |
| "6 microgram/kg-min), dobutamine (10 +/- 3 micrograms/kg-min), and milrinone (67 +/- 13 micrograms/kg-min) sequentially to 10 patients with severe (NYHA class III or IV) congestive heart failure." | 9.06 | Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. ( Baim, DS; Lanoue, AS; Monrad, ES; Smith, HS, 1986) |
| "Milrinone and dobutamine were compared in 15 patients with New York Heart Association functional class III and IV congestive heart failure." | 9.06 | Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. ( Braunwald, E; Colucci, WS; Fifer, MA; Jaski, BE; Wright, RF, 1986) |
| "Thirty-seven patients with severe chronic heart failure were entered into an open-ended trial with milrinone at an initial daily dose ranging form 20 to 30 mg." | 9.06 | Milrinone for long-term therapy of severe heart failure: clinical experience with special reference to maximal exercise tolerance. ( Chadwick, B; Gumbardo, D; LeJemtel, TH; Rutman, HI; Sonnenblick, EH, 1986) |
| "We measured systemic hemodynamics, regional blood flow, and neurohormonal parameters in 13 patients with severe chronic congestive heart failure before and after 1 month of therapy with oral milrinone, a bipyridine cardiotonic agent." | 9.06 | Regional blood flow and neurohormonal responses to milrinone in congestive heart failure. ( Cody, RJ; Covit, AB; Feldschuh, J; Kubo, SH; Laragh, JH; Leonard, D; Müller, FB; Preibisz, J; Rutman, H, 1986) |
| "Milrinone and dobutamine are positive inotropic agents with beneficial hemodynamic effects in patients with congestive heart failure." | 9.06 | Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. ( Benotti, JR; Biddle, TL; Creager, MA; Faxon, DP; Firth, BG; Fitzpatrick, PG; Kershner, RP; Konstam, MA; Krebs, C; Walton, L, 1987) |
| "To compare the effects of intravenous dobutamine and milrinone on right ventricular (RV) systolic function, 14 patients with severe congestive heart failure underwent simultaneous radionuclide-hemodynamic study." | 9.06 | Differential effects of milrinone and dobutamine on right ventricular preload, afterload and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. ( Eichhorn, EJ; Konstam, MA; Martin, TT; Roberts, DJ; Salem, DN; Stransky, NB; Weiland, DS, 1987) |
| "A randomized, double-blind, placebo-controlled protocol was used to determine whether milrinone exerts an immediate effect on exercise performance in patients with severe congestive heart failure." | 9.05 | Immediate effects of milrinone on metabolic and sympathetic responses to exercise in severe congestive heart failure. ( Colucci, WS; Hartley, LH; Ribeiro, JP; White, HD, 1985) |
| "To review the literature evaluating the clinical effects of combination therapy with a beta-blocker and milrinone in patients with severe heart failure (HF)." | 8.85 | Use of combination therapy with a beta-blocker and milrinone in patients with advanced heart failure. ( Jennings, DL; Thompson, ML, 2009) |
| " Milrinone, which is structurally similar to amrinone, is an oral agent under investigation for the treatment of congestive heart failure." | 8.77 | Milrinone, a new agent for the treatment of congestive heart failure. ( Hasegawa, GR, 1986) |
| "We report our experience using outpatient milrinone in children receiving hospice care for end-stage heart failure." | 8.31 | Home Milrinone in Pediatric Hospice Care of Children with Heart Failure. ( Brown, M; Dykes, J; Good, J; Hollander, SA; Lin, A; Liu, E; Rosenthal, D; Schmidt, J; Wujcik, K, 2023) |
| "Levosimendan and milrinone are 2 effective inotropic drugs used to maintain cardiac output in acute heart failure (AHF)." | 8.12 | Comparative Effectiveness and Safety of Milrinone and Levosimendan as Initial Inotrope Therapy in Patients With Acute Heart Failure With Renal Dysfunction. ( Cheng, Z; Cui, X; Dong, X; Han, Y; Hong, Y; Huang, X; Li, Y; Mu, Y; Wang, Z; Zhang, L, 2022) |
| "We sought to describe and compare outcomes among advanced patients with heart failure (not candidates for orthotopic heart transplant/left ventricular assist device) on long-term milrinone or dobutamine, which are not well-studied in the contemporary era." | 8.12 | Palliative Inotropes in Advanced Heart Failure: Comparing Outcomes Between Milrinone and Dobutamine. ( Acharya, P; Al-Masry, AA; Bajwa, S; Bakel, AV; Boda, I; Dalia, T; Goyal, A; Mastoris, I; Maurides, S; Noonan, G; Parimi, N; Sami, F; Sauer, A; Shah, Z; Tran, C, 2022) |
| "This study aims to determine the incidence of all-cause hospitalization in patients with advanced heart failure (AHF) receiving ambulatory continuous, intravenous dobutamine versus milrinone for palliative intent." | 8.12 | Rehospitalization of Patients with Advanced Heart Failure Receiving Continuous, Palliative Dobutamine or Milrinone. ( Eaton, RE; Haas, GJ; Kissling, KT; McLaughlin, EM; Pickworth, KK, 2022) |
| "Milrinone infusion is one of a few select "non-device" therapies for patients with New York Heart Association (NYHA) class IV, stage D heart failure, which has been associated with an increase in ventricular tachyarrhythmia and atrial fibrillation." | 7.96 | Safety of Outpatient Milrinone Infusion in End-Stage Heart Failure: ICD-Level Data on Atrial Fibrillation and Ventricular Tachyarrhythmias. ( Achu, E; Alpert, JS; Baran, DA; Cassuto, J; Goldschmidt, M; Harhash, AA; Hussein, A; Zucker, MJ, 2020) |
| "In patients with acute postoperative heart failure, before receiving milrinone, renal blood flow was lower (-33%, p < ." | 7.96 | Effects of milrinone on renal perfusion, filtration and oxygenation in patients with acute heart failure and low cardiac output early after cardiac surgery. ( Bragadottir, G; Lannemyr, L; Redfors, B; Ricksten, SE, 2020) |
| "To determine the effect of dobutamine versus milrinone on out-of-hospital mortality in the treatment of patients with acute decompensated heart failure (ADHF)." | 7.85 | Effect of Inpatient Dobutamine versus Milrinone on Out-of-Hospital Mortality in Patients with Acute Decompensated Heart Failure. ( Biskupiak, J; Bress, AP; King, JB; Munger, MA; Sainski-Nguyen, A; Shah, RU, 2017) |
| "We describe the case of a patient with refractory leukemia and end-stage CHF who developed severe dyspnea after discontinuation of milrinone." | 7.81 | Intensive symptom control of opioid-refractory dyspnea in congestive heart failure: Role of milrinone in the palliative care unit. ( Bruera, E; Elsayem, A; Montoya, M; Silvestre, J, 2015) |
| "The purpose of this study was to determine whether a low-dose β-blocker, in combination with milrinone, improves cardiac function in acute decompensated heart failure (ADHF) with tachycardia." | 7.78 | Low-dose β-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure. ( Doi, M; Fukuta, S; Kobayashi, S; Matsuzaki, M; Murakami, W; Nao, T; Okamura, T; Okuda, S; Susa, T; Tanaka, T; Wada, Y; Yamada, J; Yano, M, 2012) |
| "Our initial experience demonstrates that administration of levosimendan in patients with severe chronic heart failure not responsive to standard intravenous inotropic treatment might result in a significant clinical and hemodynamic improvement and that, in selected patients, it might be life saving." | 7.77 | [Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children]. ( Jovicić, B; Kosutić, J; Nikolić, L; Prijić, S; Rakić, S; Stajević, M; Vukomanović, V, 2011) |
| "The phosphodiesterase III inhibitor milrinone (MIL) is considered to be effective for "wet and cold" heart failure." | 7.76 | Baroreflex sensitivity might predict responders to milrinone in patients with heart failure. ( Kishi, T; Sunagawa, K, 2010) |
| " Whether biomarkers of myocardial necrosis, inflammation and apoptosis change in response to acute milrinone administration is not well established." | 7.75 | Short term effects of milrinone on biomarkers of necrosis, apoptosis, and inflammation in patients with severe heart failure. ( Bazari, R; Czerska, B; Gupta, RC; Hasan, R; Lanfear, DE; Sabbah, HN; Tita, C; Williams, C, 2009) |
| "There are no published clinical trials comparing dobutamine with milrinone in outpatients with stage D heart failure on continuous inotropes." | 7.75 | Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. ( Chu, EC; Gorodeski, EZ; Hsich, E; Reese, JR; Shishehbor, MH; Starling, RC, 2009) |
| "In a retrospective analysis of 949 patients from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure, we investigated the relation between admission values and changes in BUN and eGFR and rate of death by 60 days after discharge." | 7.74 | Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). ( Adams, KF; Califf, RM; Gheorghiade, M; Klein, L; Leimberger, JD; Massie, BM; O'Connor, CM; Piña, IL, 2008) |
| "Phosphodiesterase inhibitors such as milrinone can relieve symptoms and improve hemodynamics in patients with advanced congestive heart failure." | 7.72 | Intravenous milrinone in treatment of advanced congestive heart failure. ( Delgado, RM; Eastwood, C; Kar, MN; Nawar, M; Vrtovec, B; Zewail, AM, 2003) |
| "Dobutamine-based therapy is an attractive approach for the treatment of decompensated advanced heart failure, achieving comparable clinical efficacy to milrinone with a significantly reduced economic cost." | 7.71 | Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: Hemodynamic efficacy, clinical outcome, and economic impact. ( Albert, N; Haji, SA; Kelly, L; Knack, DL; Starling, RC; Yamani, MH; Young, JB, 2001) |
| "Milrinone and dobutamine are used to manage decompensated heart failure, but their efficacy in patients on beta-blocker therapy was unknown." | 7.71 | Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. ( Bristow, MR; Eichhorn, EJ; Gilbert, EM; Lowes, BD; Tsvetkova, T, 2001) |
| "We determined the correlation coefficients between increasing dose of inotrope and each of the parameters COtd and SvO2 in 18 patients with congestive heart failure who received a 3-day trial of either milrinone or dobutamine during admission to the Veterans Affairs Medical Center in San Diego." | 7.70 | Comparison between mixed venous oxygen saturation and thermodilution cardiac output in monitoring patients with severe heart failure treated with milrinone and dobutamine. ( Maisel, A; Nuñez, S, 1998) |
| "The goal of this study was to determine the extent to which the effects of milrinone were desensitized in heart failure (HF) and to determine the mechanisms, i." | 7.70 | Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure. ( Asai, K; Fujita-Yamaguchi, Y; Ishikawa, Y; Okumura, S; Sato, N; Shannon, RP; Takagi, G; Vatner, DE; Vatner, SF, 1999) |
| "Many reports have suggested that intermittent milrinone infusion (IMI) may be efficacious in the management of end-stage congestive heart failure (CHF), but this issue has not been clearly established." | 7.70 | Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure. ( Dalianis, N; Hatzizacharias, A; Krespi, P; Kyriakidis, M; Makris, T; Triposkiadis, F; Voyatzi, P, 1999) |
| "We experienced a Duchenne muscular dystrophy (DMD) patient with severe congestive heart failure (CHF) successfully treated with milrinone." | 7.70 | [Effective milrinone therapy to a Duchenne muscular dystrophy patient with advanced congestive heart failure]. ( Kang, J; Matsumura, T; Miyai, I; Nozaki, S; Saito, T, 1999) |
| "Milrinone is a phosphodiesterase inhibitor that has been shown to improve hemodynamic parameters in patients with class III to IV heart failure when administered intravenously for < or =48 hours." | 7.70 | Tolerability of extended duration intravenous milrinone in patients hospitalized for advanced heart failure and the usefulness of uptitration of oral angiotensin-converting enzyme inhibitors. ( Eisen, HJ; Flores, I; Mendoza, B; Milfred-LaForest, SK; Piña, IL; Shubert, J, 1999) |
| "The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension." | 7.70 | Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure. ( Chen, J; Cullinane, S; Gold, J; Landry, DW; Oliver, JA; Oz, MC; Seo, S, 2000) |
| "To evaluate the pharmocokinetics of intravenous milrinone in patients with severe congestive heart failure during continuous venovenous hemofiltration (CVVH)." | 7.70 | Pharmacokinetics of milrinone in patients with congestive heart failure during continuous venovenous hemofiltration. ( Matsumoto, H; Okeie, K; Saito, S; Shibata, K; Taniguchi, T, 2000) |
| "We wished to provide comparative information regarding the direct effects of flosequinan, a novel quinolone under development for treating heart failure, on isolated human arterial, venous, and cardiac muscle." | 7.69 | Assessment of flosequinan's direct effect on human arterial, venous, and cardiac muscle: comparison with other classes of agents used to treat heart failure. ( Britton, LW; Ferraris, VA; Kiser, LM; Sim, MF; Wallace, AM; Weishaar, RE, 1994) |
| "Bolus milrinone consistently decreases PVR in patients with pulmonary hypertension secondary to severe heart failure." | 7.69 | Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension. ( Colucci, WS; Gauthier, DF; Givertz, MM; Hare, JM; Loh, E, 1996) |
| "Milrinone, a bipyridine derivative with positive inotropic and balanced type vasodilating properties, acutely improves cardiac pump function in patients with severe and moderate to severe heart failure." | 7.68 | Preload-dependent hemodynamic effects of milrinone in moderate heart failure. ( Bruggeling, WA; Kruijssen, HA; Pieper, PG; Remme, WJ; van Hoogenhuyze, DC, 1992) |
| "The hemodynamic effects of dobutamine, milrinone, and a combination of both drugs were compared intra-individually in 14 patients with severe heart failure (NYHA III: n = 9; NYHA IV: n = 5)." | 7.68 | [Additive effects of milrinone and dobutamine in severe heart failure]. ( Gerdesmeyer, L; Herrmann, G; Meissner, A; Simon, R, 1992) |
| "Hemodynamics during 24-h dobutamine (dob) and subsequent 24-h milrinone (mil) infusion were studied in 20 patients (pts) with severe heart failure (NYHA III: 4 pts, NYHA IV: 16 pts)." | 7.68 | [Hemodynamics with dobutamine and milrinone in patients with severe heart failure in an intra-individual comparison]. ( Hilger, HH; Höpp, HW; Klocke, RK; Kux, A; Mager, G; Volkmann, A, 1991) |
| "To elucidate the mechanisms by which the new bipyridine inotropic agent milrinone improves cardiac function, we examined multiple indexes of left ventricular diastolic function before and after administration of milrinone to patients with advanced (NYHA class III or IV) congestive heart failure." | 7.67 | Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. ( Baim, DS; Colucci, WS; Fifer, MA; Grossman, W; Heller, GV; McKay, RG; Monrad, ES; Royal, HD, 1984) |
| " To determine the role of the vasodilator action in mediating systemic and regional hemodynamic responses to milrinone, we administered two equipotent inotropic doses of either milrinone or dobutamine to dogs with chronic congestive right heart failure produced by tricuspid avulsion and pulmonary artery stenosis." | 7.67 | Effects of milrinone on systemic hemodynamics and regional circulations in dogs with congestive heart failure: comparison with dobutamine. ( Hood, WB; Imai, N; Kawashima, S; Liang, CS; Stone, CK; Thomas, A, 1987) |
| "Systemic and coronary hemodynamics were measured before and every 10 min after oral milrinone (10 mg) administration for 50 min, together with the drug plasma level in 14 patients with congestive heart failure." | 7.67 | Short-term assessment of left ventricular function, coronary hemodynamics, and catecholamine balance in severe congestive heart failure after a single oral dose of milrinone. ( Jaski, BE; Piscione, F; Serruys, PW, 1988) |
| "The effects of oral milrinone treatment in cardiomyopathic hamsters with severe congestive heart failure (CHF) were evaluated." | 7.67 | Effects of milrinone treatment in cardiomyopathic hamsters (CHF 147) with severe congestive heart failure. ( Cauchy, MJ; Desjardins, S; Hubert, RS; Mueller, RW, 1989) |
| "We infused dobutamine into the left main coronary artery of 24 patients with severe congestive heart failure (CHF) and 8 normal subjects without hemodynamic dysfunction." | 7.67 | Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition. ( Colucci, WS; Denniss, AR; Gauthier, DF; Leatherman, GF; Ludmer, PL; Marsh, JD; Quigg, RJ, 1988) |
| "The long-term survival of rats with healed myocardial infarction and congestive heart failure treated with milrinone, enalapril and the combination of milrinone plus enalapril, was documented." | 7.67 | Beneficial effects of milrinone and enalapril on long-term survival of rats with healed myocardial infarction. ( Emmert, SE; Heyse, JF; Ludden, CT; Stabilito, II; Sweet, CS, 1988) |
| " Intracoronary infusion of dobutamine has also demonstrated a substantial decrease in the inotropic response to beta-adrenergic stimulation in patients with congestive heart failure, presumably because of down-regulation of beta-adrenergic receptors." | 7.67 | Observations on the intracoronary administration of milrinone and dobutamine to patients with congestive heart failure. ( Colucci, WS, 1989) |
| "Animal and human studies suggest that amrinone can cause significant improvement in the systemic hemodynamics of patients with severe congestive heart failure (CHF), and do so without increasing myocardial oxygen consumption." | 7.67 | Effects of amrinone on myocardial energetics in severe congestive heart failure. ( Baim, DS, 1985) |
| "The present study was designed to evaluate the regional vascular profile of milrinone in the setting of experimental heart failure." | 7.67 | [Central and regional vascular hemodynamics of milrinone in experimental heart failure: comparison with captopril and dobutamine]. ( Drexler, H; Faude, F; Freudenberg, N; Just, H; Winterer, H; Wollschläger, H, 1987) |
| "The new inotropic agent milrinone has both vasodilator and inotropic cardiovascular effects, but the importance of these effects in patients with severe congestive heart failure (CHF) is controversial." | 7.67 | Effect of oral milrinone on end-systolic relations in patients with severe congestive heart failure. ( Ark, CR; Miller, WP; Wiederholt, P, 1987) |
| "The effects of milrinone and captopril on ventricular performance, renal blood flow, and femoral vein oxygen content were compared in 11 patients with severe chronic heart failure." | 7.67 | Systemic and regional hemodynamic effects of captopril and milrinone administered alone and concomitantly in patients with heart failure. ( Chadwick, B; Feld, H; LeJemtel, TH; Mancini, D; Maskin, CS; Sinoway, L, 1985) |
| "The safety and efficacy of long-term oral milrinone therapy were evaluated over a 2 1/2 year period in 100 patients who had severe congestive heart failure despite conventional therapy." | 7.67 | Survival of patients with severe congestive heart failure treated with oral milrinone. ( Baim, DS; Braunwald, E; Colucci, WS; Gauthier, DF; Grossman, W; Lanoue, A; Monrad, ES; Ransil, BJ; Smith, HS; Wright, RF, 1986) |
| "The effects of dobutamine and intravenous milrinone on systemic hemodynamics, coronary blood flow and myocardial metabolism were studied in 11 patients with severe congestive heart failure." | 7.67 | Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure. ( Greenberg, M; Grose, R; LeJemtel, TH; Strain, J, 1986) |
| "Milrinone is a potent positive inotropic and vascular smooth muscle-relaxing agent in vitro, and therefore, it is not known to what extent each of these actions contributes to the drug's hemodynamic effects in patients with heart failure." | 7.67 | Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. ( Braunwald, E; Colucci, WS; Fifer, MA; Jaski, BE; Wright, RF, 1985) |
| "To determine the magnitude and time course of the optimal acute hemodynamic response to oral milrinone, an ascending dose range study was performed in 34 patients with severe chronic congestive heart failure (2." | 7.67 | Acute dose range study of milrinone in congestive heart failure. ( Chatterjee, K; Cody, RJ; Kubo, SH; Leonard, D; Rutman, H; Simonton, C, 1985) |
| "To examine the effect of milrinone on myocardial energetics in patients with congestive heart failure, we measured systemic, pulmonary, and coronary hemodynamics in 18 patients before and after intravenous administration of milrinone (125 +/- 36 micrograms/kg)." | 7.67 | Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure. ( Baim, DS; Brauwald, E; Grossman, W; Lanoue, A; Monrad, ES; Smith, HS, 1985) |
| "The effects of milrinone, a new bipyridine inotropic agent, on the haemodynamic responses to treadmill exercise were studied in 12 patients with congestive heart failure." | 7.67 | Milrinone in heart failure. Effects on exercise haemodynamics during short term treatment. ( Jewitt, DE; Smyth, P; Timmis, AD, 1985) |
| "Acute and chronic hemodynamic and clinical responses to milrinone, a new oral inotrope-vasodilator agent, were evaluated prospectively in 37 patients with severe congestive heart failure." | 7.67 | Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation. ( Chatterjee, K; Cody, RJ; Daly, P; Kubo, SH; Leonard, D; Rutman, H; Simonton, CA, 1985) |
| "Milrinone is a potent non-catecholamine, non-glycoside inotropic agent that can improve hemodynamic performance and functional capacity in patients with severe congestive heart failure." | 7.67 | Milrinone in congestive heart failure: observations on ambulatory ventricular arrhythmias. ( Cody, RJ; Holmes, JR; Kligfield, P; Kubo, SH, 1985) |
| "The acute hemodynamic effects and pharmacokinetics of bolus intravenous milrinone administration were assessed in 13 patients with severe congestive heart failure." | 7.67 | Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure. ( Alpert, JS; Benotti, JR; Lesko, LJ; McCue, JE, 1985) |
| "Cardiogenic pulmonary edema is a frequent cause of respiratory failure." | 6.71 | Milrinone improves lung compliance in patients receiving mechanical ventilation for cardiogenic pulmonary edema. ( Ikezaki, H; Kim, C; Matsumura, J; Nakanishi, K; Ogawa, R; Sakamoto, A; Sato, N; Takeda, S; Tanaka, K, 2003) |
| "Milrinone was also significantly more effective in decreasing systemic vascular resistance (P =." | 6.70 | A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure. ( Bristow, M; Cody, R; Colucci, WS; Elkayam, U; Jaski, B; Loh, E, 2001) |
| " Patients were maintained on milrinone therapy for as long as 8 weeks and demonstrated a low incidence of adverse cardiac (7%) or noncardiac (4%) events." | 6.68 | Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. ( Kapoor, C; Mehra, MR; Smart, FW; Stapleton, DD; Ventura, HO; Zimmerman, D, 1997) |
| "Thus milrinone has a definite inotropic effect in addition to its potent vasodilating properties." | 6.66 | Effects of milrinone on left ventricular performance and myocardial contractility in patients with severe heart failure. ( Grose, R; LeJemtel, TH; Sonnenblick, EH; Strain, J; Zelcer, AA, 1986) |
| "Milrinone is a new bipyridine inotrope that has shown promise in initial clinical testing when administered intravenously or orally." | 6.66 | Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study. ( Anderson, JL; Baim, DS; Fein, SA; Goldstein, RA; LeJemtel, TH; Likoff, MJ, 1987) |
| " For these purposes, we reviewed data available from randomized controlled trials on short-term, intermittent, and long-term use of intravenous inodilator agents (dobutamine, dopamine, and milrinone) in AHFS." | 6.43 | Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. ( Bayram, M; De Luca, L; Gheorghiade, M; Massie, MB, 2005) |
| "Milrinone is a bipyridine derivative with positive inotropic and vasodilating properties." | 6.38 | Role of milrinone in the management of congestive heart failure. ( Forbes, WP; Hilleman, DE, 1989) |
| "Milrinone exerts positive inotropic and dose-dependent vasodilatory effects that promote haemodynamic improvement after intravenous administration to patients with heart failure." | 6.16 | Acute effects of intravenous milrinone in heart failure. ( Rettig, GF; Schieffer, HJ, 1989) |
| "Clinical evaluation of oral milrinone in moderate to severe heart failure has demonstrated pronounced beneficial effects." | 6.16 | Clinical results with oral milrinone in heart failure. ( DiBianco, R, 1989) |
| "Milrinone use was associated with a lower adjusted risk of 30 day mortality (hazard ratio = 0." | 5.91 | Improved mortality and haemodynamics with milrinone in cardiogenic shock due to acute decompensated heart failure. ( Billia, F; Brahmbhatt, DH; Fung, NL; Luis Scolari, F; Luk, A; Mihajlovic, V; Otsuki, M; Overgaard, CB; Rodenas-Alesina, E; Wang, VN, 2023) |
| "Milrinone-treated patients with ischemic heart disease and chronic kidney disease (CKD) at stage ≥ 4 presented with greater incidence of MACCE (log rank; P < 0." | 5.56 | Comparing the effects of milrinone and olprinone in patients with congestive heart failure. ( Dobashi, S; Fujii, T; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Nakanishi, R; Oka, T; Watanabe, I, 2020) |
| " In conclusion, prolonged AI and/or LS infusions in HF are safe and beneficial even in small infants, allowing stabilization and reasonable social and family life out of the hospital." | 5.48 | Ambulatory Intravenous Inotropic Support and or Levosimendan in Pediatric and Congenital Heart Failure: Safety, Survival, Improvement, or Transplantation. ( Apostolopoulou, SC; Kakava, F; Rammos, S; Tsoutsinos, A; Vagenakis, GA, 2018) |
| "This study aims to evaluate the difference between dobutamine and milrinone in patients presenting with acute decompensated heart failure (AHF)." | 5.41 | Meta-analysis Comparing the Efficacy of Dobutamine Versus Milrinone in Acute Decompensated Heart Failure and Cardiogenic Shock. ( Bandyopadhyay, D; Biswas, S; Briasoulis, A; Fonarow, GC; Goel, A; Gupta, R; Lanier, GM; Malik, AH; Naidu, SS, 2023) |
| " In this study Olprinone, milrinone, PDE inhibitors, cardiac failure, and HF were selected as the search terms to retrieve articles published between January 1999 and March 2022." | 5.41 | Systematic review and meta-analysis of the efficacy of olprinone and MEFV gene in treating heart failure. ( Fu, Y; Pan, Y; Wang, X; Zhang, H, 2023) |
| "Two authors searched MEDLINE, PubMed, Embase, Science Direct, Cochrane Central Register of Controlled Trials, the Cochrane Library, Wanfang database, Chinese Biomedical Literature Database, China National Knowledge Infrastructure (CNKI) for randomized controlled trials (RCTs) about the application of milrinone in the treatment of heart failure caused by severe pneumonia in children with CHD in children up to December 10, 2022." | 5.41 | Milrinone for the treatment of heart failure caused by severe Pneumonia in children with congenital heart disease: a meta-analysis. ( Cai, L; Diao, S; Shao, W; Zhou, L, 2023) |
| "Milrinone levels were 216±71 ng/ml (within the reported therapeutic range: 100-300 ng/ml), followed by improvements in cardiac index, pulmonary artery and wedge pressures (p < 0." | 5.40 | Milrinone in advanced heart failure: dose and therapeutic monitor outside intensive care unit. ( Banner, NR; Charisopoulou, D; Leaver, N, 2014) |
| "The milrinone plasma level was significantly greater in group III than in the other groups (group I, 0 ng/mL; group II, 1." | 5.40 | Sustained release of milrinone delivered via microparticles in a rodent model of myocardial infarction. ( Al Kindi, H; Nepotchatykh, O; Paul, A; Prakash, S; Schwertani, A; Shum-Tim, D; You, Z, 2014) |
| "Milrinone was started at an initial dose of 50 mcg/kg, followed by continuous infusion of 0." | 5.38 | Heart failure treated with low-dose milrinone in a full-term newborn. ( Janota, J; Sebková, S; Tomek, V; Zemanová, P, 2012) |
| "Milrinone was administered as an intravenous infusion (0." | 5.34 | Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure. ( Habbazettl, H; Hentschel, T; Koster, A; Kuebler, WM; Kuppe, H; Riad, A; Tschope, C; Weimann, J; Yin, N, 2007) |
| "End-stage congestive heart failure (CHF) is associated with a high mortality rate and is often refractory to standard medical treatment." | 5.30 | Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study. ( Cesario, D; Clark, J; Maisel, A, 1998) |
| "Milrinone was administered as a bolus (50 ug/kg) and hemodynamic parameters were measured at 5, 10 and 15 minutes." | 5.30 | The use of milrinone in pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension. ( Abel, JG; Carere, RG; Cook, RC; D'yachkova, Y; Ignaszewski, AP; Pamboukian, SV; Webb, JG, 1999) |
| "Milrinone is a phosphodiesterase inhibitor which combines vasodilating effects with inotropic effects." | 5.28 | Beneficial hemodynamic effects of two weeks' milrinone treatment in conscious rats with heart failure. ( Debets, JJ; Schoemaker, RG; Smits, JF; Struyker-Boudier, HA, 1990) |
| "In 20 patients with severe congestive heart failure, intravenous milrinone resulted in significant decreases in left ventricular end-diastolic pressure (from 27 +/- 2 to 18 +/- 2 mm Hg), pulmonary wedge pressure, right atrial pressure, and systemic vascular resistance, as well as a slight reduction in mean arterial pressure." | 5.27 | Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure. ( Baim, DS; Braunwald, E; Cherniles, J; Edelson, J; Grossman, W; McDowell, AV; Monrad, ES; Parker, JA, 1983) |
| "Milrinone is a promising new inotrope, but its arrhythmogenic potential has not been defined." | 5.27 | Occurrence of ventricular arrhythmias in patients receiving acute and chronic infusions of milrinone. ( Anderson, JL; Askins, JC; Gilbert, EM; Lutz, JR; Menlove, RL, 1986) |
| "In end-stage congestive cardiac failure, intravenous milrinone and sildenafil both cause similar reductions in systemic and pulmonary vascular resistance; however, milrinone has more cardiac selective effects on left ventricular filling and heart rate." | 5.14 | Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. ( Botha, P; Dark, JH; Macgowan, GA; Parry, G, 2009) |
| "We analyzed data from the OPTIME-CHF (Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure) study, a randomized trial of intravenous milrinone versus placebo in 949 patients hospitalized with ADHF." | 5.12 | Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial. ( Califf, RM; Cuffe, MS; Echols, MR; Felker, GM; Garg, J; Gheorghiade, M; O'Connor, CM; Pieper, KS; Thomas, KL, 2006) |
| "The Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study randomized 949 patients with systolic dysfunction hospitalized for worsening heart failure to receive 48 to 72 hours of intravenous milrinone or placebo in addition to standard therapy." | 5.11 | Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) s ( Adams, KF; Califf, RM; Felker, GM; Gattis-Stough, W; Gheorghiade, M; Klein, L; Leimberger, JD; O'Connor, CM; Piña, IL, 2005) |
| "The use of dobutamine or milrinone for inotropic support in patients with heart failure awaiting cardiac transplantation is largely arbitrary and based on institutional preference." | 5.10 | Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. ( Aranda, JM; Cleeton, TS; Hill, JA; Leach, D; Lopez, LM; Monroe, VS; Pauly, DF; Schofield, RS; Walker, TC, 2003) |
| "The goal of this study was to assess the interaction between heart failure (HF) etiology and response to milrinone in decompensated HF." | 5.10 | Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. ( Benza, RL; Califf, RM; Chandler, AB; Cuffe, MS; Felker, GM; Gheorghiade, M; Leimberger, JD; O'Connor, CM, 2003) |
| "To prospectively test whether a strategy that includes short-term use of milrinone in addition to standard therapy can improve clinical outcomes of patients hospitalized with an exacerbation of chronic heart failure." | 5.10 | Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. ( Adams, KF; Benza, R; Bourge, R; Califf, RM; Colucci, WS; Cuffe, MS; Gheorghiade, M; Massie, BM; O'Connor, CM; Pina, I; Quigg, R; Silver, MA, 2002) |
| "The objective of this study was to examine the efficacy of milrinone in chronic congestive heart failure." | 5.09 | [Response to milrinone treatment in patients with chronic congestive heart failure]. ( Fang, Y; Huang, D; Liu, X; Wen, S; Zeng, H, 2000) |
| "To characterize the effect of the phosphodiesterase inhibitor (PDEI) milrinone in adult patients with a non-hyperdynamic condition during the course of the systemic inflammatory response syndrome (SIRS) or sepsis when compared with patients with congestive heart failure (CHF)." | 5.09 | IV milrinone for cardiac output increase and maintenance: comparison in nonhyperdynamic SIRS/sepsis and congestive heart failure. ( Delle Karth, G; Frossard, M; Geppert, A; Gschwandtner, ME; Heinz, G; Neunteufl, T; Reinelt, P; Siostrzonek, P; Zauner, C, 1999) |
| "To assess the hemodynamic and vasodilating effects of milrinone lactate (ML) in patients with dilated cardiomyopathy (DCM) and New York Heart Association (NYHA) class III and IV heart failure." | 5.09 | Assessment of inotropic and vasodilating effects of milrinone lactate in patients with dilated cardiomyopathy and severe heart failure. ( Bregagnollo, EA; Cicogna, AC; Fortes, AH, 1999) |
| "The OPTIME CHF (Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure) trial is an ongoing multicenter, randomized, placebo-controlled trial of a treatment strategy for patients with acute exacerbations of CHF." | 5.09 | Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. ( Adams, KF; Bourge, RC; Califf, RM; Colucci, W; Cuffe, MS; Gheorghiade, M; Leimberger, JD; Massie, B; O'Connor, CM; Pina, I; Quigg, R; Robinson, LA; Silver, M, 2000) |
| "Treatment with the PDE-III inhibitor milrinone improves hemodynamics in patients with heart failure." | 5.09 | Milrinone therapy in catecholamine-dependent critically ill patients with heart failure. ( Delle-Karth, G; Haumer, M; Heinz, G; Koller-Strametz, J; Koreny, M; Siostrzonek, P, 2000) |
| "Hemodynamic benefits of milrinone administration are accompanied by adverse effects on arterial oxygenation in mechanically ventilated patients with end-stage heart failure." | 5.09 | Effects of milrinone on pulmonary gas exchange in catecholamine-dependent heart failure. ( Delle Karth, G; Geppert, A; Heinz, G; Koreny, M; Siostrzonek, P; Wutte, M, 2000) |
| "Nineteen patients with decompensated heart failure underwent right heart catheterization and were randomized to receive an intravenous infusion of milrinone at a rate of 0." | 5.09 | Pharmacodynamic effects of milrinone with and without a bolus loading infusion. ( Baruch, L; Hameed, A; Loh, E; Patacsil, P; Pina, I, 2001) |
| "Carvedilol has been shown to improve morbidity and mortality in patients with congestive heart failure (CHF)." | 5.09 | Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. ( Antonio, C; Choudhary, G; Heaney, L; Jain, A; Just, V; Kumar, A; Papp, MA, 2001) |
| "5, 5, or 10 mg) of milrinone in 31 patients with acute or decompensated heart failure." | 5.08 | Hemodynamic effects and pharmacokinetics of oral milrinone for short-term support in acute heart failure. ( Hayakawa, H; Kamishima, G; Kanmatsuse, K; Motomiya, T; Murata, M; Saitoh, S; Saitoh, T; Seino, Y; Takano, T; Watanabe, K, 1995) |
| "To assess the hemodynamic effects of milrinone in a 48h intravenous infusion in patients with severe congestive heart failure (CHF) (NYHA class III or IV)." | 5.08 | [Value of the use of milrinone in the treatment of acute crisis in patients with congestive heart failure]. ( Bianco, AC; Freire, RB; Gun, C; Piegas, LS; Ramos, RF; Timerman, A, 1995) |
| "This study was designed to test a proposed dose modification for intravenous milrinone in congestive heart failure patients (CHF, NYHA I-II) with either moderate or severe renal impairment." | 5.08 | Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure. ( Fox, PA; Greenslade, D; Hegbrant, J; Lasher, K; Lendrem, DW; Lockwood, GF; Rogers, J; Thysell, H; Woolfrey, SG, 1995) |
| "In this multicenter, randomized, double-blind, cross-over, placebo-controlled trial, hemodynamic effects of domestic milrinone were studied in 57 patients with functional class III or IV chronic congestive heart failure." | 5.08 | [Hemodynamic effects of milrinone on patients with chronic congestive heart failure: a multicenter study. Cooperative Group for Phase II Clinical Trial of Milrinone]. ( , 1995) |
| "The purpose of this study was to compare the hemodynamic and clinical effects of milrinone, a vasodilating and positive inotropic agent, with those of dobutamine in patients with congestive heart failure (CHF) following acute myocardial infarction (AMI)." | 5.08 | Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group. ( Berk, MR; DeMaria, AN; DeWood, MA; Karlsberg, RP; Lasher, KP, 1996) |
| " Metoprolol treatment restores the blunted inotropic response to milrinone in patients with heart failure, indicating that postreceptor events (e." | 5.08 | Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. ( Böhm, M; Deutsch, HJ; Hartmann, D; Rosée, KL; Stäblein, A, 1997) |
| "To evaluate the clinical effects of milrinone in patients with severe heart failure, heart function and clinical observations were performed on 25 patients with severe congestive heart failure treated with domestic intravenous milrinone for 15 days." | 5.08 | [Heart function and clinical observations of patients with severe congestive heart failure treated with milrinone]. ( Lu, G; Zhang, L; Zheng, Z, 1998) |
| "We have analysed the hemodynamic effects of milrinone in 13 patients (11 men, 2 women, mean age 55 +/- 12 years) with advanced heart failure resistant to dopamine, dobutamine and/or nitroprusside." | 5.07 | [The hemodynamic effects of the combination of milrinone in heart failure refractory to treatment with dopamine, dobutamine and/or nitroprusside]. ( Domínguez de Rozas, JM; Guindo Soldevila, J; Martínez Vílchez, R; Rodríguez Font, E, 1994) |
| "We describe the results of two placebo-controlled trials (MIL-1077 and MIL-1078) designed to evaluate the clinical efficacy of oral milrinone administered together with converting enzyme inhibitors to patients with congestive heart failure." | 5.07 | Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The Milrinone Multicenter Trials Investigators. ( Adams, KF; Berk, M; Brozena, SC; Colucci, WS; Cowley, AJ; Grabicki, JM; Kubo, SA; LeJemtel, T; Littler, WA; Sonnenblick, EH, 1993) |
| "Serum magnesium levels were measured in 1,068 patients enrolled in a survival study of class III or IV heart failure at the time of double-blind randomization to milrinone, a phosphodiesterase inhibitor, or placebo." | 5.07 | Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study. ( DiBianco, R; Eichhorn, EJ; Fenster, PE; Packer, M; Shannon, J; Tandon, PK; Timmis, GC, 1993) |
| "The hemodynamic effects of milrinone (Mil) were studied in 11 patients with congestive heart failure (CHF) and New York Heart Association (NYHA) functional class II-IV before and after a 2-week treatment." | 5.07 | Hemodynamic effects of milrinone in patients with congestive heart failure--short- and long-term follow up studies. ( Fukuoka, Y; Maeda, T; Nanimatsu, H; Saikawa, T; Takaki, R, 1993) |
| "The hemodynamic effects and safety of milrinone, a phosphodiesterase inhibitor, were studied in 57 patients in the acute phase of cardiac failure." | 5.07 | [Efficacy of intravenous milrinone in the treatment of acute congestive cardiac failure. Results of a French multicenter study]. ( Bory, M; Brochier, M; Dubois-Randé, JL; Guérot, C; Jan, F; Lambert, H; Le Bloc'h, Y; Pony, JC; Sacrez, A; Vacheron, A, 1993) |
| "To assess the inotropic, vasodilator, and after-load-reducing effects of intravenous milrinone in patients with severe congestive heart failure, a simple noninvasive echocardiographic study coupled with a right catheterization was performed in 12 patients." | 5.07 | Physiologic assessment of milrinone therapy in severe heart failure patients. ( Brun, P; Castaigne, A; Deleuze, P; Dubois-Randé, JL; Dupouy, P; Duval-Moulin, AM; Lellouche, D; Loisance, D; Merlet, P; Saal, JP, 1991) |
| "High levels of endogenous plasma catecholamines in patients with severe congestive heart failure induce a down-regulation of the myocardial beta-adrenoreceptors and thus cause adrenoreceptor agonists, such as dobutamine, to be less effective in the treatment of these patients." | 5.07 | Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure. ( Hilger, HH; Höpp, HW; Klocke, RK; Kux, A; Mager, G, 1991) |
| "Milrinone, a phosphodiesterase inhibitor, enhances cardiac contractility by increasing intracellular levels of cyclic AMP, but the long-term effect of this type of positive inotropic agent on the survival of patients with chronic heart failure has not been determined." | 5.07 | Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. ( Bommer, WJ; Carver, JR; DiBianco, R; Elkayam, U; Hendrix, GH; Ivanhoe, RJ; Kukin, ML; Packer, M; Rodeheffer, RJ; Zeldis, SM, 1991) |
| "The response of patients with chronic severe heart failure to extended infusions (greater than or equal to 48 hours) of milrinone was evaluated in a multicenter, baseline-controlled, phase III efficacy and safety trial in 189 patients in the United States." | 5.07 | Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States. ( Anderson, JL, 1991) |
| "The systemic and pulmonary arterial hemodynamics of 40 patients with severe congestive heart failure were determined during a 24-hour infusion of milrinone (0." | 5.07 | Effects of a twenty-four-hour milrinone infusion in patients with severe heart failure and cardiogenic shock as a function of the hemodynamic initial condition. ( Hilger, HH; Höpp, HW; Klocke, RK; Kux, A; Mager, G, 1991) |
| " The acute administration of milrinone, a positive inotropic vasodilator agent, improves resting hemodynamic function and maximal and submaximal metabolic responses to exercise in patients with severe congestive heart failure." | 5.06 | Acute increase in exercise capacity with milrinone: lack of correlation with resting hemodynamic responses. ( Colucci, WS; Hartley, LH; Ribeiro, JP; White, HD, 1990) |
| "Controlled and uncontrolled hemodynamic and clinical studies have noted that the long-term treatment of patients with chronic heart failure with phosphodiesterase (PDE) inhibitors, such as amrinone, milrinone, enoximone and imazodan, may accelerate progression of the underlying disease and provoke serious ventricular arrhythmias." | 5.06 | Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure. ( Packer, M, 1989) |
| "We randomly assigned 230 patients in sinus rhythm with moderately severe heart failure to treatment with digoxin, milrinone, both, or placebo." | 5.06 | A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. ( DiBianco, R; Kostuk, W; Moran, J; Schlant, RC; Shabetai, R; Wright, R, 1989) |
| "6 microgram/kg-min), dobutamine (10 +/- 3 micrograms/kg-min), and milrinone (67 +/- 13 micrograms/kg-min) sequentially to 10 patients with severe (NYHA class III or IV) congestive heart failure." | 5.06 | Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. ( Baim, DS; Lanoue, AS; Monrad, ES; Smith, HS, 1986) |
| "Milrinone and dobutamine were compared in 15 patients with New York Heart Association functional class III and IV congestive heart failure." | 5.06 | Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. ( Braunwald, E; Colucci, WS; Fifer, MA; Jaski, BE; Wright, RF, 1986) |
| "To assess the long-term efficacy of milrinone in patients with severe congestive heart failure, we obtained hemodynamic measurements (systemic arterial and right heart catheterization) in 13 patients at baseline and after intravenous administration of milrinone." | 5.06 | Assessment of long-term therapy with milrinone and the effects of milrinone withdrawal. ( Baim, DS; Gervino, EV; Grossman, W; Lanoue, AS; Monrad, ES; Silverman, KJ; Smith, HS, 1986) |
| "Thirty-seven patients with severe chronic heart failure were entered into an open-ended trial with milrinone at an initial daily dose ranging form 20 to 30 mg." | 5.06 | Milrinone for long-term therapy of severe heart failure: clinical experience with special reference to maximal exercise tolerance. ( Chadwick, B; Gumbardo, D; LeJemtel, TH; Rutman, HI; Sonnenblick, EH, 1986) |
| "We measured systemic hemodynamics, regional blood flow, and neurohormonal parameters in 13 patients with severe chronic congestive heart failure before and after 1 month of therapy with oral milrinone, a bipyridine cardiotonic agent." | 5.06 | Regional blood flow and neurohormonal responses to milrinone in congestive heart failure. ( Cody, RJ; Covit, AB; Feldschuh, J; Kubo, SH; Laragh, JH; Leonard, D; Müller, FB; Preibisz, J; Rutman, H, 1986) |
| "Milrinone and dobutamine are positive inotropic agents with beneficial hemodynamic effects in patients with congestive heart failure." | 5.06 | Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. ( Benotti, JR; Biddle, TL; Creager, MA; Faxon, DP; Firth, BG; Fitzpatrick, PG; Kershner, RP; Konstam, MA; Krebs, C; Walton, L, 1987) |
| "To compare the effects of intravenous dobutamine and milrinone on right ventricular (RV) systolic function, 14 patients with severe congestive heart failure underwent simultaneous radionuclide-hemodynamic study." | 5.06 | Differential effects of milrinone and dobutamine on right ventricular preload, afterload and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. ( Eichhorn, EJ; Konstam, MA; Martin, TT; Roberts, DJ; Salem, DN; Stransky, NB; Weiland, DS, 1987) |
| "A randomized, double-blind, placebo-controlled protocol was used to determine whether milrinone exerts an immediate effect on exercise performance in patients with severe congestive heart failure." | 5.05 | Immediate effects of milrinone on metabolic and sympathetic responses to exercise in severe congestive heart failure. ( Colucci, WS; Hartley, LH; Ribeiro, JP; White, HD, 1985) |
| "Heart failure (HF) experts recommend initiation of continuous inotrope therapy, such as milrinone or dobutamine, for clinically decompensating patients with stage D HF." | 4.98 | Continuous Cardiac Inotropes in Patients With End-Stage Heart Failure: An Evolving Experience. ( Groninger, H; Malotte, K; Saguros, A, 2018) |
| " Albeit few, pediatric studies involving levosimendan suggest similar pharmacokinetics to adults with heart failure, an efficacy at least equal to that of milrinone, favorable myocardial oxygen effects, and an ability to decrease concomitant catecholamine dosing." | 4.87 | Newer inotropes in pediatric heart failure. ( Hoffman, TM, 2011) |
| "To review the literature evaluating the clinical effects of combination therapy with a beta-blocker and milrinone in patients with severe heart failure (HF)." | 4.85 | Use of combination therapy with a beta-blocker and milrinone in patients with advanced heart failure. ( Jennings, DL; Thompson, ML, 2009) |
| " Parenteral sympathomimetic agents, usually dobutamine, and phosphodiesterase inhibitors, usually milrinone, are used for the management of exacerbations of chronic systolic heart failure." | 4.82 | Role of nonglycosidic inotropic agents: indications, ethics, and limitations. ( Chatterjee, K; De Marco, T, 2003) |
| "Recent data have confirmed the heterogeneous nature of patients admitted with acute decompensated heart failure, and the limitations of the current therapeutic regimens with diuretics, intravenous vasodilators (ie, nitroglycerin, nitroprusside), and intravenous inotropes (ie, dobutamine, milrinone)." | 4.82 | A rational approach for the treatment of acute heart failure: current strategies and future options. ( Sharma, M; Teerlink, JR, 2004) |
| "Milrinone (Inocor-Sanofi-Winthrop) represents a second generation phosphodiesterase inhibitor currently approved for intravenous administration in the treatment of decompensated congestive heart failure." | 4.79 | Milrinone: basic and clinical pharmacology and acute and chronic management. ( Hastillo, A; Hess, ML; Shipley, JB; Tolman, D, 1996) |
| " In this article, a case of reversed ventilation-perfusion mismatch involving a patient in congestive heart failure receiving dobutamine and milrinone therapy is presented." | 4.79 | Reversed ventilation-perfusion mismatch involving a pediatric patient in congestive heart failure. ( Heyman, S; Ozdemir, S; Zucker, I, 1997) |
| " milrinone) that are beneficial in the treatment of acute and chronic heart failure." | 4.77 | Pharmacology of positive inotropic phosphodiesterase III inhibitors. ( Honerjäger, P, 1989) |
| " Milrinone, which is structurally similar to amrinone, is an oral agent under investigation for the treatment of congestive heart failure." | 4.77 | Milrinone, a new agent for the treatment of congestive heart failure. ( Hasegawa, GR, 1986) |
| "We report our experience using outpatient milrinone in children receiving hospice care for end-stage heart failure." | 4.31 | Home Milrinone in Pediatric Hospice Care of Children with Heart Failure. ( Brown, M; Dykes, J; Good, J; Hollander, SA; Lin, A; Liu, E; Rosenthal, D; Schmidt, J; Wujcik, K, 2023) |
| "The aim of this study was to assess the safety and efficacy of long-term milrinone therapy in children with acute decompensated heart failure due to dilated cardiomyopathy (DCM)." | 4.31 | Long-term milrinone therapy in children with dilated cardiomyopathy. ( Botha, P; Brown, S; Cassidy, J; Chaudhari, M; Kidd, J; Nolan, O; Poole, E, 2023) |
| " To elucidate the effect of milrinone on cardiac mitochondria and death, a rat model of catecholamine-induced heart failure was investigated." | 4.12 | Milrinone effects on cardiac mitochondria, hemodynamics, and death in catecholamine-infused rats. ( Chan, JYH; Hsieh, KS; Lin, IC; Lin, YJ; Lo, MH; Wu, CW; Wu, KLH, 2022) |
| "Levosimendan and milrinone are 2 effective inotropic drugs used to maintain cardiac output in acute heart failure (AHF)." | 4.12 | Comparative Effectiveness and Safety of Milrinone and Levosimendan as Initial Inotrope Therapy in Patients With Acute Heart Failure With Renal Dysfunction. ( Cheng, Z; Cui, X; Dong, X; Han, Y; Hong, Y; Huang, X; Li, Y; Mu, Y; Wang, Z; Zhang, L, 2022) |
| "We sought to describe and compare outcomes among advanced patients with heart failure (not candidates for orthotopic heart transplant/left ventricular assist device) on long-term milrinone or dobutamine, which are not well-studied in the contemporary era." | 4.12 | Palliative Inotropes in Advanced Heart Failure: Comparing Outcomes Between Milrinone and Dobutamine. ( Acharya, P; Al-Masry, AA; Bajwa, S; Bakel, AV; Boda, I; Dalia, T; Goyal, A; Mastoris, I; Maurides, S; Noonan, G; Parimi, N; Sami, F; Sauer, A; Shah, Z; Tran, C, 2022) |
| "This study aims to determine the incidence of all-cause hospitalization in patients with advanced heart failure (AHF) receiving ambulatory continuous, intravenous dobutamine versus milrinone for palliative intent." | 4.12 | Rehospitalization of Patients with Advanced Heart Failure Receiving Continuous, Palliative Dobutamine or Milrinone. ( Eaton, RE; Haas, GJ; Kissling, KT; McLaughlin, EM; Pickworth, KK, 2022) |
| "Milrinone infusion is one of a few select "non-device" therapies for patients with New York Heart Association (NYHA) class IV, stage D heart failure, which has been associated with an increase in ventricular tachyarrhythmia and atrial fibrillation." | 3.96 | Safety of Outpatient Milrinone Infusion in End-Stage Heart Failure: ICD-Level Data on Atrial Fibrillation and Ventricular Tachyarrhythmias. ( Achu, E; Alpert, JS; Baran, DA; Cassuto, J; Goldschmidt, M; Harhash, AA; Hussein, A; Zucker, MJ, 2020) |
| "In patients with acute postoperative heart failure, before receiving milrinone, renal blood flow was lower (-33%, p < ." | 3.96 | Effects of milrinone on renal perfusion, filtration and oxygenation in patients with acute heart failure and low cardiac output early after cardiac surgery. ( Bragadottir, G; Lannemyr, L; Redfors, B; Ricksten, SE, 2020) |
| " This study aimed to evaluate the safety and efficacy of long-term milrinone use and identify predictors of failure to bridge to orthotropic heart transplant (OHT) in a cohort of end-stage heart failure (HF) patients listed for heart transplantation and receiving inotrope therapy." | 3.96 | Long-term milrinone therapy as a bridge to heart transplantation: Safety, efficacy, and predictors of failure. ( Alexis, JD; Barrus, B; Bruckel, JT; Chen, L; Goldenberg, I; Gosev, I; Lee, EC; Martens, J; McNitt, S; Storozynsky, E; Thomas, S; Vidula, H, 2020) |
| "Although milrinone infusion is reported to benefit left ventricular function in chronic left heart failure, few insights exist regarding its effects on pulmonary circulation and right ventricular function." | 3.85 | Effect of Milrinone Infusion on Pulmonary Vasculature and Stroke Work Indices: A Single-Center Retrospective Analysis in 69 Patients Awaiting Cardiac Transplantation. ( Abramov, D; Di Salvo, TG; Haglund, NA, 2017) |
| "To determine the effect of dobutamine versus milrinone on out-of-hospital mortality in the treatment of patients with acute decompensated heart failure (ADHF)." | 3.85 | Effect of Inpatient Dobutamine versus Milrinone on Out-of-Hospital Mortality in Patients with Acute Decompensated Heart Failure. ( Biskupiak, J; Bress, AP; King, JB; Munger, MA; Sainski-Nguyen, A; Shah, RU, 2017) |
| "We describe the case of a patient with refractory leukemia and end-stage CHF who developed severe dyspnea after discontinuation of milrinone." | 3.81 | Intensive symptom control of opioid-refractory dyspnea in congestive heart failure: Role of milrinone in the palliative care unit. ( Bruera, E; Elsayem, A; Montoya, M; Silvestre, J, 2015) |
| "Peripherally inserted central catheters (PICCs) are used to deliver continuous intravenous (IV) milrinone in stage D heart failure (HF) patients awaiting heart transplantation (HT)." | 3.80 | Are peripherally inserted central catheters associated with increased risk of adverse events in status 1B patients awaiting transplantation on continuous intravenous milrinone? ( Cox, ZL; DiSalvo, TG; Haglund, NA; Keebler, ME; Lee, JT; Lenihan, DJ; Maltais, S; Song, Y; Wigger, MA, 2014) |
| "The purpose of this study is to describe the effect of levosimendan (without loading dose) on hemodynamics, inotropes/vasopressors, and mortality in acute heart failure (AHF)." | 3.79 | Levosimendan: a retrospective single-center case series. ( Barrett, NA; Berry, WT; Hewson, RW; Langrish, CJ; McKenzie, CA, 2013) |
| " Preoperative milrinone use might decrease the risk of severe right ventricular failure requiring additional RVAD insertion and improve postimplantation survival in children with advanced heart failure." | 3.79 | Factors associated with the need of biventricular mechanical circulatory support in children with advanced heart failure. ( Fan, Y; Franz, N; Hetzer, R; Huebler, M; Miera, O; Qian, GS; Weng, YG; Zhang, AM, 2013) |
| "The purpose of this study was to determine whether a low-dose β-blocker, in combination with milrinone, improves cardiac function in acute decompensated heart failure (ADHF) with tachycardia." | 3.78 | Low-dose β-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure. ( Doi, M; Fukuta, S; Kobayashi, S; Matsuzaki, M; Murakami, W; Nao, T; Okamura, T; Okuda, S; Susa, T; Tanaka, T; Wada, Y; Yamada, J; Yano, M, 2012) |
| "To describe the clinical course of a group of patients who received a rotating inotrope regimen, including levosimendan, for decompensated congestive heart failure." | 3.77 | Rotating inotrope therapy in a pediatric population with decompensated heart failure. ( Alexander, PM; Butt, WW; Penny, DJ; Ryerson, LM; Shann, FA; Shekerdemian, LS, 2011) |
| "Our initial experience demonstrates that administration of levosimendan in patients with severe chronic heart failure not responsive to standard intravenous inotropic treatment might result in a significant clinical and hemodynamic improvement and that, in selected patients, it might be life saving." | 3.77 | [Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children]. ( Jovicić, B; Kosutić, J; Nikolić, L; Prijić, S; Rakić, S; Stajević, M; Vukomanović, V, 2011) |
| "The therapeutic action of adenocine during cardiac insufficiency (heart failure) caused by ischemic (stenosis) or reperfusion (removal of ligature) injury to the myocardium prevents depletion of ATP, the major energy source for myocytes in the right and left ventricles, and a drop in NAD/NADH ratio." | 3.77 | Mechanism of cardioprotective effect of adenocine and non-glycoside cardiotonic drugs during experimental chronic cardiac insufficiency. ( Gongadze, NV; Sukoyan, GV, 2011) |
| "The phosphodiesterase III inhibitor milrinone (MIL) is considered to be effective for "wet and cold" heart failure." | 3.76 | Baroreflex sensitivity might predict responders to milrinone in patients with heart failure. ( Kishi, T; Sunagawa, K, 2010) |
| "milrinone, has presented important therapeutic possibilities." | 3.76 | Therapeutic achievements of phosphodiesterase inhibitors and the future. ( Jewitt, DE, 1989) |
| " Whether biomarkers of myocardial necrosis, inflammation and apoptosis change in response to acute milrinone administration is not well established." | 3.75 | Short term effects of milrinone on biomarkers of necrosis, apoptosis, and inflammation in patients with severe heart failure. ( Bazari, R; Czerska, B; Gupta, RC; Hasan, R; Lanfear, DE; Sabbah, HN; Tita, C; Williams, C, 2009) |
| "There are no published clinical trials comparing dobutamine with milrinone in outpatients with stage D heart failure on continuous inotropes." | 3.75 | Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. ( Chu, EC; Gorodeski, EZ; Hsich, E; Reese, JR; Shishehbor, MH; Starling, RC, 2009) |
| "In a retrospective analysis of 949 patients from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure, we investigated the relation between admission values and changes in BUN and eGFR and rate of death by 60 days after discharge." | 3.74 | Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). ( Adams, KF; Califf, RM; Gheorghiade, M; Klein, L; Leimberger, JD; Massie, BM; O'Connor, CM; Piña, IL, 2008) |
| " As treatment, three inotropes commonly used for treatment of cardiac failure were infused for 45 mins in separate animal groups-milrinone, dobutamine, and levosimendan." | 3.74 | Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone. ( Barraud, D; Damy, T; Faivre, V; Gayat, E; Heymes, C; Mebazaa, A; Payen, D; Shah, AM; Welschbillig, S, 2007) |
| "To describe the clinical management of acute decompensated heart failure (ADHF) in patients receiving intravenous treatment with dobutamine, milrinone, or nesiritide, and to evaluate differences, based on treatment received, in the in-hospital mortality rate, length of stay (LOS), total health care costs, and 30-day hospital readmission rate." | 3.73 | Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure. ( Arnold, LM; Carroll, NV; Crouch, MA; Oinonen, MJ, 2006) |
| "Phosphodiesterase inhibitors such as milrinone can relieve symptoms and improve hemodynamics in patients with advanced congestive heart failure." | 3.72 | Intravenous milrinone in treatment of advanced congestive heart failure. ( Delgado, RM; Eastwood, C; Kar, MN; Nawar, M; Vrtovec, B; Zewail, AM, 2003) |
| "Dobutamine-based therapy is an attractive approach for the treatment of decompensated advanced heart failure, achieving comparable clinical efficacy to milrinone with a significantly reduced economic cost." | 3.71 | Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: Hemodynamic efficacy, clinical outcome, and economic impact. ( Albert, N; Haji, SA; Kelly, L; Knack, DL; Starling, RC; Yamani, MH; Young, JB, 2001) |
| "Milrinone and dobutamine are used to manage decompensated heart failure, but their efficacy in patients on beta-blocker therapy was unknown." | 3.71 | Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. ( Bristow, MR; Eichhorn, EJ; Gilbert, EM; Lowes, BD; Tsvetkova, T, 2001) |
| "Patients who experience severe symptoms of heart failure and repeated hospitalizations for exacerbations may benefit from positive inotropic drug infusion therapy such as dobutamine or milrinone." | 3.71 | Positive inotropic drug infusions for patients with heart failure: current controversies and best practice. ( Gorski, LA, 2002) |
| "We determined the correlation coefficients between increasing dose of inotrope and each of the parameters COtd and SvO2 in 18 patients with congestive heart failure who received a 3-day trial of either milrinone or dobutamine during admission to the Veterans Affairs Medical Center in San Diego." | 3.70 | Comparison between mixed venous oxygen saturation and thermodilution cardiac output in monitoring patients with severe heart failure treated with milrinone and dobutamine. ( Maisel, A; Nuñez, S, 1998) |
| "The goal of this study was to determine the extent to which the effects of milrinone were desensitized in heart failure (HF) and to determine the mechanisms, i." | 3.70 | Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure. ( Asai, K; Fujita-Yamaguchi, Y; Ishikawa, Y; Okumura, S; Sato, N; Shannon, RP; Takagi, G; Vatner, DE; Vatner, SF, 1999) |
| "Many reports have suggested that intermittent milrinone infusion (IMI) may be efficacious in the management of end-stage congestive heart failure (CHF), but this issue has not been clearly established." | 3.70 | Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure. ( Dalianis, N; Hatzizacharias, A; Krespi, P; Kyriakidis, M; Makris, T; Triposkiadis, F; Voyatzi, P, 1999) |
| "We experienced a Duchenne muscular dystrophy (DMD) patient with severe congestive heart failure (CHF) successfully treated with milrinone." | 3.70 | [Effective milrinone therapy to a Duchenne muscular dystrophy patient with advanced congestive heart failure]. ( Kang, J; Matsumura, T; Miyai, I; Nozaki, S; Saito, T, 1999) |
| "Milrinone is a phosphodiesterase inhibitor that has been shown to improve hemodynamic parameters in patients with class III to IV heart failure when administered intravenously for < or =48 hours." | 3.70 | Tolerability of extended duration intravenous milrinone in patients hospitalized for advanced heart failure and the usefulness of uptitration of oral angiotensin-converting enzyme inhibitors. ( Eisen, HJ; Flores, I; Mendoza, B; Milfred-LaForest, SK; Piña, IL; Shubert, J, 1999) |
| "The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension." | 3.70 | Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure. ( Chen, J; Cullinane, S; Gold, J; Landry, DW; Oliver, JA; Oz, MC; Seo, S, 2000) |
| "Hemodynamic and biochemical variables were recorded in 29 status 1 men with symptoms of severe congestive heart failure, who received continuous intravenous milrinone alone (group 1, n = 21) or in combination with inotropic agents (group 2, n = 8) while awaiting heart transplantation." | 3.70 | Milrinone for long-term pharmacologic support of the status 1 heart transplant candidates. ( Canver, CC; Chanda, J, 2000) |
| "To evaluate the pharmocokinetics of intravenous milrinone in patients with severe congestive heart failure during continuous venovenous hemofiltration (CVVH)." | 3.70 | Pharmacokinetics of milrinone in patients with congestive heart failure during continuous venovenous hemofiltration. ( Matsumoto, H; Okeie, K; Saito, S; Shibata, K; Taniguchi, T, 2000) |
| "We wished to provide comparative information regarding the direct effects of flosequinan, a novel quinolone under development for treating heart failure, on isolated human arterial, venous, and cardiac muscle." | 3.69 | Assessment of flosequinan's direct effect on human arterial, venous, and cardiac muscle: comparison with other classes of agents used to treat heart failure. ( Britton, LW; Ferraris, VA; Kiser, LM; Sim, MF; Wallace, AM; Weishaar, RE, 1994) |
| "Bolus milrinone consistently decreases PVR in patients with pulmonary hypertension secondary to severe heart failure." | 3.69 | Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension. ( Colucci, WS; Gauthier, DF; Givertz, MM; Hare, JM; Loh, E, 1996) |
| "Milrinone, a bipyridine derivative with positive inotropic and balanced type vasodilating properties, acutely improves cardiac pump function in patients with severe and moderate to severe heart failure." | 3.68 | Preload-dependent hemodynamic effects of milrinone in moderate heart failure. ( Bruggeling, WA; Kruijssen, HA; Pieper, PG; Remme, WJ; van Hoogenhuyze, DC, 1992) |
| "Intravenous phosphodiesterase inhibition with milrinone is known to have a beneficial effect on haemodynamics in chronic heart failure." | 3.68 | Acute effects of intravenous phosphodiesterase inhibition in chronic heart failure: simultaneous pre- and afterload reduction with a single agent. ( Muir, AL; Nolan, J; Sanderson, A; Smith, S; Taddei, F, 1992) |
| "The hemodynamic effects of dobutamine, milrinone, and a combination of both drugs were compared intra-individually in 14 patients with severe heart failure (NYHA III: n = 9; NYHA IV: n = 5)." | 3.68 | [Additive effects of milrinone and dobutamine in severe heart failure]. ( Gerdesmeyer, L; Herrmann, G; Meissner, A; Simon, R, 1992) |
| "We describe the use of a milrinone infusion as a bridge to heart transplantation in the treatment of severe congestive cardiac failure secondary to viral cardiomyopathy." | 3.68 | Milrinone, a bridge to heart transplantation. ( Sherry, KM; Watson, DM; Weston, GA, 1991) |
| " In patients with congestive cardiac failure, the calcium channel blocker, felodipine, causes a marked reduction in systemic vascular resistance and left ventricular filling pressures, but venous volume remains unchanged." | 3.68 | Modulation of venous tone in heart failure. ( Muir, AL; Nolan, J, 1991) |
| "Hemodynamics during 24-h dobutamine (dob) and subsequent 24-h milrinone (mil) infusion were studied in 20 patients (pts) with severe heart failure (NYHA III: 4 pts, NYHA IV: 16 pts)." | 3.68 | [Hemodynamics with dobutamine and milrinone in patients with severe heart failure in an intra-individual comparison]. ( Hilger, HH; Höpp, HW; Klocke, RK; Kux, A; Mager, G; Volkmann, A, 1991) |
| "Cl and milrinone at A1 adenosine receptors and m-cholinoceptors were evaluated in human myocardium from patients with heart failure." | 3.68 | Antagonism of novel inotropic agents at A1 adenosine receptors and m-cholinoceptors in human myocardium. ( Böhm, M; Erdmann, E; Schwinger, RH; Ungerer, M, 1990) |
| "To elucidate the mechanisms by which the new bipyridine inotropic agent milrinone improves cardiac function, we examined multiple indexes of left ventricular diastolic function before and after administration of milrinone to patients with advanced (NYHA class III or IV) congestive heart failure." | 3.67 | Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. ( Baim, DS; Colucci, WS; Fifer, MA; Grossman, W; Heller, GV; McKay, RG; Monrad, ES; Royal, HD, 1984) |
| " To determine the role of the vasodilator action in mediating systemic and regional hemodynamic responses to milrinone, we administered two equipotent inotropic doses of either milrinone or dobutamine to dogs with chronic congestive right heart failure produced by tricuspid avulsion and pulmonary artery stenosis." | 3.67 | Effects of milrinone on systemic hemodynamics and regional circulations in dogs with congestive heart failure: comparison with dobutamine. ( Hood, WB; Imai, N; Kawashima, S; Liang, CS; Stone, CK; Thomas, A, 1987) |
| "Systemic and coronary hemodynamics were measured before and every 10 min after oral milrinone (10 mg) administration for 50 min, together with the drug plasma level in 14 patients with congestive heart failure." | 3.67 | Short-term assessment of left ventricular function, coronary hemodynamics, and catecholamine balance in severe congestive heart failure after a single oral dose of milrinone. ( Jaski, BE; Piscione, F; Serruys, PW, 1988) |
| "The effects of oral milrinone treatment in cardiomyopathic hamsters with severe congestive heart failure (CHF) were evaluated." | 3.67 | Effects of milrinone treatment in cardiomyopathic hamsters (CHF 147) with severe congestive heart failure. ( Cauchy, MJ; Desjardins, S; Hubert, RS; Mueller, RW, 1989) |
| "We infused dobutamine into the left main coronary artery of 24 patients with severe congestive heart failure (CHF) and 8 normal subjects without hemodynamic dysfunction." | 3.67 | Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition. ( Colucci, WS; Denniss, AR; Gauthier, DF; Leatherman, GF; Ludmer, PL; Marsh, JD; Quigg, RJ, 1988) |
| "The long-term survival of rats with healed myocardial infarction and congestive heart failure treated with milrinone, enalapril and the combination of milrinone plus enalapril, was documented." | 3.67 | Beneficial effects of milrinone and enalapril on long-term survival of rats with healed myocardial infarction. ( Emmert, SE; Heyse, JF; Ludden, CT; Stabilito, II; Sweet, CS, 1988) |
| "The positive inotropic effect of milrinone was investigated in isolated, electrically driven (1 Hz) human papillary muscle strips from nonfailing myocardium (control) and from patients with moderate (NYHA II-III) and severe (NYHA IV) heart failure." | 3.67 | Enhancement of the effectiveness of milrinone to increase force of contraction by stimulation of cardiac beta-adrenoceptors in the failing human heart. ( Böhm, M; Diet, F; Erdmann, E; Kemkes, B, 1988) |
| " Intracoronary infusion of dobutamine has also demonstrated a substantial decrease in the inotropic response to beta-adrenergic stimulation in patients with congestive heart failure, presumably because of down-regulation of beta-adrenergic receptors." | 3.67 | Observations on the intracoronary administration of milrinone and dobutamine to patients with congestive heart failure. ( Colucci, WS, 1989) |
| " We examined retrospectively the survival of 82 patients with severe left heart failure during long-term treatment with oral milrinone (17 patients), posicor (12 patients), enoximone (47 patients), and piroximone (6 patients)." | 3.67 | Survival in severe left ventricular failure treated with the new nonglycosidic, nonsympathomimetic oral inotropic agents. ( Chatterjee, K; Daly, PA; Kereiakes, D; Modin, G; Simonton, CA, 1987) |
| "Animal and human studies suggest that amrinone can cause significant improvement in the systemic hemodynamics of patients with severe congestive heart failure (CHF), and do so without increasing myocardial oxygen consumption." | 3.67 | Effects of amrinone on myocardial energetics in severe congestive heart failure. ( Baim, DS, 1985) |
| "The present study was designed to evaluate the regional vascular profile of milrinone in the setting of experimental heart failure." | 3.67 | [Central and regional vascular hemodynamics of milrinone in experimental heart failure: comparison with captopril and dobutamine]. ( Drexler, H; Faude, F; Freudenberg, N; Just, H; Winterer, H; Wollschläger, H, 1987) |
| "The new inotropic agent milrinone has both vasodilator and inotropic cardiovascular effects, but the importance of these effects in patients with severe congestive heart failure (CHF) is controversial." | 3.67 | Effect of oral milrinone on end-systolic relations in patients with severe congestive heart failure. ( Ark, CR; Miller, WP; Wiederholt, P, 1987) |
| "In 14 patients with severe congestive heart failure, left ventricular pressure (measured by tip manometer) and derived variables were measured before and every 10 minutes after administration of oral milrinone (10 mg) for 50 minutes along with measurements of coronary sinus blood flow and drug plasma levels." | 3.67 | Effect of a single oral dose of milrinone on left ventricular diastolic performance in the failing human heart. ( Jaski, BE; Piscione, F; Serruys, PW; Wenting, GJ, 1987) |
| "The effects of milrinone and captopril on ventricular performance, renal blood flow, and femoral vein oxygen content were compared in 11 patients with severe chronic heart failure." | 3.67 | Systemic and regional hemodynamic effects of captopril and milrinone administered alone and concomitantly in patients with heart failure. ( Chadwick, B; Feld, H; LeJemtel, TH; Mancini, D; Maskin, CS; Sinoway, L, 1985) |
| "To determine the relative contributions of milrinone's positive inotropic and vasodilator actions in patients with severe congestive heart failure, the drug was administered by constant infusion directly into the left main coronary artery of 11 patients with New York Heart Association functional class III or IV heart failure." | 3.67 | Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique. ( Arnold, JM; Braunwald, E; Colucci, WS; Ganz, P; Ludmer, PL; Wright, RF, 1986) |
| "The aminopyrine breath test (APBT) was used to study patients with chronic congestive heart failure before and after treatment with two chemically similar inotropic agents, amrinone (AR) and milrinone (MR), to determine their effects on hepatic microsomal function." | 3.67 | The effects of two new inotropic agents on microsomal liver function in patients with congestive heart failure. ( Goldfarb, JP; LeJemtel, TH; Manzione, NC; Maskin, CS; Sternlieb, I, 1986) |
| "The safety and efficacy of long-term oral milrinone therapy were evaluated over a 2 1/2 year period in 100 patients who had severe congestive heart failure despite conventional therapy." | 3.67 | Survival of patients with severe congestive heart failure treated with oral milrinone. ( Baim, DS; Braunwald, E; Colucci, WS; Gauthier, DF; Grossman, W; Lanoue, A; Monrad, ES; Ransil, BJ; Smith, HS; Wright, RF, 1986) |
| "The effects of dobutamine and intravenous milrinone on systemic hemodynamics, coronary blood flow and myocardial metabolism were studied in 11 patients with severe congestive heart failure." | 3.67 | Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure. ( Greenberg, M; Grose, R; LeJemtel, TH; Strain, J, 1986) |
| "Milrinone is a potent positive inotropic and vascular smooth muscle-relaxing agent in vitro, and therefore, it is not known to what extent each of these actions contributes to the drug's hemodynamic effects in patients with heart failure." | 3.67 | Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. ( Braunwald, E; Colucci, WS; Fifer, MA; Jaski, BE; Wright, RF, 1985) |
| "To determine the magnitude and time course of the optimal acute hemodynamic response to oral milrinone, an ascending dose range study was performed in 34 patients with severe chronic congestive heart failure (2." | 3.67 | Acute dose range study of milrinone in congestive heart failure. ( Chatterjee, K; Cody, RJ; Kubo, SH; Leonard, D; Rutman, H; Simonton, C, 1985) |
| "To examine the effect of milrinone on myocardial energetics in patients with congestive heart failure, we measured systemic, pulmonary, and coronary hemodynamics in 18 patients before and after intravenous administration of milrinone (125 +/- 36 micrograms/kg)." | 3.67 | Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure. ( Baim, DS; Brauwald, E; Grossman, W; Lanoue, A; Monrad, ES; Smith, HS, 1985) |
| "The effects of milrinone, a new bipyridine inotropic agent, on the haemodynamic responses to treadmill exercise were studied in 12 patients with congestive heart failure." | 3.67 | Milrinone in heart failure. Effects on exercise haemodynamics during short term treatment. ( Jewitt, DE; Smyth, P; Timmis, AD, 1985) |
| "Acute and chronic hemodynamic and clinical responses to milrinone, a new oral inotrope-vasodilator agent, were evaluated prospectively in 37 patients with severe congestive heart failure." | 3.67 | Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation. ( Chatterjee, K; Cody, RJ; Daly, P; Kubo, SH; Leonard, D; Rutman, H; Simonton, CA, 1985) |
| "Milrinone is a potent non-catecholamine, non-glycoside inotropic agent that can improve hemodynamic performance and functional capacity in patients with severe congestive heart failure." | 3.67 | Milrinone in congestive heart failure: observations on ambulatory ventricular arrhythmias. ( Cody, RJ; Holmes, JR; Kligfield, P; Kubo, SH, 1985) |
| "The acute hemodynamic effects and pharmacokinetics of bolus intravenous milrinone administration were assessed in 13 patients with severe congestive heart failure." | 3.67 | Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure. ( Alpert, JS; Benotti, JR; Lesko, LJ; McCue, JE, 1985) |
| "Cardiogenic pulmonary edema is a frequent cause of respiratory failure." | 2.71 | Milrinone improves lung compliance in patients receiving mechanical ventilation for cardiogenic pulmonary edema. ( Ikezaki, H; Kim, C; Matsumura, J; Nakanishi, K; Ogawa, R; Sakamoto, A; Sato, N; Takeda, S; Tanaka, K, 2003) |
| "Milrinone was also significantly more effective in decreasing systemic vascular resistance (P =." | 2.70 | A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure. ( Bristow, M; Cody, R; Colucci, WS; Elkayam, U; Jaski, B; Loh, E, 2001) |
| "Milrinone was administrated just after the aortic declamping during CPB." | 2.69 | [The effect of milrinone administrated before weaning from cardiopulmonary bypass in adult cardiac surgery]. ( Hamawaki, M; Hibino, N; Imura, M; Inukai, M; Satoh, H; Suzuki, T; Tomino, T, 2000) |
| " Patients were maintained on milrinone therapy for as long as 8 weeks and demonstrated a low incidence of adverse cardiac (7%) or noncardiac (4%) events." | 2.68 | Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. ( Kapoor, C; Mehra, MR; Smart, FW; Stapleton, DD; Ventura, HO; Zimmerman, D, 1997) |
| "Thus milrinone has a definite inotropic effect in addition to its potent vasodilating properties." | 2.66 | Effects of milrinone on left ventricular performance and myocardial contractility in patients with severe heart failure. ( Grose, R; LeJemtel, TH; Sonnenblick, EH; Strain, J; Zelcer, AA, 1986) |
| " After either oral or parenteral administration of milrinone, plasma levels were dose dependent and the drug had an apparent first-order terminal elimination half-life of approximately 2 hr." | 2.66 | Pharmacokinetics of the bipyridines amrinone and milrinone. ( Benotti, J; Benziger, DP; Chatterjee, K; Cody, R; Edelson, J; Hood, WB; Krebs, C; Luczkowec, C; Schwartz, R; Stroshane, R, 1986) |
| "Milrinone is a new bipyridine inotrope that has shown promise in initial clinical testing when administered intravenously or orally." | 2.66 | Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study. ( Anderson, JL; Baim, DS; Fein, SA; Goldstein, RA; LeJemtel, TH; Likoff, MJ, 1987) |
| " More data are needed regarding patient selection and the optimum regimen and dosing of levosimendan before this treatment modality become the first line therapy of acutely decompensated chronic heart failure patients." | 2.44 | Classical inotropes and new cardiac enhancers. ( Farmakis, D; Nieminen, M; Parissis, JT, 2007) |
| " For these purposes, we reviewed data available from randomized controlled trials on short-term, intermittent, and long-term use of intravenous inodilator agents (dobutamine, dopamine, and milrinone) in AHFS." | 2.43 | Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. ( Bayram, M; De Luca, L; Gheorghiade, M; Massie, MB, 2005) |
| "Patients with acute congestive heart failure generally present with profound fluid retention states and dyspnea due to pulmonary edema." | 2.41 | New therapeutic choices in the management of acute congestive heart failure. ( Young, JB, 2001) |
| "For amrinone, inefficacy was revealed through carefully designed, placebo-controlled studies despite initial enthusiasm generated by open uncontrolled trials." | 2.38 | Long-term oral therapy of congestive heart failure with phosphodiesterase inhibitors. ( Hess, ML; Wood, MA, 1989) |
| "Milrinone is a bipyridine derivative with positive inotropic and vasodilating properties." | 2.38 | Role of milrinone in the management of congestive heart failure. ( Forbes, WP; Hilleman, DE, 1989) |
| "Which patients with chronic congestive heart failure who are the most likely to benefit from therapy with the novel inotropic agents, and the therapeutic limitations of these agents are discussed." | 2.37 | The role of novel inotropic agents in the treatment of heart failure. ( Keren, G; LeJemtel, TH; Reis, D; Sonnenblick, EH, 1986) |
| "Milrinone is a bipyridine derivative of amrinone, with approximately 10 to 75 times greater positive inotropic potency, and separate direct vasodilatory properties." | 2.37 | Milrinone. A preliminary review of its pharmacological properties and therapeutic use. ( Ward, A; Young, RA, 1988) |
| "Milrinone use was associated with a lower adjusted risk of 30 day mortality (hazard ratio = 0." | 1.91 | Improved mortality and haemodynamics with milrinone in cardiogenic shock due to acute decompensated heart failure. ( Billia, F; Brahmbhatt, DH; Fung, NL; Luis Scolari, F; Luk, A; Mihajlovic, V; Otsuki, M; Overgaard, CB; Rodenas-Alesina, E; Wang, VN, 2023) |
| "Milrinone was started on POD six, followed by sildenafil administration on POD seven." | 1.91 | Successful echocardiography-guided medical management of severe early post-implant right ventricular failure in a patient with left ventricular assist device support: a case report. ( Fujita, T; Fukushima, N; Fukushima, S; Hada, T; Kainuma, S; Kamiya, H; Kunioka, S; Mochizuki, H; Seguchi, O; Shimojima, M; Tadokoro, N; Tsukamoto, Y; Watanabe, T, 2023) |
| "Dobutamine was associated with EMH incidence of 14% (6/43), with zero cases in the milrinone cohort." | 1.72 | Incidence and Predictors of Eosinophilic Myocardial Hypersensitivity in Patients Receiving Home Dobutamine. ( Bader, I; Bergin, P; Dagan, M; Easton, K; Hare, JL; Kaye, DM; Lankaputhra, M; Leet, A; Linton, A; McLean, C; Patel, HC; Taylor, A; Tee, SL; Yeung, T, 2022) |
| "Oral milrinone was started 1." | 1.72 | Oral milrinone for management of refractory right ventricular failure in patients with left ventricular assist devices. ( Akhtar, W; Baston, V; Butcher, C; Dar, O; Dunning, J; Lyster, H; Morley-Smith, A; Riesgo Gil, F, 2022) |
| "Milrinone-treated patients with ischemic heart disease and chronic kidney disease (CKD) at stage ≥ 4 presented with greater incidence of MACCE (log rank; P < 0." | 1.56 | Comparing the effects of milrinone and olprinone in patients with congestive heart failure. ( Dobashi, S; Fujii, T; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Nakanishi, R; Oka, T; Watanabe, I, 2020) |
| "Milrinone use was associated with a greater 1-year survival than dobutamine (70." | 1.56 | Survival With Continuous Outpatient Intravenous Inotrope Therapy in the Modern Era. ( Ahn, C; Aronow, WS; Cooper, HA; Gass, AL; Gupta, CA; Khan, MH; Lanier, GM; Levine, A; Lloji, A; Mody, BP; Zaid, S, 2020) |
| " In conclusion, prolonged AI and/or LS infusions in HF are safe and beneficial even in small infants, allowing stabilization and reasonable social and family life out of the hospital." | 1.48 | Ambulatory Intravenous Inotropic Support and or Levosimendan in Pediatric and Congenital Heart Failure: Safety, Survival, Improvement, or Transplantation. ( Apostolopoulou, SC; Kakava, F; Rammos, S; Tsoutsinos, A; Vagenakis, GA, 2018) |
| "Bacteremia was the most common type of infection." | 1.43 | Infections, Arrhythmias, and Hospitalizations on Home Intravenous Inotropic Therapy. ( Acharya, D; Hashim, T; Loyaga-Rendon, RY; Morgan, CJ; Pamboukian, SV; Revilla-Martinez, M; Sanam, K; Tallaj, JA, 2016) |
| "Given the increasing use of LVADs to treat end-stage heart failure, these issues are likely to become more frequently encountered in the future." | 1.43 | Prolonged asystole in a patient with an isolated left ventricular assist device. ( Chaggar, PS; Javed, W; Shaw, SM; Venkateswaran, R, 2016) |
| "Milrinone levels were 216±71 ng/ml (within the reported therapeutic range: 100-300 ng/ml), followed by improvements in cardiac index, pulmonary artery and wedge pressures (p < 0." | 1.40 | Milrinone in advanced heart failure: dose and therapeutic monitor outside intensive care unit. ( Banner, NR; Charisopoulou, D; Leaver, N, 2014) |
| "The milrinone plasma level was significantly greater in group III than in the other groups (group I, 0 ng/mL; group II, 1." | 1.40 | Sustained release of milrinone delivered via microparticles in a rodent model of myocardial infarction. ( Al Kindi, H; Nepotchatykh, O; Paul, A; Prakash, S; Schwertani, A; Shum-Tim, D; You, Z, 2014) |
| "Dobutamine, a common cause of HSM, was administered to 12 patients (57%)." | 1.39 | Characteristics of patients with advanced heart failure having eosinophilic infiltration of the myocardium in the recent era. ( C Marboe, C; Mancini, D; Sugiyama Kato, T; Yoshizawa, S, 2013) |
| "Milrinone is a bipyridine phosphodiesterase inhibitor with positive inotropic and vasodilatory effects." | 1.38 | A clinical assay for the measurement of milrinone in plasma by HPLC mass spectrometry. ( Banner, NR; Chihoho, B; Leaver, NV; Rose, ML; Sage, AB; Smolenski, RT; Vazir, A, 2012) |
| "Milrinone was started at an initial dose of 50 mcg/kg, followed by continuous infusion of 0." | 1.38 | Heart failure treated with low-dose milrinone in a full-term newborn. ( Janota, J; Sebková, S; Tomek, V; Zemanová, P, 2012) |
| "Milrinone was administered as an intravenous infusion (0." | 1.34 | Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure. ( Habbazettl, H; Hentschel, T; Koster, A; Kuebler, WM; Kuppe, H; Riad, A; Tschope, C; Weimann, J; Yin, N, 2007) |
| "Transcatheter closure of atrial septal defects (ASDs) is a safe and effective treatment." | 1.33 | Left ventricular conditioning in the elderly patient to prevent congestive heart failure after transcatheter closure of atrial septal defect. ( Abdul-Khaliq, H; Ewert, P; Lange, PE; Nagdyman, N; Peters, B; Schubert, S, 2005) |
| "Their mitral regurgitation (MR) is a result of left ventricular (LV) geometrical distortion." | 1.33 | Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair. ( Bolling, SF; Geltz, A; Spoor, MT, 2006) |
| " We report the use of a short-acting intravenous beta blocker in combination with inotropic therapy as a means to bridge five patients with advanced heart failure to chronic oral beta blockade; two of these patients had been chronically managed with intravenous inotrope." | 1.31 | Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure. ( Hauptman, PJ; Prirzker, MR; Woods, D, 2002) |
| "Heart failure is associated with pathobiochemical changes that can reduce the responsiveness of the myocardium to positive inotropic agents." | 1.30 | The effect of positive inotropes on the failing human myocardium. ( Erdmann, E, 1997) |
| "End-stage congestive heart failure (CHF) is associated with a high mortality rate and is often refractory to standard medical treatment." | 1.30 | Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study. ( Cesario, D; Clark, J; Maisel, A, 1998) |
| "Levosimendan was shown to increase calcium sensitivity by a novel mechanism and to inhibit phosphodiesterase III activity in animal myocardium." | 1.30 | Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. ( Castell, M; Hasenfuss, G; Just, H; Kretschmann, B; Maier, LS; Pieske, B, 1998) |
| "Milrinone was administered as a bolus (50 ug/kg) and hemodynamic parameters were measured at 5, 10 and 15 minutes." | 1.30 | The use of milrinone in pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension. ( Abel, JG; Carere, RG; Cook, RC; D'yachkova, Y; Ignaszewski, AP; Pamboukian, SV; Webb, JG, 1999) |
| " Dose-response curves plotted as percentage change from baseline versus concentration of drug were determined for acetylstrophanthidin, isoproterenol, isobutylmethylxanthine, and milrinone." | 1.29 | Decreased inotropic but relatively preserved relaxation response to cyclic adenosine monophosphate-dependent agents in myopathic human myocardium. ( Bruce, E; Flemmal, K; Grossman, W; Gutstein, DE; Gwathmey, JK; Markis, JE; Morgan, JP; Ransil, BJ; Travers, KE, 1996) |
| "Milrinone is a phosphodiesterase inhibitor which combines vasodilating effects with inotropic effects." | 1.28 | Beneficial hemodynamic effects of two weeks' milrinone treatment in conscious rats with heart failure. ( Debets, JJ; Schoemaker, RG; Smits, JF; Struyker-Boudier, HA, 1990) |
| "The pathophysiology of the syndrome of congestive heart failure (CHF) includes 2 major components that closely interact." | 1.28 | Effects of phosphodiesterase inhibition on skeletal muscle vasculature. ( LeJemtel, TH; Levitt, B; Scortichini, D; Sonnenblick, EH, 1989) |
| "Significant proarrhythmia is uncommon, but can occur." | 1.28 | Electrophysiology of phosphodiesterase inhibitors. ( Goldstein, RA; Naccarelli, GV, 1989) |
| "Milrinone (Win 47203) is a dipyridine related to amrinone, which is about 20-50 times as effective as amrinone when assayed on cardiac contractility." | 1.27 | The search for a digitalis substitute II milrinone (Win 47203). Its action on the heart-lung preparation of the dog. ( Farah, A; Kabela, E; Mendez, R; Pastelin, G, 1983) |
| " If long-term administration remains well tolerated and without side effects, this drug appears to be very promising for treatment of chronic severe congestive heart failure." | 1.27 | Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure. ( Chadwick, B; Le Jemtel, TH; Maskin, CS; Sinoway, L; Sonnenblick, EH, 1983) |
| "Seven patients with severe chronic congestive heart failure were treated with a new cardiotonic agent, WIN 47203 (an analog of amrinone), for an average of 7." | 1.27 | Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease. ( Chadwick, B; Forman, R; Le Jemtel, TH; Maskin, CS; Sinoway, LS; Sonnenblick, EH, 1983) |
| "In 20 patients with severe congestive heart failure, intravenous milrinone resulted in significant decreases in left ventricular end-diastolic pressure (from 27 +/- 2 to 18 +/- 2 mm Hg), pulmonary wedge pressure, right atrial pressure, and systemic vascular resistance, as well as a slight reduction in mean arterial pressure." | 1.27 | Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure. ( Baim, DS; Braunwald, E; Cherniles, J; Edelson, J; Grossman, W; McDowell, AV; Monrad, ES; Parker, JA, 1983) |
| "Increased plasma levels in congestive heart failure (CHF) have been reported." | 1.27 | Atrial natriuretic peptide during acute treatment of congestive heart failure. ( Berglund, H; Bevegård, S; Carlens, P; Hedner, J; Hedner, T, 1988) |
| "Enalaprilat was tested in a similar design with the infusion phase (70 micrograms/kg, total dose) separated by oral enalapril (Enal), 1 mg/kg/day." | 1.27 | Acute and subacute hemodynamic effects of enalaprilat, milrinone and combination therapy in rats with chronic left ventricular dysfunction. ( Emmert, SE; Stabilito, II; Sweet, CS, 1987) |
| " Moreover, the changes in peak skeletal muscle blood flow noted during long-term administration of captopril, an angiotensin-converting enzyme inhibitor, appears to correlate with the changes in aerobic capacity." | 1.27 | Direct and indirect assessment of skeletal muscle blood flow in chronic congestive heart failure. ( Katz, S; LeJemtel, TH; Scortichini, D, 1988) |
| "Milrinone (M) has been shown to improve left ventricular (LV) performance in animal and human studies." | 1.27 | Evaluation of the vasodilator vs inotropic effect of milrinone using an animal model of left ventricular failure: reversal of disopyramide depression of the myocardium with milrinone. ( Berdoff, R; Goldberg, E; Haimowitz, A; Spivack, G; Tay, S, 1987) |
| "Milrinone is a promising new inotrope, but its arrhythmogenic potential has not been defined." | 1.27 | Occurrence of ventricular arrhythmias in patients receiving acute and chronic infusions of milrinone. ( Anderson, JL; Askins, JC; Gilbert, EM; Lutz, JR; Menlove, RL, 1986) |
| "Milrinone is a recently synthesized bypyridine compound with positive inotropic and arteriolar dilating properties in persons and experimental animals." | 1.27 | Echocardiographic and clinical effects of milrinone in dogs with myocardial failure. ( Keister, DM; Kittleson, MD; Knauer, KW; Knowlen, GG; Miner, WS; Pipers, FS, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 105 (28.00) | 18.7374 |
| 1990's | 86 (22.93) | 18.2507 |
| 2000's | 87 (23.20) | 29.6817 |
| 2010's | 63 (16.80) | 24.3611 |
| 2020's | 34 (9.07) | 2.80 |
| Authors | Studies |
|---|---|
| Sircar, I | 3 |
| Steffen, RP | 2 |
| Bobowski, G | 2 |
| Burke, SE | 1 |
| Newton, RS | 1 |
| Weishaar, RE | 3 |
| Bristol, JA | 3 |
| Evans, DB | 3 |
| Venuti, MC | 1 |
| Stephenson, RA | 1 |
| Alvarez, R | 1 |
| Bruno, JJ | 1 |
| Strosberg, AM | 1 |
| Duell, BL | 1 |
| Erhardt, PW | 1 |
| Moos, WH | 1 |
| Nomoto, Y | 1 |
| Takai, H | 1 |
| Ohno, T | 1 |
| Nagashima, K | 1 |
| Yao, K | 1 |
| Yamada, K | 1 |
| Kubo, K | 1 |
| Ichimura, M | 1 |
| Mihara, A | 1 |
| Kase, H | 1 |
| Ravinder, M | 1 |
| Mahendar, B | 1 |
| Mattapally, S | 1 |
| Hamsini, KV | 1 |
| Reddy, TN | 1 |
| Rohit, C | 1 |
| Srinivas, K | 1 |
| Banerjee, SK | 1 |
| Rao, VJ | 1 |
| Milwidsky, A | 2 |
| Frydman, S | 1 |
| Laufer-Perl, M | 2 |
| Sadeh, B | 2 |
| Sapir, O | 2 |
| Granot, Y | 2 |
| Hochstadt, A | 1 |
| Korotetski, L | 2 |
| Ketchker, L | 2 |
| Topilsky, Y | 1 |
| Banai, S | 2 |
| Havakuk, O | 2 |
| Lin, IC | 1 |
| Wu, CW | 1 |
| Lin, YJ | 1 |
| Lo, MH | 1 |
| Hsieh, KS | 1 |
| Chan, JYH | 1 |
| Wu, KLH | 1 |
| Wolfe, A | 1 |
| Watt, CL | 1 |
| Downar, J | 1 |
| Bush, SH | 1 |
| Sadon, S | 1 |
| Zahler, D | 1 |
| Rosh, M | 1 |
| Szarpak, L | 1 |
| Szwed, P | 1 |
| Gasecka, A | 1 |
| Rafique, Z | 1 |
| Pruc, M | 1 |
| Filipiak, KJ | 1 |
| Jaguszewski, MJ | 1 |
| Cui, X | 2 |
| Wang, Z | 1 |
| Dong, X | 1 |
| Cheng, Z | 1 |
| Zhang, L | 2 |
| Mu, Y | 1 |
| Huang, X | 1 |
| Li, Y | 1 |
| Hong, Y | 1 |
| Han, Y | 1 |
| Biswas, S | 1 |
| Malik, AH | 1 |
| Bandyopadhyay, D | 1 |
| Gupta, R | 1 |
| Goel, A | 1 |
| Briasoulis, A | 1 |
| Fonarow, GC | 2 |
| Lanier, GM | 2 |
| Naidu, SS | 1 |
| Tariq, H | 1 |
| Ahmed, B | 1 |
| Hafiz, MY | 1 |
| Dagan, M | 1 |
| Lankaputhra, M | 1 |
| Yeung, T | 1 |
| Tee, SL | 1 |
| Bader, I | 1 |
| Easton, K | 1 |
| Linton, A | 1 |
| McLean, C | 1 |
| Taylor, A | 1 |
| Bergin, P | 2 |
| Kaye, DM | 4 |
| Leet, A | 1 |
| Hare, JL | 1 |
| Patel, HC | 1 |
| Akhtar, W | 1 |
| Butcher, C | 1 |
| Morley-Smith, A | 1 |
| Riesgo Gil, F | 1 |
| Dar, O | 1 |
| Baston, V | 1 |
| Dunning, J | 1 |
| Lyster, H | 2 |
| Sami, F | 1 |
| Acharya, P | 1 |
| Noonan, G | 1 |
| Maurides, S | 1 |
| Al-Masry, AA | 1 |
| Bajwa, S | 1 |
| Parimi, N | 1 |
| Boda, I | 1 |
| Tran, C | 1 |
| Goyal, A | 1 |
| Mastoris, I | 1 |
| Dalia, T | 1 |
| Sauer, A | 1 |
| Bakel, AV | 1 |
| Shah, Z | 1 |
| Eaton, RE | 1 |
| Kissling, KT | 1 |
| Haas, GJ | 1 |
| McLaughlin, EM | 1 |
| Pickworth, KK | 1 |
| Shringi, S | 1 |
| Joshi, S | 1 |
| Suffredini, JM | 1 |
| Schenk, A | 1 |
| Rajagopalan, N | 1 |
| Guglin, M | 1 |
| Nakagawa, Y | 3 |
| Imamura, T | 3 |
| Hollander, SA | 3 |
| Wujcik, K | 3 |
| Schmidt, J | 3 |
| Liu, E | 3 |
| Lin, A | 3 |
| Dykes, J | 3 |
| Good, J | 3 |
| Brown, M | 3 |
| Rosenthal, D | 3 |
| Viéitez Flórez, JM | 1 |
| Hernández Pérez, FJ | 1 |
| Mitroi, C | 1 |
| Lozano Jiménez, S | 1 |
| Gómez Bueno, M | 1 |
| Segovia Cubero, J | 1 |
| Kumar, N | 1 |
| Reeves, J | 1 |
| Hussain, N | 1 |
| Essandoh, M | 1 |
| Brown, S | 1 |
| Nolan, O | 1 |
| Poole, E | 1 |
| Kidd, J | 1 |
| Cassidy, J | 1 |
| Botha, P | 2 |
| Chaudhari, M | 1 |
| Alkadri, J | 1 |
| Hu, R | 1 |
| Jeffers, MS | 1 |
| Ross, J | 1 |
| McIsaac, DI | 1 |
| McDonald, B | 1 |
| Fu, Y | 1 |
| Wang, X | 1 |
| Pan, Y | 1 |
| Zhang, H | 1 |
| Rodenas-Alesina, E | 1 |
| Luis Scolari, F | 1 |
| Wang, VN | 1 |
| Brahmbhatt, DH | 1 |
| Mihajlovic, V | 1 |
| Fung, NL | 1 |
| Otsuki, M | 1 |
| Billia, F | 1 |
| Overgaard, CB | 1 |
| Luk, A | 1 |
| Gerhartz, B | 1 |
| Damodharan, S | 1 |
| Puccetti, DM | 1 |
| Boriosi, JP | 1 |
| Hokanson, JS | 1 |
| Capitini, CM | 1 |
| Kunioka, S | 1 |
| Seguchi, O | 1 |
| Hada, T | 1 |
| Mochizuki, H | 1 |
| Shimojima, M | 1 |
| Watanabe, T | 1 |
| Tsukamoto, Y | 1 |
| Tadokoro, N | 1 |
| Kainuma, S | 1 |
| Fukushima, S | 1 |
| Fujita, T | 1 |
| Kamiya, H | 1 |
| Fukushima, N | 1 |
| Shao, W | 1 |
| Diao, S | 1 |
| Zhou, L | 1 |
| Cai, L | 1 |
| Dobashi, S | 1 |
| Watanabe, I | 1 |
| Nakanishi, R | 1 |
| Hisatake, S | 1 |
| Kiuchi, S | 1 |
| Kabuki, T | 1 |
| Oka, T | 1 |
| Fujii, T | 1 |
| Ikeda, T | 1 |
| Harhash, AA | 1 |
| Cassuto, J | 1 |
| Hussein, A | 1 |
| Achu, E | 1 |
| Zucker, MJ | 1 |
| Goldschmidt, M | 1 |
| Alpert, JS | 2 |
| Baran, DA | 1 |
| Lannemyr, L | 1 |
| Bragadottir, G | 1 |
| Redfors, B | 1 |
| Ricksten, SE | 1 |
| Kelly, J | 1 |
| Cheng, J | 1 |
| Malloy, R | 1 |
| Lupi, K | 1 |
| Lee, EC | 1 |
| McNitt, S | 1 |
| Martens, J | 1 |
| Bruckel, JT | 1 |
| Chen, L | 1 |
| Alexis, JD | 1 |
| Storozynsky, E | 1 |
| Thomas, S | 1 |
| Gosev, I | 1 |
| Barrus, B | 1 |
| Goldenberg, I | 1 |
| Vidula, H | 1 |
| Silverman, DN | 1 |
| Houston, BA | 1 |
| Tedford, RJ | 1 |
| Mody, BP | 1 |
| Khan, MH | 1 |
| Zaid, S | 1 |
| Ahn, C | 1 |
| Lloji, A | 1 |
| Aronow, WS | 1 |
| Gupta, CA | 1 |
| Levine, A | 1 |
| Gass, AL | 1 |
| Cooper, HA | 1 |
| Blink, M | 1 |
| Buddingh', EP | 1 |
| Filippini, LHPM | 1 |
| Brinkman, DMC | 1 |
| Joosten, SA | 1 |
| Klein, RH | 1 |
| Sia, YT | 1 |
| Gebhard, CE | 2 |
| Denault, AY | 5 |
| Coleman, RD | 1 |
| Chartan, CA | 1 |
| Mourani, PM | 1 |
| Abramov, D | 1 |
| Haglund, NA | 3 |
| Di Salvo, TG | 1 |
| King, JB | 1 |
| Shah, RU | 1 |
| Sainski-Nguyen, A | 1 |
| Biskupiak, J | 1 |
| Munger, MA | 1 |
| Bress, AP | 1 |
| Tremblay, JA | 2 |
| Beaubien-Souligny, W | 1 |
| Elmi-Sarabi, M | 3 |
| Desjardins, G | 2 |
| Nanayakkara, S | 3 |
| Mak, V | 2 |
| Crannitch, K | 2 |
| Malotte, K | 1 |
| Saguros, A | 1 |
| Groninger, H | 2 |
| Nielsen, DV | 1 |
| Torp-Pedersen, C | 1 |
| Skals, RK | 1 |
| Gerds, TA | 1 |
| Karaliunaite, Z | 1 |
| Jakobsen, CJ | 1 |
| Jacky, A | 1 |
| Rudiger, A | 1 |
| Krüger, B | 1 |
| Wilhelm, MJ | 1 |
| Paal, S | 1 |
| Seifert, B | 1 |
| Spahn, DR | 1 |
| Bettex, D | 1 |
| Apostolopoulou, SC | 1 |
| Vagenakis, GA | 1 |
| Tsoutsinos, A | 1 |
| Kakava, F | 1 |
| Rammos, S | 1 |
| Byrne, M | 2 |
| Couture, EJ | 2 |
| Lamarche, Y | 1 |
| Heringlake, M | 1 |
| Berggreen, AE | 1 |
| Rochon, A | 1 |
| Cogan, J | 1 |
| Ased, H | 1 |
| Deschamps, A | 2 |
| Gavra, P | 1 |
| Lebon, JS | 1 |
| Couture, P | 1 |
| Ayoub, C | 1 |
| Levesque, S | 1 |
| Hastenteufel, LCT | 1 |
| Clausell, N | 1 |
| Neyeloff, JL | 1 |
| Domingues, FB | 1 |
| Caballero, LG | 1 |
| Silva, ERRD | 1 |
| Goldraich, LA | 1 |
| Soucy-Giguere, MC | 1 |
| Charbonneau, É | 1 |
| Cinq Mars, A | 1 |
| Dubois, M | 1 |
| Sénéchal, M | 1 |
| Charisopoulou, D | 1 |
| Leaver, N | 2 |
| Banner, NR | 3 |
| St-Pierre, P | 1 |
| Cartier, R | 1 |
| Basmadjian, AJ | 1 |
| Cox, ZL | 3 |
| Calcutt, MW | 1 |
| Morrison, TB | 1 |
| Akers, WS | 2 |
| Davis, MB | 1 |
| Lenihan, DJ | 2 |
| Yoshizawa, S | 1 |
| Sugiyama Kato, T | 1 |
| Mancini, D | 2 |
| C Marboe, C | 1 |
| Berry, WT | 1 |
| Hewson, RW | 1 |
| Langrish, CJ | 1 |
| McKenzie, CA | 1 |
| Barrett, NA | 1 |
| Orstavik, O | 1 |
| Ata, SH | 1 |
| Riise, J | 1 |
| Dahl, CP | 1 |
| Andersen, GØ | 1 |
| Levy, FO | 1 |
| Skomedal, T | 1 |
| Osnes, JB | 1 |
| Qvigstad, E | 1 |
| Costello, JM | 1 |
| Dunbar-Masterson, C | 1 |
| Allan, CK | 1 |
| Gauvreau, K | 1 |
| Newburger, JW | 1 |
| McGowan, FX | 1 |
| Wessel, DL | 1 |
| Mayer, JE | 1 |
| Salvin, JW | 1 |
| Dionne, RE | 1 |
| Laussen, PC | 1 |
| Lee, JT | 1 |
| Song, Y | 1 |
| Keebler, ME | 1 |
| DiSalvo, TG | 1 |
| Maltais, S | 1 |
| Wigger, MA | 1 |
| Gorodeski, EZ | 2 |
| Kim, A | 1 |
| Al Kindi, H | 1 |
| Paul, A | 1 |
| You, Z | 1 |
| Nepotchatykh, O | 1 |
| Schwertani, A | 1 |
| Prakash, S | 1 |
| Shum-Tim, D | 1 |
| Berger, J | 1 |
| Chabot, J | 1 |
| Pun, S | 1 |
| Pelletier, JP | 1 |
| Vautour, L | 1 |
| Giannetti, N | 1 |
| Tang, X | 1 |
| Liu, P | 1 |
| Li, R | 1 |
| Jing, Q | 1 |
| Lv, J | 1 |
| Liu, L | 2 |
| Liu, Y | 1 |
| Silvestre, J | 1 |
| Montoya, M | 1 |
| Bruera, E | 1 |
| Elsayem, A | 1 |
| Burdorf, A | 1 |
| Jones, T | 1 |
| Shostrom, V | 1 |
| Um, J | 1 |
| Ryan, T | 1 |
| Shillcutt, S | 1 |
| Fischer, P | 1 |
| Raichlin, E | 1 |
| Anderson, DR | 1 |
| Lowes, BD | 2 |
| Dumitru, I | 1 |
| Hyldebrandt, JA | 3 |
| Sivén, E | 2 |
| Agger, P | 2 |
| Frederiksen, CA | 3 |
| Heiberg, J | 3 |
| Wemmelund, KB | 2 |
| Ravn, HB | 3 |
| Lanfear, DE | 2 |
| Mittal, M | 1 |
| Radhakrishnan, M | 1 |
| UmamaheswaraRao, GS | 1 |
| Novaes, RD | 1 |
| Gonçalves, RV | 1 |
| Acharya, D | 1 |
| Sanam, K | 1 |
| Revilla-Martinez, M | 1 |
| Hashim, T | 1 |
| Morgan, CJ | 1 |
| Pamboukian, SV | 2 |
| Loyaga-Rendon, RY | 1 |
| Tallaj, JA | 1 |
| von Scheidt, W | 1 |
| Pauschinger, M | 1 |
| Ertl, G | 1 |
| Kirk, R | 1 |
| Peng, E | 1 |
| Woods, A | 1 |
| Flett, J | 1 |
| Hewitt, T | 1 |
| Griselli, M | 1 |
| Schueler, S | 1 |
| Wrightson, N | 1 |
| Hasan, A | 1 |
| Reimche, R | 1 |
| Salcedo, D | 1 |
| Vizi, D | 1 |
| Mariani, JA | 1 |
| Furck, AK | 1 |
| Bentley, S | 1 |
| Bartsota, M | 1 |
| Rigby, ML | 1 |
| Slavik, Z | 1 |
| Kelemen, A | 1 |
| Ruiz, G | 1 |
| Javed, W | 1 |
| Chaggar, PS | 1 |
| Venkateswaran, R | 1 |
| Shaw, SM | 1 |
| Støttrup, NB | 1 |
| Dupont Birkler, RI | 1 |
| Johannsen, M | 1 |
| Schmidt, MR | 1 |
| Liu, XK | 1 |
| Ma, LX | 1 |
| Wei, ZY | 1 |
| Zhan, S | 1 |
| Yin, XM | 1 |
| Piao, HR | 1 |
| Assad-Kottner, C | 1 |
| Chen, D | 1 |
| Jahanyar, J | 1 |
| Cordova, F | 1 |
| Summers, N | 1 |
| Loebe, M | 1 |
| Merla, R | 1 |
| Youker, K | 1 |
| Torre-Amione, G | 1 |
| Donlan, SM | 1 |
| Quattromani, E | 1 |
| Pang, PS | 1 |
| Gheorghiade, M | 13 |
| Parry, G | 1 |
| Dark, JH | 1 |
| Macgowan, GA | 1 |
| Hasan, R | 1 |
| Gupta, RC | 1 |
| Williams, C | 1 |
| Czerska, B | 1 |
| Tita, C | 1 |
| Bazari, R | 1 |
| Sabbah, HN | 1 |
| Jennings, DL | 1 |
| Thompson, ML | 1 |
| Klein, L | 4 |
| Massie, BM | 4 |
| Leimberger, JD | 7 |
| O'Connor, CM | 10 |
| Piña, IL | 4 |
| Adams, KF | 9 |
| Califf, RM | 7 |
| Chu, EC | 1 |
| Reese, JR | 1 |
| Shishehbor, MH | 1 |
| Hsich, E | 1 |
| Starling, RC | 2 |
| Kato, M | 2 |
| Sanada, S | 1 |
| Kitakaze, M | 1 |
| Ryerson, LM | 1 |
| Alexander, PM | 1 |
| Butt, WW | 1 |
| Shann, FA | 1 |
| Penny, DJ | 1 |
| Shekerdemian, LS | 1 |
| Coons, JC | 1 |
| McGraw, M | 1 |
| Murali, S | 1 |
| Kishi, T | 1 |
| Sunagawa, K | 1 |
| Hoffman, TM | 1 |
| Vazir, A | 2 |
| Alexanian, A | 1 |
| Wilton, P | 1 |
| Montalto, M | 1 |
| Chihoho, B | 1 |
| Sage, AB | 1 |
| Smolenski, RT | 1 |
| Rose, ML | 1 |
| Leaver, NV | 1 |
| Schweigmann, U | 1 |
| Velik-Salchner, C | 1 |
| Kilo, J | 1 |
| Schermer, E | 1 |
| Vinetti, M | 1 |
| Haufroid, V | 1 |
| Capron, A | 1 |
| Classen, JF | 1 |
| Marchandise, S | 1 |
| Hantson, P | 1 |
| Prijić, S | 1 |
| Rakić, S | 1 |
| Nikolić, L | 1 |
| Jovicić, B | 1 |
| Stajević, M | 1 |
| Vukomanović, V | 1 |
| Kosutić, J | 1 |
| Sukoyan, GV | 1 |
| Gongadze, NV | 1 |
| Sebková, S | 1 |
| Tomek, V | 1 |
| Zemanová, P | 1 |
| Janota, J | 1 |
| Kobayashi, S | 1 |
| Susa, T | 1 |
| Tanaka, T | 1 |
| Murakami, W | 1 |
| Fukuta, S | 1 |
| Okuda, S | 1 |
| Doi, M | 1 |
| Wada, Y | 1 |
| Nao, T | 1 |
| Yamada, J | 1 |
| Okamura, T | 1 |
| Yano, M | 1 |
| Matsuzaki, M | 1 |
| Yasumura, Y | 1 |
| Ahmad, T | 1 |
| Patel, CB | 1 |
| Milano, CA | 1 |
| Rogers, JG | 1 |
| Hirayama, A | 1 |
| Fan, Y | 1 |
| Zhang, AM | 1 |
| Weng, YG | 1 |
| Huebler, M | 1 |
| Miera, O | 1 |
| Franz, N | 1 |
| Qian, GS | 1 |
| Hetzer, R | 1 |
| Rosner, GF | 1 |
| Garan, AR | 1 |
| Uriel, N | 1 |
| van der Linden, J | 1 |
| Albåge, A | 1 |
| Dellgren, G | 1 |
| Takeno, M | 1 |
| Takagi, S | 1 |
| Sakuragi, S | 1 |
| Suzuki, S | 1 |
| Tsutsumi, Y | 1 |
| Nonogi, H | 2 |
| Goto, Y | 3 |
| Young, JB | 3 |
| Zeng, H | 1 |
| Wen, S | 1 |
| Huang, D | 1 |
| Liu, X | 1 |
| Fang, Y | 1 |
| Gattis, WA | 4 |
| Felker, GM | 7 |
| Jain, P | 1 |
| Aranda, JM | 2 |
| Schofield, RS | 1 |
| Pauly, DF | 2 |
| Cleeton, TS | 1 |
| Walker, TC | 1 |
| Monroe, VS | 1 |
| Leach, D | 1 |
| Lopez, LM | 1 |
| Hill, JA | 2 |
| Benza, RL | 1 |
| Chandler, AB | 1 |
| Cuffe, MS | 6 |
| Lang, CC | 1 |
| Hankins, S | 1 |
| Hauff, H | 1 |
| Maybaum, S | 1 |
| Edwards, N | 1 |
| Mancini, DM | 2 |
| Chatterjee, K | 5 |
| De Marco, T | 1 |
| Hsu, K | 1 |
| Schofield, R | 1 |
| Takeda, S | 1 |
| Matsumura, J | 1 |
| Ikezaki, H | 1 |
| Kim, C | 1 |
| Sato, N | 3 |
| Nakanishi, K | 1 |
| Sakamoto, A | 1 |
| Ogawa, R | 1 |
| Tanaka, K | 2 |
| Zewail, AM | 1 |
| Nawar, M | 1 |
| Vrtovec, B | 1 |
| Eastwood, C | 1 |
| Kar, MN | 1 |
| Delgado, RM | 2 |
| Li, M | 1 |
| Sun, ZX | 1 |
| López-Candales, A | 1 |
| Vora, T | 1 |
| Gibbons, W | 1 |
| Carron, C | 2 |
| Simmons, P | 1 |
| Schwartz, J | 2 |
| Lewis, DA | 1 |
| Gurram, NR | 1 |
| Abraham, WT | 2 |
| Nussmeier, NA | 1 |
| Probert, CB | 1 |
| Hirsch, D | 1 |
| Cooper, JR | 1 |
| Gregoric, ID | 1 |
| Myers, TJ | 1 |
| Frazier, OH | 1 |
| Paul, S | 1 |
| Trupp, RJ | 1 |
| López-Candales, AL | 1 |
| Manito, N | 1 |
| Kaplinsky, EJ | 1 |
| Pujol, R | 1 |
| Sethi, R | 1 |
| Tempe, DK | 1 |
| Ganjoo, P | 1 |
| Upadya, S | 1 |
| Lee, FA | 1 |
| Saldarriaga, C | 1 |
| Verma, S | 1 |
| Sedrakyan, A | 1 |
| Nystrom, K | 1 |
| Katz, SD | 1 |
| Sharma, M | 1 |
| Teerlink, JR | 1 |
| De Luca, L | 2 |
| Proietti, P | 1 |
| Palombaro, GL | 1 |
| Battagliese, A | 1 |
| Celotto, A | 1 |
| Bucciarelli Ducci, C | 1 |
| Fedele, F | 1 |
| Chi, NH | 1 |
| Huang, SC | 1 |
| Yu, HY | 1 |
| Chen, YS | 1 |
| Wang, SS | 1 |
| Saltzberg, MT | 1 |
| Smull, DL | 1 |
| Jorde, UP | 1 |
| Schubert, S | 1 |
| Peters, B | 1 |
| Abdul-Khaliq, H | 1 |
| Nagdyman, N | 1 |
| Lange, PE | 1 |
| Ewert, P | 1 |
| Gattis-Stough, W | 1 |
| Dean, AS | 1 |
| Margulies, KB | 1 |
| Nicholas, JJ | 1 |
| Rubin, S | 2 |
| Gaughan, JP | 1 |
| Libonati, JR | 1 |
| Costanzo, MR | 1 |
| Berkowitz, RL | 1 |
| LeJemtel, TH | 11 |
| Cheng, ML | 1 |
| Wynne, J | 1 |
| Dec, GW | 1 |
| Zhang, Q | 1 |
| Lazar, M | 1 |
| Molino, B | 1 |
| Rodriguez, R | 1 |
| Davidov, T | 1 |
| Su, J | 1 |
| Tse, J | 1 |
| Weiss, HR | 1 |
| Scholz, PM | 1 |
| Albrecht, CA | 1 |
| Giesler, GM | 1 |
| Kar, B | 1 |
| Hariharan, R | 1 |
| Bayram, M | 1 |
| Massie, MB | 1 |
| White, M | 1 |
| Ducharme, A | 1 |
| Ibrahim, R | 1 |
| Whittom, L | 1 |
| Lavoie, J | 1 |
| Guertin, MC | 1 |
| Racine, N | 1 |
| He, Y | 1 |
| Yao, G | 1 |
| Rouleau, JL | 1 |
| Schiffrin, EL | 1 |
| Touyz, RM | 1 |
| Mehra, MR | 3 |
| Price, JF | 1 |
| Towbin, JA | 1 |
| Dreyer, WJ | 1 |
| Moffett, BS | 1 |
| Kertesz, NJ | 1 |
| Clunie, SK | 1 |
| Denfield, SW | 1 |
| Yamamoto, T | 1 |
| Akutsu, K | 1 |
| Fujita, N | 1 |
| Asai, K | 2 |
| Takayama, M | 1 |
| Takano, T | 2 |
| Spoor, MT | 1 |
| Geltz, A | 1 |
| Bolling, SF | 1 |
| Arnold, LM | 1 |
| Crouch, MA | 1 |
| Carroll, NV | 1 |
| Oinonen, MJ | 1 |
| Kurien, S | 1 |
| Warfield, KT | 1 |
| Wood, CM | 1 |
| Miller, WL | 1 |
| Hauptman, PJ | 2 |
| Mikolajczak, P | 1 |
| George, A | 1 |
| Mohr, CJ | 1 |
| Hoover, R | 1 |
| Swindle, J | 1 |
| Schnitzler, MA | 1 |
| Echols, MR | 1 |
| Thomas, KL | 1 |
| Pieper, KS | 1 |
| Garg, J | 1 |
| Hentschel, T | 1 |
| Yin, N | 1 |
| Riad, A | 1 |
| Habbazettl, H | 1 |
| Weimann, J | 1 |
| Koster, A | 1 |
| Tschope, C | 1 |
| Kuppe, H | 1 |
| Kuebler, WM | 1 |
| Han, XZ | 1 |
| Sun, Y | 1 |
| Saltzman, HE | 1 |
| Sharma, K | 1 |
| Mather, PJ | 1 |
| Adams, S | 1 |
| Whellan, DJ | 1 |
| Barraud, D | 1 |
| Faivre, V | 1 |
| Damy, T | 1 |
| Welschbillig, S | 1 |
| Gayat, E | 1 |
| Heymes, C | 1 |
| Payen, D | 1 |
| Shah, AM | 1 |
| Mebazaa, A | 1 |
| Ghali, JK | 1 |
| Berg, AM | 1 |
| Snell, L | 1 |
| Mahle, WT | 1 |
| Parissis, JT | 1 |
| Farmakis, D | 1 |
| Nieminen, M | 1 |
| Watanabe, H | 1 |
| Kajimoto, K | 1 |
| Kawana, M | 1 |
| Herweg, B | 1 |
| Ilercil, A | 1 |
| Cutro, R | 1 |
| Dewhurst, R | 1 |
| Krishnan, S | 1 |
| Weston, M | 1 |
| Barold, SS | 1 |
| Heywood, JT | 1 |
| Khan, TA | 1 |
| el Allaf, D | 1 |
| D'Orio, V | 1 |
| Carlier, J | 1 |
| Maskin, CS | 6 |
| Le Jemtel, TH | 3 |
| Sonnenblick, EH | 9 |
| Monrad, ES | 6 |
| McKay, RG | 1 |
| Baim, DS | 9 |
| Colucci, WS | 22 |
| Fifer, MA | 4 |
| Heller, GV | 1 |
| Royal, HD | 1 |
| Grossman, W | 7 |
| Jaski, BE | 5 |
| Wright, RF | 8 |
| Braunwald, E | 10 |
| Pastelin, G | 1 |
| Mendez, R | 1 |
| Kabela, E | 1 |
| Farah, A | 1 |
| Sinoway, L | 2 |
| Chadwick, B | 4 |
| Sinoway, LS | 1 |
| Forman, R | 1 |
| McDowell, AV | 1 |
| Cherniles, J | 1 |
| Parker, JA | 1 |
| Edelson, J | 2 |
| Wallace, AM | 1 |
| Kiser, LM | 1 |
| Ferraris, VA | 1 |
| Britton, LW | 1 |
| Sim, MF | 2 |
| Seino, Y | 1 |
| Hayakawa, H | 1 |
| Kanmatsuse, K | 1 |
| Saitoh, S | 1 |
| Saitoh, T | 1 |
| Kamishima, G | 1 |
| Watanabe, K | 1 |
| Motomiya, T | 1 |
| Murata, M | 1 |
| Iizuka, M | 1 |
| Domínguez de Rozas, JM | 1 |
| Guindo Soldevila, J | 1 |
| Rodríguez Font, E | 1 |
| Martínez Vílchez, R | 1 |
| Berk, M | 1 |
| Brozena, SC | 1 |
| Cowley, AJ | 1 |
| Grabicki, JM | 1 |
| Kubo, SA | 1 |
| LeJemtel, T | 1 |
| Littler, WA | 1 |
| Eichhorn, EJ | 3 |
| Tandon, PK | 2 |
| DiBianco, R | 4 |
| Timmis, GC | 1 |
| Fenster, PE | 1 |
| Shannon, J | 1 |
| Packer, M | 3 |
| Nanimatsu, H | 1 |
| Saikawa, T | 1 |
| Maeda, T | 1 |
| Fukuoka, Y | 1 |
| Takaki, R | 1 |
| Dubois-Randé, JL | 3 |
| Guérot, C | 1 |
| Jan, F | 2 |
| Brochier, M | 1 |
| Sacrez, A | 1 |
| Vacheron, A | 1 |
| Bory, M | 1 |
| Lambert, H | 1 |
| Pony, JC | 1 |
| Le Bloc'h, Y | 1 |
| Shubert, J | 2 |
| Mancano, MA | 1 |
| Milfred, SK | 1 |
| Bethke, T | 2 |
| Klimkiewicz, A | 2 |
| Meyer, W | 2 |
| Schumacher, C | 1 |
| Schmitz, W | 2 |
| Scholz, H | 2 |
| Starbatty, J | 1 |
| Wenzlaff, H | 1 |
| Zimmermann, W | 1 |
| Gun, C | 1 |
| Piegas, LS | 1 |
| Bianco, AC | 1 |
| Freire, RB | 1 |
| Ramos, RF | 1 |
| Timerman, A | 1 |
| Woolfrey, SG | 1 |
| Hegbrant, J | 1 |
| Thysell, H | 1 |
| Fox, PA | 1 |
| Lendrem, DW | 1 |
| Lockwood, GF | 1 |
| Lasher, K | 1 |
| Rogers, J | 1 |
| Greenslade, D | 1 |
| Focaccio, A | 1 |
| Peeters, G | 1 |
| Movsesian, M | 1 |
| Roden, R | 1 |
| Eki, Y | 1 |
| Krall, J | 1 |
| Bristow, MR | 2 |
| Shipley, JB | 1 |
| Tolman, D | 1 |
| Hastillo, A | 1 |
| Hess, ML | 2 |
| Marius-Nunez, AL | 1 |
| Heaney, L | 2 |
| Fernandez, RN | 1 |
| Clark, WA | 1 |
| Ranganini, A | 1 |
| Silber, E | 1 |
| Denes, P | 1 |
| Karlsberg, RP | 1 |
| DeWood, MA | 1 |
| DeMaria, AN | 1 |
| Berk, MR | 1 |
| Lasher, KP | 1 |
| Givertz, MM | 1 |
| Hare, JM | 1 |
| Loh, E | 4 |
| Gauthier, DF | 4 |
| Gutstein, DE | 1 |
| Flemmal, K | 1 |
| Bruce, E | 1 |
| Travers, KE | 1 |
| Gwathmey, JK | 2 |
| Ransil, BJ | 2 |
| Markis, JE | 1 |
| Morgan, JP | 3 |
| Erdmann, E | 6 |
| Araki, S | 1 |
| Uematsu, T | 1 |
| Nagashima, S | 1 |
| Matsuzaki, T | 1 |
| Gotanda, K | 1 |
| Ochiai, H | 1 |
| Hashimoto, H | 1 |
| Nakashima, M | 1 |
| Ventura, HO | 2 |
| Kapoor, C | 1 |
| Stapleton, DD | 2 |
| Zimmerman, D | 1 |
| Smart, FW | 2 |
| Böhm, M | 5 |
| Deutsch, HJ | 1 |
| Hartmann, D | 1 |
| Rosée, KL | 1 |
| Stäblein, A | 1 |
| Harjai, KJ | 1 |
| Lapeyre, YM | 1 |
| Murgo, JP | 1 |
| Zucker, I | 1 |
| Heyman, S | 1 |
| Ozdemir, S | 1 |
| Smith, CJ | 1 |
| Huang, R | 1 |
| Sun, D | 1 |
| Ricketts, S | 1 |
| Hoegler, C | 1 |
| Ding, JZ | 1 |
| Moggio, RA | 1 |
| Hintze, TH | 1 |
| Cesario, D | 1 |
| Clark, J | 1 |
| Maisel, A | 2 |
| Nuñez, S | 1 |
| McCloskey, WW | 1 |
| Hasenfuss, G | 1 |
| Pieske, B | 2 |
| Castell, M | 1 |
| Kretschmann, B | 1 |
| Maier, LS | 1 |
| Just, H | 3 |
| Cusick, DA | 1 |
| Pfeifer, PB | 1 |
| Quigg, RJ | 3 |
| Kanda, M | 1 |
| Yasuda, S | 1 |
| Sumida, H | 1 |
| Baba, T | 1 |
| Noguchi, T | 1 |
| Carere, RG | 1 |
| Webb, JG | 1 |
| Cook, RC | 1 |
| D'yachkova, Y | 1 |
| Abel, JG | 1 |
| Ignaszewski, AP | 1 |
| Lu, G | 1 |
| Zheng, Z | 1 |
| Pritzker, MR | 1 |
| Okumura, S | 1 |
| Takagi, G | 1 |
| Shannon, RP | 1 |
| Fujita-Yamaguchi, Y | 1 |
| Ishikawa, Y | 1 |
| Vatner, SF | 1 |
| Vatner, DE | 1 |
| Zhao, SP | 1 |
| Heinz, G | 3 |
| Geppert, A | 2 |
| Delle Karth, G | 2 |
| Reinelt, P | 1 |
| Gschwandtner, ME | 1 |
| Neunteufl, T | 1 |
| Zauner, C | 1 |
| Frossard, M | 1 |
| Siostrzonek, P | 3 |
| Silver, MA | 2 |
| Hatzizacharias, A | 1 |
| Makris, T | 1 |
| Krespi, P | 1 |
| Triposkiadis, F | 1 |
| Voyatzi, P | 1 |
| Dalianis, N | 1 |
| Kyriakidis, M | 1 |
| Bregagnollo, EA | 1 |
| Fortes, AH | 1 |
| Cicogna, AC | 1 |
| Matsumura, T | 1 |
| Saito, T | 1 |
| Miyai, I | 1 |
| Nozaki, S | 1 |
| Kang, J | 1 |
| Milfred-LaForest, SK | 1 |
| Mendoza, B | 1 |
| Flores, I | 1 |
| Eisen, HJ | 1 |
| Bourge, RC | 1 |
| Colucci, W | 1 |
| Massie, B | 1 |
| Pina, I | 3 |
| Quigg, R | 2 |
| Silver, M | 1 |
| Robinson, LA | 1 |
| Gold, J | 1 |
| Cullinane, S | 1 |
| Chen, J | 1 |
| Seo, S | 1 |
| Oz, MC | 1 |
| Oliver, JA | 1 |
| Landry, DW | 1 |
| Koreny, M | 2 |
| Delle-Karth, G | 1 |
| Haumer, M | 1 |
| Koller-Strametz, J | 1 |
| Thackray, S | 1 |
| Witte, K | 1 |
| Clark, AL | 1 |
| Cleland, JG | 1 |
| Canver, CC | 1 |
| Chanda, J | 1 |
| Shibata, M | 1 |
| Perez de Arenaza, D | 1 |
| Wutte, M | 1 |
| Moen, EK | 1 |
| Taniguchi, T | 1 |
| Shibata, K | 1 |
| Saito, S | 1 |
| Matsumoto, H | 1 |
| Okeie, K | 1 |
| Hibino, N | 1 |
| Tomino, T | 1 |
| Satoh, H | 1 |
| Hamawaki, M | 1 |
| Imura, M | 1 |
| Suzuki, T | 1 |
| Inukai, M | 1 |
| Baruch, L | 1 |
| Patacsil, P | 1 |
| Hameed, A | 1 |
| Li, Z | 1 |
| Elkayam, U | 2 |
| Cody, R | 2 |
| Bristow, M | 1 |
| Jaski, B | 1 |
| Kumar, A | 1 |
| Choudhary, G | 1 |
| Antonio, C | 1 |
| Just, V | 1 |
| Jain, A | 1 |
| Papp, MA | 1 |
| Yamani, MH | 1 |
| Haji, SA | 1 |
| Kelly, L | 1 |
| Albert, N | 1 |
| Knack, DL | 1 |
| Tsvetkova, T | 1 |
| Gilbert, EM | 2 |
| Kihara, S | 1 |
| Kawai, A | 1 |
| Fukuda, T | 1 |
| Yamamoto, N | 1 |
| Aomi, S | 1 |
| Nishida, H | 1 |
| Endo, M | 1 |
| Koyanagi, H | 1 |
| Benza, R | 1 |
| Bourge, R | 1 |
| Poole-Wilson, PA | 2 |
| Gorski, LA | 1 |
| Woods, D | 1 |
| Prirzker, MR | 1 |
| Wastila, WB | 1 |
| Boesch, C | 1 |
| Pochmalicki, G | 1 |
| Lellouche, D | 2 |
| Teiger, E | 1 |
| Saal, JP | 2 |
| Cachin, JC | 1 |
| Mallo, C | 1 |
| Castaigne, A | 2 |
| Perreault, CL | 1 |
| Hague, NL | 1 |
| Hunneyball, IM | 1 |
| Murray, KJ | 1 |
| England, PJ | 1 |
| Pagani, ED | 1 |
| Buchholz, RA | 1 |
| Silver, PJ | 1 |
| Hof, RP | 1 |
| Novosel, D | 1 |
| Evenou, JP | 1 |
| Hof, A | 1 |
| Skoyles, JR | 1 |
| Sherry, KM | 2 |
| Price, C | 1 |
| Desjardins, S | 2 |
| Feldman, AM | 1 |
| Baughman, KL | 1 |
| Strobeck, JE | 1 |
| Lindsay, D | 1 |
| Harris, MN | 1 |
| Daborn, AK | 1 |
| O'Dwyer, JP | 1 |
| Remme, WJ | 1 |
| van Hoogenhuyze, DC | 1 |
| Kruijssen, HA | 1 |
| Pieper, PG | 1 |
| Bruggeling, WA | 1 |
| Nolan, J | 2 |
| Sanderson, A | 1 |
| Taddei, F | 1 |
| Smith, S | 1 |
| Muir, AL | 2 |
| Meissner, A | 1 |
| Herrmann, G | 1 |
| Gerdesmeyer, L | 1 |
| Simon, R | 1 |
| Schwarz, RP | 2 |
| Duval-Moulin, AM | 1 |
| Merlet, P | 1 |
| Deleuze, P | 1 |
| Dupouy, P | 1 |
| Brun, P | 1 |
| Loisance, D | 1 |
| Kohl, C | 1 |
| von der Leyen, H | 1 |
| Mehl, H | 1 |
| Mende, U | 1 |
| Neumann, J | 1 |
| Costa, R | 1 |
| De Marino, V | 1 |
| Marino, A | 1 |
| Mager, G | 4 |
| Klocke, RK | 4 |
| Kux, A | 4 |
| Höpp, HW | 4 |
| Hilger, HH | 4 |
| Steffen, HM | 1 |
| Wambach, G | 1 |
| Degenhardt, S | 1 |
| Carver, JR | 1 |
| Rodeheffer, RJ | 1 |
| Ivanhoe, RJ | 1 |
| Zeldis, SM | 1 |
| Hendrix, GH | 1 |
| Bommer, WJ | 1 |
| Kukin, ML | 1 |
| Curfman, GD | 1 |
| Kohn, IJ | 1 |
| Ribeiro, LG | 1 |
| Watson, DM | 1 |
| Weston, GA | 1 |
| Anderson, JL | 3 |
| Volkmann, A | 1 |
| Schoemaker, RG | 2 |
| Smits, JF | 2 |
| Ribeiro, JP | 5 |
| White, HD | 3 |
| Hartley, LH | 5 |
| Corbalán, R | 1 |
| Jalil, J | 1 |
| Chamorro, G | 1 |
| Casanegra, P | 1 |
| Valenzuela, P | 1 |
| Stander, H | 1 |
| Debets, JJ | 1 |
| Struyker-Boudier, HA | 1 |
| Ferrick, KJ | 2 |
| Fein, SA | 3 |
| Ferrick, AM | 2 |
| Doyle, JT | 2 |
| Ungerer, M | 1 |
| Schwinger, RH | 1 |
| Feldman, MD | 1 |
| Copelas, L | 1 |
| Phillips, P | 1 |
| Warren, SE | 1 |
| Schoen, FJ | 1 |
| Keren, G | 1 |
| Reis, D | 1 |
| Liang, CS | 2 |
| Thomas, A | 1 |
| Imai, N | 1 |
| Stone, CK | 1 |
| Kawashima, S | 1 |
| Hood, WB | 4 |
| Piscione, F | 2 |
| Serruys, PW | 2 |
| Diet, F | 3 |
| Feiler, G | 1 |
| Kemkes, B | 2 |
| Kreuzer, E | 1 |
| Weinhold, C | 1 |
| Falotico, R | 1 |
| Haertlein, BJ | 1 |
| Lakas-Weiss, CS | 1 |
| Salata, JJ | 1 |
| Tobia, AJ | 1 |
| Wood, MA | 1 |
| Rocco, MB | 2 |
| Creager, MA | 2 |
| Marsh, JD | 2 |
| Honerjäger, P | 1 |
| Mueller, RW | 1 |
| Hubert, RS | 1 |
| Cauchy, MJ | 1 |
| Cody, RJ | 6 |
| Shabetai, R | 1 |
| Kostuk, W | 1 |
| Moran, J | 1 |
| Schlant, RC | 1 |
| Wright, R | 1 |
| Hilleman, DE | 1 |
| Forbes, WP | 1 |
| Rettig, GF | 1 |
| Schieffer, HJ | 1 |
| Jewitt, DE | 3 |
| Denniss, AR | 1 |
| Leatherman, GF | 1 |
| Ludmer, PL | 4 |
| Sweet, CS | 2 |
| Ludden, CT | 1 |
| Stabilito, II | 2 |
| Emmert, SE | 2 |
| Heyse, JF | 1 |
| Johnston, GD | 1 |
| Weber, KT | 1 |
| Janicki, JS | 1 |
| Andersson, KE | 1 |
| Dhainaut, JF | 1 |
| Scortichini, D | 2 |
| Levitt, B | 1 |
| Naccarelli, GV | 2 |
| Goldstein, RA | 3 |
| Cohn, JN | 1 |
| Leier, CV | 1 |
| Simonton, CA | 2 |
| Daly, PA | 1 |
| Kereiakes, D | 1 |
| Modin, G | 1 |
| Berglund, H | 1 |
| Bevegård, S | 1 |
| Carlens, P | 1 |
| Hedner, J | 1 |
| Hedner, T | 1 |
| Colombo, F | 1 |
| Libretti, A | 1 |
| Tommaso, CL | 1 |
| Ruggie, N | 1 |
| Katz, S | 1 |
| Young, RA | 1 |
| Ward, A | 1 |
| Hertzeanu, H | 1 |
| Pines, A | 1 |
| Knutzen, A | 1 |
| Drexler, H | 2 |
| Faude, F | 2 |
| Winterer, H | 1 |
| Wollschläger, H | 1 |
| Freudenberg, N | 1 |
| Grose, R | 2 |
| Strain, J | 2 |
| Zelcer, AA | 1 |
| Stroshane, R | 1 |
| Benziger, DP | 1 |
| Benotti, J | 1 |
| Luczkowec, C | 1 |
| Krebs, C | 2 |
| Schwartz, R | 1 |
| Smith, HS | 4 |
| Lanoue, AS | 2 |
| Silverman, KJ | 1 |
| Gervino, EV | 1 |
| Gumbardo, D | 1 |
| Rutman, HI | 1 |
| Kubo, SH | 5 |
| Covit, AB | 1 |
| Müller, FB | 2 |
| Rutman, H | 4 |
| Leonard, D | 4 |
| Laragh, JH | 1 |
| Feldschuh, J | 1 |
| Preibisz, J | 1 |
| Hasegawa, GR | 1 |
| Arnold, JM | 4 |
| Likoff, MJ | 1 |
| Biddle, TL | 2 |
| Benotti, JR | 2 |
| Faxon, DP | 1 |
| Firth, BG | 1 |
| Fitzpatrick, PG | 2 |
| Konstam, MA | 2 |
| Walton, L | 1 |
| Kershner, RP | 1 |
| Cinquegrani, MP | 1 |
| Vakiener, AR | 1 |
| Baggs, JG | 1 |
| Miller, WP | 1 |
| Ark, CR | 1 |
| Wiederholt, P | 1 |
| Goldberg, E | 1 |
| Berdoff, R | 1 |
| Spivack, G | 1 |
| Haimowitz, A | 1 |
| Tay, S | 1 |
| Höing, S | 1 |
| Wenting, GJ | 1 |
| Weiland, DS | 1 |
| Roberts, DJ | 1 |
| Martin, TT | 1 |
| Stransky, NB | 1 |
| Salem, DN | 1 |
| Lemke, JV | 1 |
| Ganz, P | 3 |
| Brown, L | 1 |
| Näbauer, M | 1 |
| Feld, H | 1 |
| Johnston, D | 1 |
| Manzione, NC | 1 |
| Goldfarb, JP | 1 |
| Sternlieb, I | 1 |
| Oddie, CJ | 1 |
| Jackman, GP | 1 |
| Bobik, A | 1 |
| Lanoue, A | 2 |
| Askins, JC | 1 |
| Menlove, RL | 1 |
| Lutz, JR | 1 |
| Geraci, SA | 1 |
| Gray, EL | 1 |
| Rinkenberger, RL | 1 |
| Dougherty, AH | 1 |
| Greenberg, M | 1 |
| Simonton, C | 1 |
| Brauwald, E | 1 |
| Timmis, AD | 2 |
| Smyth, P | 2 |
| Monaghan, M | 1 |
| Walker, L | 1 |
| Daly, K | 1 |
| McLeod, AA | 1 |
| Daly, P | 1 |
| Kittleson, MD | 1 |
| Pipers, FS | 1 |
| Knauer, KW | 1 |
| Keister, DM | 1 |
| Knowlen, GG | 1 |
| Miner, WS | 1 |
| Holmes, JR | 1 |
| Kligfield, P | 1 |
| Lesko, LJ | 1 |
| McCue, JE | 1 |
| Chong, LJ | 1 |
| Smith, TD | 1 |
| Povzhitkov, MM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)[NCT02405195] | 28 participants (Actual) | Observational | 2011-10-31 | Completed | |||
| Impact of CArdiopulmonary Bypass Flow on Renal Blood Flow, Function and OXygenation[NCT02549066] | 18 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| Comparison of Milrinone Versus Dobutamine in a Heterogeneous Population of Critically Ill Patients[NCT03207165] | Phase 4 | 192 participants (Actual) | Interventional | 2017-08-30 | Completed | ||
| Paceport Swan-Ganz Data Collection Study[NCT04782154] | 136 participants (Actual) | Observational | 2021-08-09 | Completed | |||
| Validation of Cerebral Non-invasive Monitoring and Prediction of Post-operative Delirium and Outcomes: A Prospective Observational Study[NCT04643834] | 151 participants (Anticipated) | Observational | 2019-11-21 | Recruiting | |||
| Early Identification and Prediction of Right Ventricular Dysfunction and Failure in Critically Ill Patients: An Observational Non-Interventional Cohort Study[NCT04092855] | 112 participants (Anticipated) | Observational | 2018-12-10 | Recruiting | |||
| Impact of Empiric Nesiritide or Milrinone Infusion on Early Postoperative Recovery Following Fontan Surgery: a Randomized, Double-blind, Placebo-controlled Clinical Trial[NCT00543309] | Phase 2 | 106 participants (Actual) | Interventional | 2007-10-31 | Terminated (stopped due to DSMB recommended termination based on interim outcomes analysis) | ||
| High-Dose Aldactone for Treatment of Diuretic Resistant Heart Failure[NCT02429388] | Phase 4 | 0 participants (Actual) | Interventional | 2014-05-31 | Withdrawn (stopped due to Principal Investigator left institution prior to subjects being enrolled) | ||
| Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure (AVOID-HF)[NCT01474200] | 224 participants (Actual) | Interventional | 2012-01-31 | Terminated (stopped due to Closed due to patient recruitment challenges. No interim analyses were completed; study closure was not related to any concerns about safety or futility.) | |||
| French Observatory on the Management of Cardiogenic Shock in 2016[NCT02703038] | 777 participants (Actual) | Observational | 2016-04-30 | Completed | |||
| The Effects of Intra Aortic Balloon Pump Prior to Revascularization on Mortality of Patients With Acute Coronary Syndrome Complicated With Cardiogenic Shock[NCT03635840] | 92 participants (Anticipated) | Interventional | 2018-01-04 | Recruiting | |||
| Comparison of Dobutamine Versus Milrinone for Renal Recovery in Patients With Cardiorenal Syndrome-A Prospective Cohort Study in Patients With Acute Decompensated Heart Failure[NCT02644057] | Phase 2 | 0 participants (Actual) | Interventional | 2016-03-31 | Withdrawn (stopped due to Could not enroll patients) | ||
| Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure Reduced Ejection Fraction and Acute Decompensation With Low Cardiac Output: A Single Center, Randomized, Non-Blinded, and Parallel Study (PRIORITY-ADHF Study)[NCT02767024] | Phase 4 | 0 participants (Actual) | Interventional | 2018-05-01 | Withdrawn (stopped due to No patients enrolled) | ||
| Perioperative Use of Levosimendan in Patients With Impaired Right Ventricular Function Undergoing Cardiac Surgery With Cardiopulmonary Bypass[NCT05063370] | Phase 2 | 40 participants (Actual) | Interventional | 2021-08-18 | Active, not recruiting | ||
| Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children[NCT02728128] | 53 participants (Actual) | Observational | 2016-08-31 | Completed | |||
| 2- Inhaled Milrinone Prevents the Increase in Pulmonary Artery Pressure After CPB[NCT00819377] | Phase 2 | 124 participants (Anticipated) | Interventional | 2009-02-28 | Completed | ||
| Immunogenetic Modulators of Mucosal Protection From HIV-1: The Kinga Study[NCT03701802] | 812 participants (Actual) | Observational | 2018-09-27 | Completed | |||
| The Influence of Beta Blocker Therapy on the Hemodynamic Response to Inotrope Infusion in Patients With Acute Decompensated Heart Failure[NCT01971944] | 50 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| Innovative Strategies for Implementing New CHF Guideline Recommendations[NCT00012974] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2005-11-30 | Completed | ||
| Heart Failure in Adult Patients With a History of Congenital Heart Disease.[NCT00208754] | 350 participants | Observational | 2004-05-31 | Terminated | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
GFR measured by renal extraction of 51Cr-EDTA (NCT02405195)
Timeframe: 6 hours
| Intervention | ml per minute per 1.73 m2 body surface (Mean) | |||
|---|---|---|---|---|
| Before CPB | CPB 30 minutes | CPB 60 minutes | Post CPB (30 - 60 minutes) | |
| CardioPulmonaryBypass | 67 | 68 | 70 | 67 |
Renal blood flow measured with PAH clearance (NCT02405195)
Timeframe: 6 hours
| Intervention | ml per minute per 1.73 m2 body surface (Mean) | |||
|---|---|---|---|---|
| Pre CPB | CPB 30 minutes | CPB 60 minutes | Post CPB (30 - 60 minutes) | |
| CardioPulmonaryBypass | 554 | 524 | 564 | 558 |
Renal oxygen extraction, defined as renal oxygen consumption divided by renal oxygen delivery (NCT02405195)
Timeframe: 6 hours
| Intervention | fraction (Mean) | |||
|---|---|---|---|---|
| Pre CPB | CPB 30 minutes | CPB 60 minutes | Post CPB (30 - 60 minutes) | |
| CardioPulmonaryBypass | 0.09 | 0.12 | 0.13 | 0.16 |
arrhythmia lasting >30 seconds or requiring treatment (NCT00543309)
Timeframe: Postoperative day (POD) #0 through 5
| Intervention | Participants (Count of Participants) |
|---|---|
| I- Nesiritide | 16 |
| II- Milrinone | 21 |
| III- Placebo | 13 |
Cardiac index measured using Fick principle with measured oxygen consumption. (NCT00543309)
Timeframe: Postoperative hour #1
| Intervention | L/min/m2 (Median) |
|---|---|
| I- Nesiritide | 3.5 |
| II- Milrinone | 2.8 |
| III- Placebo | 2.5 |
Cardiac index measured using Fick principle with measured oxygen consumption. (NCT00543309)
Timeframe: Postoperative hour #8
| Intervention | L/min/m2 (Median) |
|---|---|
| I- Nesiritide | 3.2 |
| II- Milrinone | 2.9 |
| III- Placebo | 2.5 |
"Peak Inotrope Score = Doses of dopamine in mcg/kg/minute + dobutamine in mcg/kg/minute + (epinephrine in mcg/kg/minute x 100).~The lowest (best) possible Peak Inotrope Score = 0 dose equivalents. There is no maximum Peak Inotrope Score." (NCT00543309)
Timeframe: Initial 24 hours in CICU
| Intervention | dose equivalents (Median) |
|---|---|
| I- Nesiritide | 5 |
| II- Milrinone | 5 |
| III- Placebo | 5 |
(NCT00543309)
Timeframe: Initial 24 hours in CICU
| Intervention | mEq/liter (Median) |
|---|---|
| I- Nesiritide | 2.6 |
| II- Milrinone | 3.1 |
| III- Placebo | 3.1 |
(NCT00543309)
Timeframe: 30 days
| Intervention | days (Median) |
|---|---|
| I- Nesiritide | 20 |
| II- Milrinone | 18 |
| III- Placebo | 20 |
(NCT00543309)
Timeframe: 14 days after surgery
| Intervention | mg/dL (Median) |
|---|---|
| I- Nesiritide | 0.1 |
| II- Milrinone | 0.2 |
| III- Placebo | 0.2 |
Volume of urine in mL/kg per day (NCT00543309)
Timeframe: first 24 hours CICU admit
| Intervention | mL/kg per day (Median) |
|---|---|
| I- Nesiritide | 43 |
| II- Milrinone | 37 |
| III- Placebo | 34 |
Days during which one or more chest tubes were in place following the Fontan operation. (NCT00543309)
Timeframe: From Fontan operation until final chest tube removed, assessed during postoperative hospitalization, up to 90 days.
| Intervention | days (Median) |
|---|---|
| I- Nesiritide | 5 |
| II- Milrinone | 5 |
| III- Placebo | 5 |
Days the patient was alive and out of hospital within the 180 days after Fontan surgery (NCT00543309)
Timeframe: 180 days
| Intervention | days (Median) |
|---|---|
| I- Nesiritide | 167 |
| II- Milrinone | 168 |
| III- Placebo | 170 |
Days of initial postoperative CICU care following the Fontan operation. (NCT00543309)
Timeframe: From Fontan operation until initial discharge from the CICU, assessed during the postoperative hospitalization, up to 90 days.
| Intervention | days (Median) |
|---|---|
| I- Nesiritide | 3 |
| II- Milrinone | 3 |
| III- Placebo | 2 |
Hours of mechanical ventilation until initial extubation following the Fontan operation. (NCT00543309)
Timeframe: From Fontan operation until initial extubation, assessed during initial CICU stay, up to 30 days.
| Intervention | hours (Median) |
|---|---|
| I- Nesiritide | 24 |
| II- Milrinone | 23 |
| III- Placebo | 22 |
Plasma epinephrine levels measured at preoperative baseline and postoperative CICU hour 1, 8, 24. (NCT00543309)
Timeframe: Preoperative baseline to 24 hours after CICU admission
| Intervention | ng/mL (Median) | |||
|---|---|---|---|---|
| Preoperative baseline | 1 hour after CICU admit | 8 hours after CICU admit | 24 hours after CICU admit | |
| I- Nesiritide | 0 | 1.2 | 0.5 | 0.2 |
| II- Milrinone | 0 | 2.7 | 0.5 | 1.5 |
| III- Placebo | 0 | 2.1 | 1.0 | 1.3 |
N-terminal pro-brain natriuretic peptide levels measured at preoperative baseline and postoperative CICU hour 1, 8, 24. (NCT00543309)
Timeframe: Preoperative baseline to 24 hours after CICU admission
| Intervention | fmol/mL (Median) | |||
|---|---|---|---|---|
| Preoperative baseline | 1 hour after CICU admit | 8 hours after CICU admit | 24 hours after CICU admit | |
| I- Nesiritide | 77 | 81 | 91 | 142 |
| II- Milrinone | 77 | 61 | 71 | 136 |
| III- Placebo | 88 | 77 | 88 | 109 |
Plasma norepinephrine levels measured at preoperative baseline and postoperative CICU hour 1, 8, 24. (NCT00543309)
Timeframe: Preoperative baseline to 24 hours after CICU admission
| Intervention | ng/mL (Median) | |||
|---|---|---|---|---|
| Preoperative baseline | 1 hour after CICU admit | 8 hours after CICU admit | 24 hours after CICU admit | |
| I- Nesiritide | 0.2 | 2.0 | 2.3 | 1.3 |
| II- Milrinone | 0.4 | 2.1 | 2.4 | 1.5 |
| III- Placebo | 0.5 | 2.9 | 1.3 | 1.3 |
Defined as jugular venous distention of < or equal to 8 cm, with no orthopnea, and with trace peripheral edema or no edema at hospital discharge (NCT01474200)
Timeframe: Index Hospitalization, an average of 8 days
| Intervention | Participants (Number) |
|---|---|
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 40 |
| IV Loop Diuretics (LD) | 46 |
AQ-Fluid removed by AQ plus urine voided minus fluid intake versus urine voided minus fluid intake with the IV diuretics. (NCT01474200)
Timeframe: Index Hospitalization, an average of 8 days
| Intervention | mL (Mean) |
|---|---|
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 12921 |
| IV Loop Diuretics (LD) | 8907 |
Time from hospital admission to time patient is free of congestion in the hospital. Freedom from congestion is defined as jugular venous distention of < or equal to 8 cm, with no orthopnea and with trace peripheral edema or no edema. Measurement taken every 24 hours after treatment initiation. (NCT01474200)
Timeframe: Index Hospitalization, an average of 8 days
| Intervention | Days (Mean) |
|---|---|
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 5.28 |
| IV Loop Diuretics (LD) | 3.86 |
AQ-Fluid removed by AQ plus urine voided versus urine voided when treated with IV diuretics (NCT01474200)
Timeframe: Index Hospitalization, an average of 8 days
| Intervention | mL (Mean) |
|---|---|
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 18700 |
| IV Loop Diuretics (LD) | 14043 |
Weight at hospital discharge minus weight at hospital admission. Negative mean values indicate weight loss. (NCT01474200)
Timeframe: Index Hospitalization, an average of 8 days
| Intervention | lbs (Mean) |
|---|---|
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | -17.12 |
| IV Loop Diuretics (LD) | -16.21 |
Weight at 72 hours after treatment initiation minus weight at treatment initiation. Negative mean values indicate weight loss. (NCT01474200)
Timeframe: 72 hours after treatment initiation
| Intervention | lbs (Mean) |
|---|---|
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | -10.69 |
| IV Loop Diuretics (LD) | -10.30 |
Number of days patient is in hospital for HF treatment. (NCT01474200)
Timeframe: Index hospitalization admission to index hospitalization discharge
| Intervention | Days (Mean) |
|---|---|
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 8.49 |
| IV Loop Diuretics (LD) | 7.19 |
Death due to any cause within index hospitalization and 90 days following hospital discharge. (NCT01474200)
Timeframe: Time from randomization to 90 days post-hospital discharge
| Intervention | Percentage of Participants (Number) |
|---|---|
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 15.45 |
| IV Loop Diuretics (LD) | 12.61 |
"Time to first HF event within 90 days after discharge from index HF hospitalization. HF events are defined as~HF rehospitalization or~unscheduled outpatient or emergency room treatment with IV loop diuretics or~unscheduled outpatient Aquapheresis treatment" (NCT01474200)
Timeframe: 90 days after discharge from index HF hospitalization.
| Intervention | Days (Median) |
|---|---|
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 62 |
| IV Loop Diuretics (LD) | 34 |
Any cause that required hospitalization for treatment within 90 days of index hospitalization discharge. (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge
| Intervention | Rehospitalizations/100 Pt-Days at Risk (Number) | |
|---|---|---|
| 30 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 0.899 | 1.109 |
| IV Loop Diuretics (LD) | 1.278 | 1.237 |
KCCQ Questionnaire analysis based on patient's self-assessment of how they feel at various intervals compared to how they felt prior to index treatment. Scores were transformed to a range of 0-100, in which higher scores reflect better health status. (NCT01474200)
Timeframe: Within 90 days after hospital discharge
| Intervention | Scores on a Scale (Mean) | ||
|---|---|---|---|
| Baseline | 30 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 28.26 | 54.78 | 57.21 |
| IV Loop Diuretics (LD) | 31.83 | 53.08 | 60.56 |
CV symptoms that required hospitalization for treatment within 90 days of index hospitalization discharge. (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge
| Intervention | Rehospitalizations (Number) | |
|---|---|---|
| 30 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 17 | 46 |
| IV Loop Diuretics (LD) | 33 | 66 |
The total number of days spent in the hospital due to CV related events at 30 days and 90 days from hospital discharge. (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge
| Intervention | Days (Number) | |
|---|---|---|
| 30 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 88 | 377 |
| IV Loop Diuretics (LD) | 207 | 554 |
Days rehospitalized for HF symptoms requiring hospital, emergency room or clinic treatment involving the use of IV diuretics and /or positive inotropic or vasodilator drugs. (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge
| Intervention | Days (Number) | |
|---|---|---|
| 30 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 68 | 338 |
| IV Loop Diuretics (LD) | 172 | 460 |
Number of visits for HF symptoms requiring ED or clinic treatment involving the use of IV diuretics and /or positive inotropic or vasodilator drugs (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge
| Intervention | Visits (Number) | |
|---|---|---|
| 30 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 4 | 7 |
| IV Loop Diuretics (LD) | 5 | 8 |
Number of different times patient was admitted to hospital for HF symptoms within 90 days of index hospitalization discharge. (NCT01474200)
Timeframe: Within 30 days and 90 days after hospital discharge
| Intervention | Rehospitalizations (Number) | |
|---|---|---|
| 30 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 11 | 36 |
| IV Loop Diuretics (LD) | 24 | 52 |
Number of days patients were alive and out of the hospital at 30 and 90 days after discharge. (NCT01474200)
Timeframe: Within 30 and 90 days after hospital discharge
| Intervention | Days (Mean) | |
|---|---|---|
| 30 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 27.29 | 62 |
| IV Loop Diuretics (LD) | 26.46 | 61.38 |
Change in BNP levels over time at 72 hours, discharge, and 90 days after discharge. (NCT01474200)
Timeframe: Baseline and at 72 hours from baseline, hospital discharge and at 90 days after hospital discharge
| Intervention | pg/mL (Mean) | |||
|---|---|---|---|---|
| Baseline | 72 hours from baseline | Discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 814.0 | -169.8 | -250.2 | -159.9 |
| IV Loop Diuretics (LD) | 904.1 | -120.5 | -219.1 | -201.3 |
Questionnaire assessed patients quality of life prior to index treatment versus timeframes following hospital discharge. Scores were transformed to a range of 0-100, in which higher scores reflect better health status. (NCT01474200)
Timeframe: Within 90 days after hospital discharge
| Intervention | Scores on a Scale (Mean) | ||
|---|---|---|---|
| Baseline | 30 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 25.39 | 52.06 | 59.72 |
| IV Loop Diuretics (LD) | 28.64 | 49.36 | 58.50 |
Changes in renal function prior to index treatment compared to various intervals by assessing the patient's serum creatinine (sCr), Blood Urea Nitrogen(BUN), BUN/sCr ratio and estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula (NCT01474200)
Timeframe: Within 90 days of randomization
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| Discharge | 30 days after discharge | 60 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 8.38 | 1.72 | 1.85 | 2.50 |
| IV Loop Diuretics (LD) | 7.62 | 6.56 | 3.16 | -3.78 |
Changes in renal function prior to index treatment compared to various intervals by assessing the patient's serum creatinine (sCr), Blood Urea Nitrogen(BUN), BUN/sCr ratio and estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula (NCT01474200)
Timeframe: Within 90 days of randomization
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| Discharge | 30 days after discharge | 60 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 3.77 | 0.28 | 0.07 | 5.66 |
| IV Loop Diuretics (LD) | 3.03 | 1.65 | 1.97 | 1.72 |
Changes in renal function prior to index treatment compared to various intervals by assessing the patient's serum creatinine (sCr), Blood Urea Nitrogen(BUN), BUN/sCr ratio and estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula (NCT01474200)
Timeframe: Within 90 days of randomization
| Intervention | mL/min/1.73m2 (Mean) | |||
|---|---|---|---|---|
| Discharge | 30 days after discharge | 60 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | -2.31 | -0.56 | -2.49 | 5.70 |
| IV Loop Diuretics (LD) | -2.68 | -3.33 | 2.15 | 7.41 |
Changes in renal function prior to index treatment compared to various intervals by assessing the patient's serum creatinine (sCr), Blood Urea Nitrogen(BUN), BUN/sCr ratio and estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula (NCT01474200)
Timeframe: Within 90 days of randomization
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| Discharge | 30 days after discharge | 60 days after discharge | 90 days after discharge | |
| Aquapheresis (AQ) - Isolated Veno-venous Ultrafiltration | 0.12 | 0.37 | 1.34 | -0.30 |
| IV Loop Diuretics (LD) | 0.12 | 0.17 | -0.01 | -0.24 |
56 reviews available for milrinone and Heart Failure
| Article | Year |
|---|---|
In search of the digitalis replacement.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiotonic Agents; Cyclic AMP; Digitalis Glycosides; Heart Fai | 1987 |
Milrinone or dobutamine in patients with heart failure: evidence from meta-analysis.
Topics: Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Milrinone | 2022 |
Meta-analysis Comparing the Efficacy of Dobutamine Versus Milrinone in Acute Decompensated Heart Failure and Cardiogenic Shock.
Topics: Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Milrinone; Randomized Controlled Trials as To | 2023 |
Comparison of milrinone with dobutamine in patients undergoing cardiac surgery: a systematic review and meta-analysis.
Topics: Cardiac Surgical Procedures; Cardiotonic Agents; Dobutamine; Heart Failure; Hemodynamics; Humans; Mi | 2023 |
Systematic review and meta-analysis of the efficacy of olprinone and MEFV gene in treating heart failure.
Topics: Heart Failure; Humans; Imidazoles; Milrinone; Phosphodiesterase Inhibitors; Pyridones | 2023 |
Milrinone for the treatment of heart failure caused by severe Pneumonia in children with congenital heart disease: a meta-analysis.
Topics: Child; China; Heart Defects, Congenital; Heart Failure; Humans; Milrinone; Pneumonia | 2023 |
Intensive care management of right ventricular failure and pulmonary hypertension crises.
Topics: Biomarkers; Capnography; Central Venous Pressure; Critical Care; Echocardiography; Epinephrine; Epop | 2021 |
Continuous Cardiac Inotropes in Patients With End-Stage Heart Failure: An Evolving Experience.
Topics: Cardiotonic Agents; Heart Failure; Hospice Care; Humans; Infusions, Intravenous; Male; Middle Aged; | 2018 |
Milrinone for the Treatment of Acute Heart Failure After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis.
Topics: Cardiotonic Agents; Heart Failure; Humans; Milrinone; Myocardial Infarction | 2015 |
Long-term intravenous inotropes in low-output terminal heart failure?
Topics: Administration, Intravenous; Cardiac Output; Cardiac Output, Low; Cardiotonic Agents; Chi-Square Dis | 2016 |
Therapy for acute heart failure syndromes.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiotonic Agents; Digoxin; Diuretics; Dobutamine; Drug The | 2009 |
Use of combination therapy with a beta-blocker and milrinone in patients with advanced heart failure.
Topics: Adrenergic beta-Antagonists; Cardiotonic Agents; Drug Therapy, Combination; Heart Failure; Humans; M | 2009 |
Pharmacotherapy for acute heart failure syndromes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Digoxin; Diuretics; Dobutamine; Heart Failure; Humans; Mil | 2011 |
Newer inotropes in pediatric heart failure.
Topics: Cardiotonic Agents; Child; Clinical Trials as Topic; Drug Administration Schedule; Etiocholanolone; | 2011 |
[Combination therapy; dobutamine and milrinone].
Topics: Cardiomyopathy, Dilated; Cardiotonic Agents; Dobutamine; Drug Therapy, Combination; Heart Failure; H | 2011 |
New therapeutic choices in the management of acute congestive heart failure.
Topics: Acute Disease; Heart Failure; Humans; Hydrazones; Milrinone; Natriuretic Agents; Natriuretic Peptide | 2001 |
Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization.
Topics: Aged; Diuretics; Dobutamine; Enalaprilat; Female; Heart Failure; Hemodynamics; Hospitalization; Huma | 2003 |
Role of nonglycosidic inotropic agents: indications, ethics, and limitations.
Topics: Adrenergic beta-Antagonists; Cardiac Glycosides; Cardiotonic Agents; Dobutamine; Ethics, Clinical; H | 2003 |
[Inotropic therapy in heart failure: general aspects and clinical results].
Topics: Cardiotonic Agents; Clinical Trials as Topic; Dobutamine; Heart Failure; Humans; Milrinone; Treatmen | 2004 |
A rational approach for the treatment of acute heart failure: current strategies and future options.
Topics: Acute Disease; Adenosine; Cardiotonic Agents; Catheterization, Swan-Ganz; Dobutamine; Drug Therapy; | 2004 |
New positive inotropic agents in the treatment of left ventricular dysfunction.
Topics: Cardiotonic Agents; Diastole; Heart Failure; Humans; Hydrazones; Milrinone; Myocardial Ischemia; Pho | 2004 |
Beneficial effects of early initiation of vasoactive agents in patients with acute decompensated heart failure.
Topics: Cardiotonic Agents; Decision Trees; Emergency Treatment; Heart Failure; Humans; Milrinone; Natriuret | 2004 |
Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes.
Topics: Acute Disease; Cardiotonic Agents; Dobutamine; Dopamine; Heart Failure; Humans; Milrinone; Syndrome | 2005 |
Optimizing outcomes in the patient with acute decompensated heart failure.
Topics: Biomarkers; Cardiotonic Agents; Diuretics; Heart Failure; Hemodynamics; Humans; Hydrazones; Milrinon | 2006 |
Renal dysfunction in heart failure patients: what is the evidence?
Topics: Acute Disease; Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Con | 2007 |
Classical inotropes and new cardiac enhancers.
Topics: Algorithms; Cardiotonic Agents; Dobutamine; Dopamine; Heart Failure; Humans; Hydrazones; Milrinone; | 2007 |
[How to use PDE III inhibitors].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Acute Disease; Blood Pressure; Cyclic Nucleotide Phosphodiester | 2007 |
[Combination therapy with PDE III inhibitor for heart failure].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Chronic | 2007 |
The use of vasoactive therapy for acute decompensated heart failure: hemodynamic and renal considerations.
Topics: Acute Disease; Cardiac Output; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Kidney; Milr | 2007 |
The new inotropic phosphodiesterase inhibitors.
Topics: Aminopyridines; Amrinone; Calcium; Carbamates; Cardiotonic Agents; Cardiovascular Agents; Enoximone; | 1984 |
[Inotropic agents in the treatment of congestive heart failure].
Topics: Cardiotonic Agents; Heart Failure; Humans; Milrinone; Pyridones; Survival Rate | 1993 |
Milrinone: basic and clinical pharmacology and acute and chronic management.
Topics: Acute Disease; Administration, Oral; Calcium Channels; Cardiac Output; Cardiotonic Agents; Clinical | 1996 |
Reversed ventilation-perfusion mismatch involving a pediatric patient in congestive heart failure.
Topics: Adolescent; Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Lung; Male; Milrinone; Pulmonary | 1997 |
Use of intravenous inotropic therapy in the home.
Topics: Amrinone; Cardiotonic Agents; Dobutamine; Heart Failure; Home Infusion Therapy; Humans; Infusions, I | 1998 |
Outpatient parenteral inotropic therapy for advanced heart failure.
Topics: Adrenergic beta-Agonists; Aged; Ambulatory Care; Cardiotonic Agents; Clinical Trials as Topic; Dobut | 2000 |
Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents.
Topics: 2',3'-Cyclic-Nucleotide Phosphodiesterases; 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Ph | 1992 |
[Physiological bases and therapeutic uses of inodilator drugs].
Topics: Amrinone; Cardiotonic Agents; Deoxyepinephrine; Dobutamine; Dopamine; Heart Failure; Humans; Milrino | 1991 |
Phosphodiesterase inhibitors. Its role in heart failure therapy.
Topics: Calcium Channels; Chronic Disease; Cyclic AMP; Heart Failure; Humans; Milrinone; Myocardial Contract | 1990 |
New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1986 |
The role of novel inotropic agents in the treatment of heart failure.
Topics: Amrinone; Animals; Cardiotonic Agents; Dobutamine; Enoximone; Heart Failure; Hemodynamics; Humans; I | 1986 |
Controlled and uncontrolled studies of phosphodiesterase III inhibitors in contemporary cardiovascular medicine.
Topics: Clinical Trials as Topic; Enoximone; Heart Failure; Hemodynamics; Humans; Imidazoles; Milrinone; Pho | 1989 |
Long-term oral therapy of congestive heart failure with phosphodiesterase inhibitors.
Topics: Administration, Oral; Amrinone; Enoximone; Heart Failure; Humans; Imidazoles; Milrinone; Phosphodies | 1989 |
Pharmacology of positive inotropic phosphodiesterase III inhibitors.
Topics: Adenylyl Cyclases; Cardiotonic Agents; Cyclic AMP; Heart Failure; Humans; Milrinone; Myocardial Cont | 1989 |
Role of milrinone in the management of congestive heart failure.
Topics: Cardiotonic Agents; Heart Failure; Humans; Milrinone; Pyridones | 1989 |
Myocardial and vascular actions of milrinone.
Topics: Cardiotonic Agents; Dose-Response Relationship, Drug; Heart Failure; Hemodynamics; Humans; Milrinone | 1989 |
Acute effects of intravenous milrinone in heart failure.
Topics: Cardiotonic Agents; Dose-Response Relationship, Drug; Heart Failure; Hemodynamics; Humans; Injection | 1989 |
Clinical results with oral milrinone in heart failure.
Topics: Administration, Oral; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Milrino | 1989 |
Therapeutic achievements of phosphodiesterase inhibitors and the future.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Milrinone; Multicenter Studies as Topic; Ph | 1989 |
Effects of new inotropic agents on exercise performance.
Topics: Adrenergic beta-Agonists; Aminopyridines; Amrinone; Cardiac Output; Cardiotonic Agents; Chronic Dise | 1986 |
Some new positive inotropic agents.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Aminopyridines; Amrinone; Cardiotonic Agents; D | 1986 |
[Rational and irrational approach to the inotropic agent therapy of heart failure].
Topics: Amrinone; Cardiotonic Agents; Digitalis Glycosides; Heart Failure; Humans; Imidazoles; Milrinone; Py | 1988 |
Non-glycoside, non-catecholamine inotropic agents in the treatment of congestive heart failure.
Topics: Administration, Oral; Aminopyridines; Amrinone; Arrhythmias, Cardiac; Calcium; Cardiac Output; Cardi | 1986 |
Congestive heart failure.
Topics: Aminopyridines; Amrinone; Angiotensin-Converting Enzyme Inhibitors; Cardiac Glycosides; Cardiotonic | 1986 |
Milrinone. A preliminary review of its pharmacological properties and therapeutic use.
Topics: Animals; Blood Pressure; Cardiotonic Agents; Half-Life; Heart Failure; Humans; Milrinone; Pyridones | 1988 |
[New inotropic agents in the treatment of refractory congestive heart failure].
Topics: Amrinone; Cardiotonic Agents; Heart Failure; Humans; Milrinone; Pyridones | 1988 |
Milrinone, a new agent for the treatment of congestive heart failure.
Topics: Aminopyridines; Amrinone; Animals; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Milrinon | 1986 |
80 trials available for milrinone and Heart Failure
| Article | Year |
|---|---|
Comparison of Levosimendan and Milrinone for ECLS Weaning in Patients After Cardiac Surgery-A Retrospective Before-and-After Study.
Topics: Aged; Cardiac Surgical Procedures; Cardiotonic Agents; Extracorporeal Membrane Oxygenation; Female; | 2018 |
Extended Release Oral Milrinone, CRD-102, for Advanced Heart Failure.
Topics: Aged; Animals; Cardiotonic Agents; Delayed-Action Preparations; Female; Heart Failure; Humans; Male; | 2018 |
Impact of empiric nesiritide or milrinone infusion on early postoperative recovery after Fontan surgery: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Cardiotonic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Bl | 2014 |
Inhaled Milrinone After Left Ventricular Assist Device Implantation.
Topics: Administration, Inhalation; Aged; Cost-Benefit Analysis; Female; Heart Failure; Heart Ventricles; He | 2015 |
Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
Topics: Adult; Blood Pressure; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodieste | 2009 |
Is monitoring milrinone therapy useful in advanced heart failure?
Topics: Adult; Cardiotonic Agents; Drug Monitoring; Female; Heart Failure; Heart Transplantation; Humans; Ki | 2011 |
[Response to milrinone treatment in patients with chronic congestive heart failure].
Topics: Adolescent; Adult; Cardiotonic Agents; Female; Heart Failure; Humans; Male; Middle Aged; Milrinone; | 2000 |
Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedilol; Double-Blind Method; | 2003 |
OPTIME in CHF trial: rethinking the use of inotropes in the management of worsening chronic heart failure resulting in hospitalization.
Topics: Cardiotonic Agents; Chronic Disease; Heart Failure; Humans; Infusions, Intravenous; Milrinone; Patie | 2003 |
Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Cardiotonic Agents; Dobutamine; Drug Costs; F | 2003 |
Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study.
Topics: Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Double-Blind Method; Female; Heart Failure; Huma | 2003 |
Milrinone improves lung compliance in patients receiving mechanical ventilation for cardiogenic pulmonary edema.
Topics: Aged; Blood Gas Analysis; Female; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Lung | 2003 |
Symptomatic improvement in patients treated with intermittent infusion of inotropes: a double-blind placebo controled pilot study.
Topics: Aged; Cardiotonic Agents; Cross-Over Studies; Dobutamine; Double-Blind Method; Echocardiography; Exe | 2002 |
Anesthetic management for implantation of the Jarvik 2000 left ventricular assist system.
Topics: Aged; Anesthesia; Aorta, Thoracic; Cardiac Output; Echocardiography, Transesophageal; Female; Heart | 2003 |
Need for hospice and palliative care services in patients with end-stage heart failure treated with intermittent infusion of inotropes.
Topics: Aged; Ambulatory Care; Cardiotonic Agents; Dobutamine; Double-Blind Method; Drug Administration Sche | 2004 |
Risk stratification after hospitalization for decompensated heart failure.
Topics: Aged; Cardiotonic Agents; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Milrino | 2004 |
Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) s
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Female; Heart Failure; Hosp | 2005 |
Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support.
Topics: Biomarkers; C-Reactive Protein; Cardiotonic Agents; Case-Control Studies; Cell Adhesion Molecules; C | 2006 |
Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial.
Topics: Acute Disease; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Black or African American; Car | 2006 |
Cardiac resynchronization therapy in patients with end-stage inotrope-dependent class IV heart failure.
Topics: Adult; Aged; Cardiac Pacing, Artificial; Cardiotonic Agents; Defibrillators, Implantable; Dobutamine | 2007 |
Hemodynamic effects and pharmacokinetics of oral milrinone for short-term support in acute heart failure.
Topics: Acute Disease; Administration, Oral; Aged; Female; Heart Failure; Hemodynamics; Humans; Male; Milrin | 1995 |
[The hemodynamic effects of the combination of milrinone in heart failure refractory to treatment with dopamine, dobutamine and/or nitroprusside].
Topics: Adult; Aged; Analysis of Variance; Dobutamine; Dopamine; Drug Synergism; Drug Therapy, Combination; | 1994 |
Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The Milrinone Multicenter Trials Investigators.
Topics: Angiotensin-Converting Enzyme Inhibitors; Digitalis; Double-Blind Method; Drug Therapy, Combination; | 1993 |
Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study.
Topics: Aged; Double-Blind Method; Female; Heart Failure; Humans; Magnesium; Male; Middle Aged; Milrinone; P | 1993 |
Hemodynamic effects of milrinone in patients with congestive heart failure--short- and long-term follow up studies.
Topics: Aged; Cardiotonic Agents; Drug Evaluation; Female; Follow-Up Studies; Heart Failure; Hemodynamics; H | 1993 |
[Efficacy of intravenous milrinone in the treatment of acute congestive cardiac failure. Results of a French multicenter study].
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Female; Heart Failure | 1993 |
[Value of the use of milrinone in the treatment of acute crisis in patients with congestive heart failure].
Topics: Acute Disease; Adult; Aged; Cardiotonic Agents; Female; Heart Failure; Hemodynamics; Humans; Infusio | 1995 |
Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure.
Topics: Adult; Aged; Cardiotonic Agents; Chromatography, High Pressure Liquid; Chromium; Edetic Acid; Female | 1995 |
[Hemodynamic effects of milrinone on patients with chronic congestive heart failure: a multicenter study. Cooperative Group for Phase II Clinical Trial of Milrinone].
Topics: Adolescent; Adult; Aged; Cardiotonic Agents; Cross-Over Studies; Double-Blind Method; Female; Heart | 1995 |
Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group.
Topics: Acute Disease; Aged; Cardiotonic Agents; Dobutamine; Echocardiography; Electrocardiography, Ambulato | 1996 |
Cardiac and hemodynamic effects of TZC-5665, a novel pyridazinone derivative, and its metabolite in humans and dogs.
Topics: Adult; Animals; Area Under Curve; Cardiovascular Agents; Dogs; Electrocardiography; Female; Half-Lif | 1997 |
Safety and clinical utility of long-term intravenous milrinone in advanced heart failure.
Topics: Adult; Aged; Cardiotonic Agents; Cohort Studies; Dobutamine; Drug Administration Schedule; Drug Ther | 1997 |
Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Cardiomyopathy, Dilated; Cardiotonic Agents; Drug Synergis | 1997 |
[Heart function and clinical observations of patients with severe congestive heart failure treated with milrinone].
Topics: Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Female; Heart; Heart Failure; Humans; Injections | 1998 |
The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic | 1999 |
IV milrinone for cardiac output increase and maintenance: comparison in nonhyperdynamic SIRS/sepsis and congestive heart failure.
Topics: Adult; Aged; Cardiotonic Agents; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Mil | 1999 |
Assessment of inotropic and vasodilating effects of milrinone lactate in patients with dilated cardiomyopathy and severe heart failure.
Topics: Adult; Cardiomyopathy, Dilated; Cardiotonic Agents; Female; Heart Failure; Hemodynamics; Humans; Mal | 1999 |
Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure.
Topics: Adolescent; Cost-Benefit Analysis; Female; Heart Failure; Hospital Mortality; Humans; Injections, In | 2000 |
Milrinone therapy in catecholamine-dependent critically ill patients with heart failure.
Topics: Aged; Cardiotonic Agents; Catecholamines; Critical Illness; Dobutamine; Drug Therapy, Combination; F | 2000 |
Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme | 2000 |
Effects of milrinone on pulmonary gas exchange in catecholamine-dependent heart failure.
Topics: Aged; Cardiotonic Agents; Catecholamines; Female; Heart Failure; Humans; Male; Middle Aged; Milrinon | 2000 |
[The effect of milrinone administrated before weaning from cardiopulmonary bypass in adult cardiac surgery].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Aged; Cardiopulmonary Bypass; Cyclic Nucleotide Phosphod | 2000 |
Pharmacodynamic effects of milrinone with and without a bolus loading infusion.
Topics: Blood Pressure; Cardiotonic Agents; Female; Heart Failure; Humans; Infusions, Intravenous; Male; Mid | 2001 |
A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure.
Topics: Cardiac Output; Cardiotonic Agents; Female; Heart Failure; Hemodynamics; Humans; Infusions, Intraven | 2001 |
Carvedilol titration in patients with congestive heart failure receiving inotropic therapy.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedilol; Dose-Response Relatio | 2001 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
[Hemodynamic study of intravenous milrinone in 26 patients with NYHA class III or IV cardiac failure].
Topics: Adult; Aged; Cardiotonic Agents; Drug Evaluation; Female; Heart Failure; Hemodynamics; Humans; Injec | 1992 |
Oral milrinone in severe chronic heart failure.
Topics: Cardiotonic Agents; Heart Failure; Humans; Milrinone; Pyrazines; Pyridones; Quinolines | 1992 |
Advances in the treatment of chronic heart failure.
Topics: Diuretics; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Milrinone; Phosphodiesterase | 1992 |
Milrinone and the pulmonary vascular system.
Topics: Adult; Cardiac Surgical Procedures; Heart Failure; Humans; Milrinone; Phosphodiesterase Inhibitors; | 1992 |
Maintaining integrity and credibility in industry-sponsored clinical research.
Topics: Cardiotonic Agents; Clinical Trials as Topic; Drug Industry; Heart Failure; Humans; Milrinone; Prosp | 1991 |
PROMISE results slam milrinone.
Topics: Cardiotonic Agents; Heart Failure; Humans; Milrinone; Prospective Studies; Pyridones; Risk Factors | 1991 |
Physiologic assessment of milrinone therapy in severe heart failure patients.
Topics: Adult; Aged; Cardiotonic Agents; Catheterization; Electrocardiography; Female; Heart Failure; Hemody | 1991 |
Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure.
Topics: Adult; Aged; Dobutamine; Female; Heart Failure; Heart Rate; Hemodynamics; Humans; Infusions, Intrave | 1991 |
[The effect of hemodynamic changes in 24-hour milrinone infusion on sympathetic activity and the renin-angiotensin-aldosterone system in patients with severe heart failure].
Topics: Adult; Cardiomyopathy, Dilated; Cardiotonic Agents; Catecholamines; Coronary Disease; Drug Administr | 1991 |
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Topics: Aged; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Evaluation; Female; Follow-Up S | 1991 |
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Topics: Aged; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Evaluation; Female; Follow-Up S | 1991 |
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Topics: Aged; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Evaluation; Female; Follow-Up S | 1991 |
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Topics: Aged; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Evaluation; Female; Follow-Up S | 1991 |
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Topics: Aged; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Evaluation; Female; Follow-Up S | 1991 |
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Topics: Aged; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Evaluation; Female; Follow-Up S | 1991 |
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Topics: Aged; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Evaluation; Female; Follow-Up S | 1991 |
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Topics: Aged; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Evaluation; Female; Follow-Up S | 1991 |
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Topics: Aged; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Evaluation; Female; Follow-Up S | 1991 |
Inotropic therapy for heart failure--an unfulfilled promise.
Topics: Cardiotonic Agents; Heart Failure; Humans; Milrinone; Myocardial Contraction; Prospective Studies; P | 1991 |
Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Chronic Disease; Drug Evaluation; Fe | 1991 |
Effects of a twenty-four-hour milrinone infusion in patients with severe heart failure and cardiogenic shock as a function of the hemodynamic initial condition.
Topics: Adult; Aged; Cardiotonic Agents; Drug Evaluation; Female; Heart Failure; Hemodynamics; Humans; Male; | 1991 |
Acute increase in exercise capacity with milrinone: lack of correlation with resting hemodynamic responses.
Topics: Anaerobic Threshold; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Injections, Intrave | 1990 |
Effects of captopril versus milrinone therapy in modulating the adrenergic nervous system response to exercise in congestive heart failure.
Topics: Aged; Captopril; Cardiotonic Agents; Double-Blind Method; Exercise; Female; Heart Failure; Humans; M | 1990 |
Application of new two-sample tests to data from a randomized placebo-controlled heart-failure trial.
Topics: Adult; Data Interpretation, Statistical; Digoxin; Double-Blind Method; Female; Heart Failure; Humans | 1990 |
Controlled and uncontrolled studies of phosphodiesterase III inhibitors in contemporary cardiovascular medicine.
Topics: Clinical Trials as Topic; Enoximone; Heart Failure; Hemodynamics; Humans; Imidazoles; Milrinone; Pho | 1989 |
Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure.
Topics: Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Clinical Trials as Topic; Heart Failure; Humans; | 1989 |
A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure.
Topics: Administration, Oral; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Digoxin; Double | 1989 |
Acute effects of intravenous milrinone in heart failure.
Topics: Cardiotonic Agents; Dose-Response Relationship, Drug; Heart Failure; Hemodynamics; Humans; Injection | 1989 |
Clinical results with oral milrinone in heart failure.
Topics: Administration, Oral; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Milrino | 1989 |
Therapeutic achievements of phosphodiesterase inhibitors and the future.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Milrinone; Multicenter Studies as Topic; Ph | 1989 |
Effects of milrinone on left ventricular performance and myocardial contractility in patients with severe heart failure.
Topics: Animals; Cardiotonic Agents; Clinical Trials as Topic; Dogs; Dose-Response Relationship, Drug; Femal | 1986 |
Pharmacokinetics of the bipyridines amrinone and milrinone.
Topics: Administration, Oral; Aminopyridines; Amrinone; Clinical Trials as Topic; Half-Life; Heart Failure; | 1986 |
Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure.
Topics: Clinical Trials as Topic; Dobutamine; Ferricyanides; Heart Failure; Hemodynamics; Humans; Milrinone; | 1986 |
Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness.
Topics: Aged; Blood Pressure; Cardiac Output; Cardiotonic Agents; Clinical Trials as Topic; Dobutamine; Dose | 1986 |
Assessment of long-term therapy with milrinone and the effects of milrinone withdrawal.
Topics: Administration, Oral; Adult; Aged; Cardiac Catheterization; Cardiotonic Agents; Clinical Trials as T | 1986 |
Milrinone for long-term therapy of severe heart failure: clinical experience with special reference to maximal exercise tolerance.
Topics: Adult; Aged; Captopril; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Drug Therapy, | 1986 |
Regional blood flow and neurohormonal responses to milrinone in congestive heart failure.
Topics: Aged; Blood Pressure; Cardiac Output; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fe | 1986 |
Exercise responses before and after long-term treatment with oral milrinone in patients with severe heart failure.
Topics: Administration, Oral; Aged; Anaerobiosis; Cardiotonic Agents; Clinical Trials as Topic; Double-Blind | 1986 |
Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study.
Topics: Adolescent; Adult; Aged; Cardiotonic Agents; Clinical Trials as Topic; Dose-Response Relationship, D | 1987 |
Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Coronary Disease; Dobutamine; Heart Failure; Hemodynamics; Humans; Infusion | 1987 |
Differential effects of milrinone and dobutamine on right ventricular preload, afterload and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Topics: Adult; Aged; Cardiomyopathy, Dilated; Dobutamine; Female; Heart; Heart Failure; Hemodynamics; Humans | 1987 |
Immediate effects of milrinone on metabolic and sympathetic responses to exercise in severe congestive heart failure.
Topics: Aged; Female; Heart Failure; Humans; Male; Middle Aged; Milrinone; Physical Exertion; Placebos; Pyri | 1985 |
243 other studies available for milrinone and Heart Failure
| Article | Year |
|---|---|
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for t
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cardiotonic Agents; Dogs; Female; Fibrinolytic Agents; | 1989 |
Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Platelets; Cardiotonic Agents; Dogs; Drug Evalua | 1988 |
Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents.
Topics: Adrenergic beta-Antagonists; Animals; Cardiotonic Agents; Chemical Phenomena; Chemistry, Physical; D | 1985 |
Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure.
Topics: Animals; Cardiotonic Agents; Dogs; Guinea Pigs; Heart Failure; Myocardial Contraction; Phosphodieste | 1984 |
Studies of cardiotonic agents. 8. Synthesis and biological activities of optically active 6-(4-(benzylamino)-7-quinazolinyl)-4,5-dihydro-5-methyl-3(2H)- pyridazinone (KF15232).
Topics: Animals; Aorta; Calcium; Cardiotonic Agents; Cattle; Dogs; Guinea Pigs; Heart Failure; In Vitro Tech | 1996 |
Synthesis and evaluation of novel 2-pyridone derivatives as inhibitors of phosphodiesterase3 (PDE3): a target for heart failure and platelet aggregation.
Topics: Cardiotonic Agents; Dose-Response Relationship, Drug; Heart Failure; Humans; Models, Molecular; Mole | 2012 |
Intermittent inotropic therapy with levosimendan vs. milrinone in advanced heart failure patients.
Topics: Aged; Aged, 80 and over; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Milrinone; Pyridazine | 2022 |
Milrinone effects on cardiac mitochondria, hemodynamics, and death in catecholamine-infused rats.
Topics: Animals; Cardiotonic Agents; Catecholamines; Heart Failure; Hemodynamics; Hypertension; Male; Milrin | 2022 |
Use and Discontinuation of Milrinone for Advanced Heart Failure in an Academic Palliative Care Unit: A Case Report and Discussion of Recommendations.
Topics: Death; Heart Failure; Humans; Milrinone; Palliative Care | 2022 |
Repetitive milrinone therapy in ambulatory advanced heart failure patients.
Topics: Adrenergic beta-Antagonists; Aged; Cardiotonic Agents; Echocardiography; Female; Heart Failure; Huma | 2022 |
Comparative Effectiveness and Safety of Milrinone and Levosimendan as Initial Inotrope Therapy in Patients With Acute Heart Failure With Renal Dysfunction.
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Kidney Diseases; Milrinone; Pyridazines; Retr | 2022 |
Milrinone: An advancement in the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cardiotonic Agents; Heart Failure; Humans; Milrinone; Pyridones | 2022 |
Incidence and Predictors of Eosinophilic Myocardial Hypersensitivity in Patients Receiving Home Dobutamine.
Topics: Adult; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Incidence; Male; Middle Aged; | 2022 |
Oral milrinone for management of refractory right ventricular failure in patients with left ventricular assist devices.
Topics: Defibrillators, Implantable; Heart Failure; Heart-Assist Devices; Humans; Milrinone; Retrospective S | 2022 |
Palliative Inotropes in Advanced Heart Failure: Comparing Outcomes Between Milrinone and Dobutamine.
Topics: Adrenergic beta-Antagonists; Adult; Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Milrinone | 2022 |
Rehospitalization of Patients with Advanced Heart Failure Receiving Continuous, Palliative Dobutamine or Milrinone.
Topics: Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Milrinone; Retrospective Studies; Stroke Volu | 2022 |
Long-Term Ambulatory Intravenous Milrinone Therapy in Advanced Heart Failure.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Milrinone; Retrospective Studies | 2022 |
Clinical implication of ambulatory milrinone therapy in patients with advanced heart failure.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Milrinone; Pyridones | 2023 |
Clinical implication of ambulatory milrinone therapy in patients with advanced heart failure.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Milrinone; Pyridones | 2023 |
Clinical implication of ambulatory milrinone therapy in patients with advanced heart failure.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Milrinone; Pyridones | 2023 |
Clinical implication of ambulatory milrinone therapy in patients with advanced heart failure.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Milrinone; Pyridones | 2023 |
Clinical implication of ambulatory milrinone therapy in patients with advanced heart failure.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Milrinone; Pyridones | 2023 |
Clinical implication of ambulatory milrinone therapy in patients with advanced heart failure.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Milrinone; Pyridones | 2023 |
Clinical implication of ambulatory milrinone therapy in patients with advanced heart failure.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Milrinone; Pyridones | 2023 |
Clinical implication of ambulatory milrinone therapy in patients with advanced heart failure.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Milrinone; Pyridones | 2023 |
Clinical implication of ambulatory milrinone therapy in patients with advanced heart failure.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Milrinone; Pyridones | 2023 |
Home Milrinone in Pediatric Hospice Care of Children with Heart Failure.
Topics: Child; Diuretics; Heart Failure; Hospice Care; Humans; Infusions, Intravenous; Milrinone; Pain | 2023 |
Home Milrinone in Pediatric Hospice Care of Children with Heart Failure.
Topics: Child; Diuretics; Heart Failure; Hospice Care; Humans; Infusions, Intravenous; Milrinone; Pain | 2023 |
Home Milrinone in Pediatric Hospice Care of Children with Heart Failure.
Topics: Child; Diuretics; Heart Failure; Hospice Care; Humans; Infusions, Intravenous; Milrinone; Pain | 2023 |
Home Milrinone in Pediatric Hospice Care of Children with Heart Failure.
Topics: Child; Diuretics; Heart Failure; Hospice Care; Humans; Infusions, Intravenous; Milrinone; Pain | 2023 |
Home Milrinone in Pediatric Hospice Care of Children with Heart Failure.
Topics: Child; Diuretics; Heart Failure; Hospice Care; Humans; Infusions, Intravenous; Milrinone; Pain | 2023 |
Home Milrinone in Pediatric Hospice Care of Children with Heart Failure.
Topics: Child; Diuretics; Heart Failure; Hospice Care; Humans; Infusions, Intravenous; Milrinone; Pain | 2023 |
Home Milrinone in Pediatric Hospice Care of Children with Heart Failure.
Topics: Child; Diuretics; Heart Failure; Hospice Care; Humans; Infusions, Intravenous; Milrinone; Pain | 2023 |
Home Milrinone in Pediatric Hospice Care of Children with Heart Failure.
Topics: Child; Diuretics; Heart Failure; Hospice Care; Humans; Infusions, Intravenous; Milrinone; Pain | 2023 |
Home Milrinone in Pediatric Hospice Care of Children with Heart Failure.
Topics: Child; Diuretics; Heart Failure; Hospice Care; Humans; Infusions, Intravenous; Milrinone; Pain | 2023 |
Usefulness of ambulatory milrinone perfusion in a cohort of advanced heart failure patients.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Milrinone; Perfusion; Pyridones | 2023 |
Dispelling Dogma: Milrinone Therapy Is Safe and Effective in Renally-Impaired Patients, and We Knew This!
Topics: Cardiotonic Agents; Heart Failure; Humans; Milrinone | 2023 |
Long-term milrinone therapy in children with dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Child; Heart Failure; Heart Transplantation; Humans; Infant; Milrinone; Ret | 2023 |
Improved mortality and haemodynamics with milrinone in cardiogenic shock due to acute decompensated heart failure.
Topics: Dobutamine; Heart Failure; Hemodynamics; Humans; Milrinone; Retrospective Studies; Shock, Cardiogeni | 2023 |
Use of milrinone to support therapy-induced heart failure through hematopoietic stem cell transplantation in a pediatric patient with high-risk FLT3+ acute myeloid leukemia.
Topics: Child; fms-Like Tyrosine Kinase 3; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; L | 2023 |
Successful echocardiography-guided medical management of severe early post-implant right ventricular failure in a patient with left ventricular assist device support: a case report.
Topics: Adolescent; Dobutamine; Echocardiography; Female; Heart Failure; Heart-Assist Devices; Humans; Milri | 2023 |
Comparing the effects of milrinone and olprinone in patients with congestive heart failure.
Topics: Aged; Aged, 80 and over; Cardiotonic Agents; Disease Progression; Female; Heart Failure; Hospitaliza | 2020 |
Safety of Outpatient Milrinone Infusion in End-Stage Heart Failure: ICD-Level Data on Atrial Fibrillation and Ventricular Tachyarrhythmias.
Topics: Aged; Atrial Fibrillation; Cardiotonic Agents; Defibrillators, Implantable; Dose-Response Relationsh | 2020 |
Effects of milrinone on renal perfusion, filtration and oxygenation in patients with acute heart failure and low cardiac output early after cardiac surgery.
Topics: Aged; Cardiac Output; Cardiac Output, Low; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Fema | 2020 |
Effects of milrinone on renal perfusion, filtration and oxygenation in patients with acute heart failure and low cardiac output early after cardiac surgery.
Topics: Aged; Cardiac Output; Cardiac Output, Low; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Fema | 2020 |
Effects of milrinone on renal perfusion, filtration and oxygenation in patients with acute heart failure and low cardiac output early after cardiac surgery.
Topics: Aged; Cardiac Output; Cardiac Output, Low; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Fema | 2020 |
Effects of milrinone on renal perfusion, filtration and oxygenation in patients with acute heart failure and low cardiac output early after cardiac surgery.
Topics: Aged; Cardiac Output; Cardiac Output, Low; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Fema | 2020 |
Comparison of Positive Inotropic Agents in the Management of Acute Decompensated Heart Failure.
Topics: Aged; Cardiotonic Agents; Cause of Death; Disease Progression; Dobutamine; Female; Heart Failure; Hu | 2020 |
Long-term milrinone therapy as a bridge to heart transplantation: Safety, efficacy, and predictors of failure.
Topics: Adult; Female; Heart Failure; Heart Transplantation; Heart-Assist Devices; Humans; Male; Milrinone; | 2020 |
Old Drug, New Trick? Oral Milrinone for Heart Failure With Preserved Ejection Fraction.
Topics: Cardiotonic Agents; Heart Failure; Humans; Milrinone; Pharmaceutical Preparations; Stroke Volume | 2020 |
Survival With Continuous Outpatient Intravenous Inotrope Therapy in the Modern Era.
Topics: Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Milrinone; Outpatients; Retrospective Studies | 2020 |
[COVID-19-associated hyperinflammatory state in a 15-year-old female patient].
Topics: Adolescent; Anti-Inflammatory Agents; Aspirin; Cardiotonic Agents; COVID-19; COVID-19 Serological Te | 2020 |
Reversal of Acute Right Ventricular Failure Early Post Left Ventricular Assist Device Placement by Intratracheal Milrinone Administration: Case Report.
Topics: Cardiotonic Agents; Echocardiography, Transesophageal; Heart Failure; Heart-Assist Devices; Humans; | 2021 |
Effect of Milrinone Infusion on Pulmonary Vasculature and Stroke Work Indices: A Single-Center Retrospective Analysis in 69 Patients Awaiting Cardiac Transplantation.
Topics: Adult; Cardiac Catheterization; Female; Heart Failure; Heart Transplantation; Hemodynamics; Humans; | 2017 |
Effect of Inpatient Dobutamine versus Milrinone on Out-of-Hospital Mortality in Patients with Acute Decompensated Heart Failure.
Topics: Acute Disease; Aged; Cardiotonic Agents; Cohort Studies; Dobutamine; Female; Heart Failure; Hospital | 2017 |
Point-of-Care Ultrasonography to Assess Portal Vein Pulsatility and the Effect of Inhaled Milrinone and Epoprostenol in Severe Right Ventricular Failure: A Report of 2 Cases.
Topics: Administration, Inhalation; Aged, 80 and over; Epoprostenol; Female; Heart Failure; Heart Ventricles | 2017 |
Extended release oral milrinone as an adjunct to heart failure therapy.
Topics: Administration, Oral; Adult; Cardiotonic Agents; Delayed-Action Preparations; Drug Therapy, Combinat | 2017 |
Intraoperative milrinone versus dobutamine in cardiac surgery patients: a retrospective cohort study on mortality.
Topics: Aged; Aged, 80 and over; Cardiac Surgical Procedures; Cardiotonic Agents; Cohort Studies; Denmark; D | 2018 |
Ambulatory Intravenous Inotropic Support and or Levosimendan in Pediatric and Congenital Heart Failure: Safety, Survival, Improvement, or Transplantation.
Topics: Adolescent; Adult; Cardiotonic Agents; Child; Child, Preschool; Dobutamine; Female; Follow-Up Studie | 2018 |
Noninvasive Administration of Inhaled Epoprostenol and Inhaled Milrinone in Extubated, Spontaneously Breathing Patients With Right Ventricular Failure and Portal Hypertension: A Report of 2 Cases.
Topics: Administration, Inhalation; Aged; Airway Extubation; Antihypertensive Agents; Cardiac Surgical Proce | 2019 |
Intratracheal Milrinone for Acute Right Heart Dysfunction: Another Tool in the Pocket.
Topics: Cardiopulmonary Bypass; Heart Failure; Humans; Milrinone; Retrospective Studies; Ventricular Dysfunc | 2019 |
Acute Right Ventricular Failure in Cardiac Surgery During Cardiopulmonary Bypass Separation: A Retrospective Case Series of 12 Years' Experience With Intratracheal Milrinone Administration.
Topics: Acute Disease; Aged; Cardiopulmonary Bypass; Cardiotonic Agents; Echocardiography, Transesophageal; | 2019 |
Continuous Intravenous Inotropes in Ward Units: Expanding Therapy Outside Intensive Care using a Safety-Oriented Protocol.
Topics: Adult; Aged; Cardiotonic Agents; Clinical Protocols; Critical Care; Dobutamine; Female; Follow-Up St | 2019 |
Temporary left ventricular assist device for complete recovery from reversible acute heart failure due to tumor necrosis factor-α inhibitor.
Topics: Adult; Arthritis; Cardiomyopathy, Dilated; Cardiotonic Agents; Crohn Disease; Etanercept; Female; Fu | 2019 |
Milrinone in advanced heart failure: dose and therapeutic monitor outside intensive care unit.
Topics: Adult; Cardiac Catheterization; Cardiotonic Agents; Chromatography, High Pressure Liquid; Chronic Di | 2014 |
Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Brain Chemistry; Cardiac Surgical Proced | 2014 |
Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Brain Chemistry; Cardiac Surgical Proced | 2014 |
Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Brain Chemistry; Cardiac Surgical Proced | 2014 |
Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Brain Chemistry; Cardiac Surgical Proced | 2014 |
Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Brain Chemistry; Cardiac Surgical Proced | 2014 |
Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Brain Chemistry; Cardiac Surgical Proced | 2014 |
Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Brain Chemistry; Cardiac Surgical Proced | 2014 |
Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Brain Chemistry; Cardiac Surgical Proced | 2014 |
Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Brain Chemistry; Cardiac Surgical Proced | 2014 |
Elevation of plasma milrinone concentrations in stage D heart failure associated with renal dysfunction.
Topics: Adult; Aged; Cardiac Catheterization; Cardiotonic Agents; Creatinine; Defibrillators, Implantable; F | 2013 |
Characteristics of patients with advanced heart failure having eosinophilic infiltration of the myocardium in the recent era.
Topics: Biopsy; Dobutamine; Eosinophils; Heart Failure; Heart Transplantation; Humans; Milrinone; Myocarditi | 2013 |
Levosimendan: a retrospective single-center case series.
Topics: Aged; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Hemodynamics; Hospital Mortality; Human | 2013 |
Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Cardiotonic Agents; Heart; Heart Failure; Humans; Hydraz | 2014 |
Are peripherally inserted central catheters associated with increased risk of adverse events in status 1B patients awaiting transplantation on continuous intravenous milrinone?
Topics: Academic Medical Centers; Cardiotonic Agents; Catheter-Related Infections; Catheterization, Central | 2014 |
Implications of central venous catheters in patients with stage D heart failure who are stable but inotrope dependent.
Topics: Cardiotonic Agents; Catheterization, Central Venous; Catheterization, Peripheral; Female; Heart Fail | 2014 |
Sustained release of milrinone delivered via microparticles in a rodent model of myocardial infarction.
Topics: Animals; Blood Pressure; Cardiotonic Agents; Cell Adhesion Molecules; Chemistry, Pharmaceutical; Chr | 2014 |
Discussion.
Topics: Animals; Cardiotonic Agents; Female; Heart Failure; Milrinone; Myocardial Infarction | 2014 |
An unexpected post-partum fulminant heart failure.
Topics: Adrenal Gland Neoplasms; Adult; Cardiotonic Agents; Catecholamines; Echocardiography; Female; Heart | 2014 |
Intensive symptom control of opioid-refractory dyspnea in congestive heart failure: Role of milrinone in the palliative care unit.
Topics: Analgesics, Opioid; Dyspnea; Female; Heart Failure; Humans; Leukemia; Middle Aged; Milrinone; Pallia | 2015 |
Effects of milrinone and epinephrine or dopamine on biventricular function and hemodynamics in an animal model with right ventricular failure after pulmonary artery banding.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Dopamine; Epinephrine; Heart Failure; Heart Ven | 2015 |
Effects of milrinone and epinephrine or dopamine on biventricular function and hemodynamics in right heart failure after pulmonary regurgitation.
Topics: Animals; Cardiotonic Agents; Dopamine; Epinephrine; Heart Failure; Hemodynamics; Milrinone; Pulmonar | 2015 |
Waiting to Inhale … Milrinone.
Topics: Female; Heart Failure; Heart-Assist Devices; Humans; Male; Milrinone | 2015 |
Management of catecholamine-induced stunned myocardium--a case report.
Topics: Blood Pressure; Cardiotonic Agents; Catecholamines; Dobutamine; Dopamine; Female; Fluid Therapy; Hea | 2015 |
Methodological Perspectives from 'Milrinone for the Treatment of Acute Heart Failure After Acute Myocardial Infarction: A Systematic Review and Meta-analysis'.
Topics: Cardiotonic Agents; Heart Failure; Humans; Milrinone; Myocardial Infarction | 2015 |
Infections, Arrhythmias, and Hospitalizations on Home Intravenous Inotropic Therapy.
Topics: Administration, Intravenous; Adult; Aged; Alabama; Atrial Fibrillation; Bacteremia; Cardiotonic Agen | 2016 |
Successful HeartWare Bridge to Recovery in a 3-Year Old: A Game Changer?
Topics: Anticoagulants; Biopsy; Cardiomyopathy, Dilated; Child, Preschool; Combined Modality Therapy; Heart | 2016 |
Canadian Palliative Community Milrinone Infusions: A Case Series.
Topics: Aged; Aged, 80 and over; Canada; Cardiotonic Agents; Heart Failure; Home Care Services; Humans; Infu | 2016 |
Effects of Milrinone on Rest and Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Exercise; Heart Failure; Hemodynamics; Humans; Milrinone; Phosphodiesterase 3 Inhibitors; Rest | 2016 |
Oral Enoximone as an Alternative to Protracted Intravenous Medication in Severe Pediatric Myocardial Failure.
Topics: Adrenergic beta-Antagonists; Cardiotonic Agents; Child; Enoximone; Heart Failure; Hemodynamics; Huma | 2016 |
A PIECE OF MY MIND. "Vote for Me".
Topics: Cardiotonic Agents; Communication; Decision Making; Family; Heart Failure; Heart-Assist Devices; Hum | 2016 |
Prolonged asystole in a patient with an isolated left ventricular assist device.
Topics: Adult; Ambulatory Care; Cardiotonic Agents; Fatal Outcome; Female; Heart Arrest; Heart Failure; Hear | 2016 |
Citric Acid Cycle Metabolites Predict the Severity of Myocardial Stunning and Mortality in Newborn Pigs.
Topics: Animals; Biomarkers; Cardiotonic Agents; Chromatography, Liquid; Citric Acid Cycle; Dobutamine; Drug | 2016 |
Synthesis and Positive Inotropic Activity of [1,2,4]Triazolo[4,3-a] Quinoxaline Derivatives Bearing Substituted Benzylpiperazine and Benzoylpiperazine Moieties.
Topics: Animals; Cardiotonic Agents; Dose-Response Relationship, Drug; Heart Atria; Heart Failure; Milrinone | 2017 |
The use of continuous milrinone therapy as bridge to transplant is safe in patients with short waiting times.
Topics: Adult; Aged; Female; Follow-Up Studies; Heart Failure; Heart Transplantation; Heart-Assist Devices; | 2008 |
Short term effects of milrinone on biomarkers of necrosis, apoptosis, and inflammation in patients with severe heart failure.
Topics: Adult; Aged; Apoptosis; Biomarkers; Cardiotonic Agents; Dose-Response Relationship, Drug; Fas Ligand | 2009 |
Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF).
Topics: Blood Urea Nitrogen; Cardiotonic Agents; Female; Forecasting; Glomerular Filtration Rate; Heart Fail | 2008 |
Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure.
Topics: Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Infusions, Intravenous; Male; Middle | 2009 |
Should we use outpatient dobutamine or milrinone?
Topics: Cardiac Output; Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Injections, Intravenous; Milr | 2009 |
Rotating inotrope therapy in a pediatric population with decompensated heart failure.
Topics: Adolescent; Cardiotonic Agents; Dobutamine; Drug Therapy, Combination; Echocardiography; Female; Hea | 2011 |
Baroreflex sensitivity might predict responders to milrinone in patients with heart failure.
Topics: Aged; Baroreflex; Cardiotonic Agents; Female; Heart Failure; Humans; Male; Middle Aged; Milrinone; R | 2010 |
Hospital in the home.
Topics: Australia; Cardiotonic Agents; Dobutamine; Heart Failure; Home Care Services; Humans; Infusions, Int | 2011 |
A clinical assay for the measurement of milrinone in plasma by HPLC mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Heart Failure; Humans; Linear | 2012 |
How mechanical circulatory support helps not to need it--new strategies in pediatric heart failure.
Topics: Adolescent; Cardiomyopathies; Cardiotonic Agents; Catecholamines; Child, Preschool; Extracorporeal M | 2011 |
Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Cardiomyopathies; Cyclohexanols; Cytochrome P-450 CYP2C19; Cyt | 2011 |
[Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children].
Topics: Acute Disease; Adolescent; Cardiotonic Agents; Child, Preschool; Dobutamine; Heart Failure; Humans; | 2011 |
Mechanism of cardioprotective effect of adenocine and non-glycoside cardiotonic drugs during experimental chronic cardiac insufficiency.
Topics: Acetyldigoxins; Adenosine; Adenosine Triphosphate; Animals; Apoptosis; Cardiotonic Agents; Constrict | 2011 |
Heart failure treated with low-dose milrinone in a full-term newborn.
Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Infant, Newborn; Milrinone; Persistent Fetal Circ | 2012 |
Low-dose β-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Cardiotonic Agents; C | 2012 |
Combination of β-blocker and milrinone for acute heart failure.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Cardiotonic Agents; Female; Heart Failure; Hemody | 2012 |
When the heart runs out of heartbeats: treatment options for refractory end-stage heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiotonic Agent | 2012 |
Factors associated with the need of biventricular mechanical circulatory support in children with advanced heart failure.
Topics: Adolescent; Cardiac Surgical Procedures; Child; Child, Preschool; Female; Heart Failure; Heart-Assis | 2013 |
Letter by Rosner et al regarding article, "When the heart runs out of heartbeats: treatment options for refractory end-stage heart failure".
Topics: Carbazoles; Heart Failure; Heart-Assist Devices; Humans; Lisinopril; Male; Milrinone; Propanolamines | 2013 |
Megadose of milrinone as an alternative to extracorporeal membrane oxygenation for treatment of graft failure early after cardiac transplantation.
Topics: Dose-Response Relationship, Drug; Extracorporeal Membrane Oxygenation; Female; Graft Rejection; Hear | 2002 |
Continuous milrinone infusion during preoperative anti-inflammatory therapy in inflammatory aortic aneurysm complicating severe congestive heart failure.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Aortic Aneurysm, Thoracic; Aortic Valve Insuffici | 2002 |
A bridge for the 21st century in heart transplantation?
Topics: Cardiotonic Agents; Dobutamine; Heart Failure; Heart Transplantation; Humans; Milrinone; Prospective | 2003 |
Morbidity and mortality of UNOS status 1B cardiac transplant candidates at home.
Topics: Adult; Aged; Cardiotonic Agents; Cost-Benefit Analysis; Dobutamine; Electric Countershock; Female; H | 2003 |
Sustained use of nesiritide to aid in bridging to heart transplant.
Topics: Adult; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronary Disease; Diuretics; Dobutamine; Dopamin | 2003 |
Intravenous milrinone in treatment of advanced congestive heart failure.
Topics: Adrenergic beta-Antagonists; Drug Synergism; Drug Therapy, Combination; Female; Heart Failure; Human | 2003 |
[Application of noninvasive hemodynamic monitoring in patients with heart failure caused by chronic pulmonary heart diseases].
Topics: Aged; Aged, 80 and over; Blood Pressure; Female; Heart Failure; Heart Rate; Humans; Male; Middle Age | 2003 |
Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure.
Topics: Aged; Anemia; Cardiotonic Agents; Comorbidity; Female; Follow-Up Studies; Heart Failure; Hemoglobins | 2003 |
Effect of nesiritide versus milrinone in the treatment of acute decompensated heart failure.
Topics: Acute Disease; Aged; Endpoint Determination; Heart Failure; Hemodynamics; Humans; Length of Stay; Mi | 2003 |
Case studies in heart failure.
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiac Catheteriz | 2003 |
Milrinone improves lung compliance.
Topics: Aged; Female; Heart Failure; Hemodynamics; Humans; Lung Compliance; Male; Middle Aged; Milrinone; Pu | 2004 |
Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure.
Topics: Adult; Cardiotonic Agents; Defibrillators, Implantable; Dobutamine; Dopamine; Empirical Research; Fe | 2004 |
Application of papillary muscle sling concept in an infant as a biological bridge to transplantation.
Topics: Cardiomyopathy, Dilated; Cardiotonic Agents; Combined Modality Therapy; Disease Progression; Heart F | 2005 |
Concomitant use of nesiritide and milrinone in decompensated congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiotonic Agents; Drug Synergism; Drug Therapy, Combination; Female; | 2005 |
Left ventricular conditioning in the elderly patient to prevent congestive heart failure after transcatheter closure of atrial septal defect.
Topics: Aged; Aged, 80 and over; Cardiac Catheterization; Cardiotonic Agents; Catheterization; Diuretics; Do | 2005 |
Impaired vasoreactivity in end-stage heart failure patients on intravenous inotropic support.
Topics: Blood Flow Velocity; Brachial Artery; Cardiac Catheterization; Cardiotonic Agents; Dobutamine; Echoc | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
Acute decompensated heart failure: the shrinking role of inotropic therapy.
Topics: Acute Disease; Cardiovascular Agents; Dobutamine; Heart Failure; Humans; Milrinone; Natriuretic Pept | 2005 |
Reduction in interaction between cGMP and cAMP in dog ventricular myocytes with hypertrophic failure.
Topics: Adenine; Animals; Body Weight; Cardiotonic Agents; Cyclic AMP; Cyclic GMP; Dogs; Drug Interactions; | 2005 |
Intravenous milrinone infusion improves congestive heart failure caused by diastolic dysfunction: a brief case series.
Topics: Adult; Aged; Cardiotonic Agents; Diastole; Echocardiography; Heart Failure; Humans; Infusions, Intra | 2005 |
Outpatient continuous parenteral inotropic therapy as bridge to transplantation in children with advanced heart failure.
Topics: Adolescent; Adult; Ambulatory Care; Cardiotonic Agents; Child; Dopamine; Emergency Service, Hospital | 2006 |
Arterial baroreflex sensitivity is a good predictor of inotropic responses to a phosphodiesterase inhibitor in human heart failure.
Topics: Adult; Aged; Baroreflex; Cardiotonic Agents; Female; Heart Failure; Humans; Male; Middle Aged; Milri | 2006 |
Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiomyopathy, Dilated; Combined Modality | 2006 |
Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Cardiotonic Agents; Cohort Studies; Dobutamine; Female; Health Care Costs; Hear | 2006 |
Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide.
Topics: Aged; Cardiotonic Agents; Creatinine; Diuretics; Dobutamine; Dopamine; Drug Therapy, Combination; Fe | 2006 |
Chronic inotropic therapy in end-stage heart failure.
Topics: Aged; Cardiotonic Agents; Dobutamine; Drug Administration Schedule; Drug Costs; Female; Heart Failur | 2006 |
Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure.
Topics: Administration, Inhalation; Animals; Cyclic AMP; Cyclic GMP; Disease Models, Animal; Dose-Response R | 2007 |
[Intravenous milrinone in the treatment of pediatric heart failure].
Topics: Adolescent; Child; Child, Preschool; Female; Heart Failure; Humans; Infant; Male; Milrinone; Phospho | 2007 |
Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone.
Topics: Animals; Cardiotonic Agents; Diastole; Disease Models, Animal; Dobutamine; Heart Failure; Hydrazones | 2007 |
Hydralazine and nitrates: beyond race and ethnicity.
Topics: Cardiotonic Agents; Drug Combinations; Heart Failure; Humans; Isosorbide Dinitrate; Milrinone; Racia | 2007 |
Home inotropic therapy in children.
Topics: Adolescent; Cardiotonic Agents; Child; Dobutamine; Female; Health Care Costs; Heart Failure; Heart T | 2007 |
Inotropic drugs for treatment of the failing heart.
Topics: Aminophylline; Aminopyridines; Amrinone; Cardiotonic Agents; Catecholamines; Digitalis Glycosides; G | 1984 |
Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone.
Topics: Aged; Cardiac Volume; Cardiotonic Agents; Diastole; Female; Heart Failure; Hemodynamics; Humans; Mal | 1984 |
Milrinone: a positive inotropic vasodilator.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Milrinone; Nitroprusside; Pyridones; Vasodi | 1984 |
The search for a digitalis substitute II milrinone (Win 47203). Its action on the heart-lung preparation of the dog.
Topics: Animals; Cardiotonic Agents; Dinitrophenols; Dogs; Heart; Heart Failure; Milrinone; Nifedipine; Papa | 1983 |
Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Cardiac Output; Cardiotonic Agents; Exercise Test; Follow-Up Stud | 1983 |
Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease.
Topics: Cardiac Output; Cardiotonic Agents; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; | 1983 |
Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Cardiotonic Agents; Drug Evaluation; Female; Follow-Up Studies; H | 1983 |
Assessment of flosequinan's direct effect on human arterial, venous, and cardiac muscle: comparison with other classes of agents used to treat heart failure.
Topics: Captopril; Diltiazem; Heart Failure; Humans; In Vitro Techniques; Milrinone; Muscle Contraction; Mus | 1994 |
Criteria for use of intravenous milrinone in adult inpatients.
Topics: Adult; Arrhythmias, Cardiac; Cardiotonic Agents; Female; Heart Failure; Humans; Hypotension; Infusio | 1995 |
Characterization of the phosphodiesterase inhibition by 2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo-(4,5-c)-pyridine HCl and its sulfide- and sulfone derivatives in myocardial preparations from failing human hearts.
Topics: 1-Methyl-3-isobutylxanthine; Adult; Chromatography, DEAE-Cellulose; Cyclic AMP; Female; Heart Failur | 1995 |
Mechanism of action of OPC-8490 in human ventricular myocardium.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Action Potentials; Adult; Azetidines; Cardiotonic Agents; Cycli | 1996 |
Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure.
Topics: Ambulatory Care; Amrinone; Cardiotonic Agents; Cost-Benefit Analysis; Dobutamine; Drug Administratio | 1996 |
Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension.
Topics: Adult; Aged; Cardiac Output; Female; Heart Failure; Heart Transplantation; Hemodynamics; Humans; Hyp | 1996 |
Decreased inotropic but relatively preserved relaxation response to cyclic adenosine monophosphate-dependent agents in myopathic human myocardium.
Topics: 1-Methyl-3-isobutylxanthine; Adrenergic beta-Antagonists; Adult; Analysis of Variance; Cardiotonic A | 1996 |
The effect of positive inotropes on the failing human myocardium.
Topics: 1-Methyl-3-isobutylxanthine; Adrenergic beta-Agonists; Calcium; Cardiotonic Agents; Dobutamine; Hear | 1997 |
[Current views on Milrinon--a PDE-III-inhibitor].
Topics: Cardiotonic Agents; Dobutamine; Drug Therapy, Combination; Heart Failure; Heart Ventricles; Humans; | 1994 |
Home inotropic therapy in advanced heart failure: cost analysis and clinical outcomes.
Topics: Cardiotonic Agents; Cause of Death; Costs and Cost Analysis; Direct Service Costs; Dobutamine; Femal | 1997 |
Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blotting, Northern; Cardiac Pacing, Artificial; Cardio | 1997 |
Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Cardiomyopathy, Dilated; Cardiotonic Agents; Drug Administration Sch | 1998 |
Comparison between mixed venous oxygen saturation and thermodilution cardiac output in monitoring patients with severe heart failure treated with milrinone and dobutamine.
Topics: Aged; Aged, 80 and over; Cardiac Output; Cardiotonic Agents; Dobutamine; Heart Failure; Hemodynamics | 1998 |
Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium.
Topics: Calcium; Cardiotonic Agents; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Hydraz | 1998 |
Effects of intravenous milrinone followed by titration of high-dose oral vasodilator therapy on clinical outcome and rehospitalization rates in patients with severe heart failure.
Topics: Adult; Cardiotonic Agents; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Hospitali | 1998 |
Diuretic effect of phosphodiesterase inhibitors depends on baseline renal function in patients with congestive heart failure.
Topics: Aged; Aged, 80 and over; Amrinone; Creatinine; Diuresis; Female; Follow-Up Studies; Heart Failure; H | 1999 |
The use of milrinone in pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Cardiotonic Agents; Female; Follow-Up Studies; Heart Fa | 1999 |
Severe heart failure: balancing length and quality of life.
Topics: Amrinone; Cardiotonic Agents; Heart Failure; Humans; Milrinone; Phosphodiesterase Inhibitors; Pyrazi | 1999 |
Chronic heart failure and the quality of life.
Topics: Cardiotonic Agents; Heart Failure; Humans; Milrinone; Palliative Care; Pyrazines; Quality of Life; Q | 1999 |
Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure.
Topics: Animals; Blood Pressure; Consciousness; Cyclic AMP; Dogs; Dose-Response Relationship, Drug; Female; | 1999 |
Intermittent inotropes for advanced heart failure: inquiring minds want to know.
Topics: Cardiotonic Agents; Dobutamine; Heart Failure; Hemodynamics; Humans; Milrinone; Treatment Outcome | 1999 |
Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure.
Topics: Cardiotonic Agents; Female; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Male; Milri | 1999 |
[Effective milrinone therapy to a Duchenne muscular dystrophy patient with advanced congestive heart failure].
Topics: Adult; Heart Failure; Humans; Male; Milrinone; Muscular Dystrophy, Duchenne; Phosphodiesterase Inhib | 1999 |
Tolerability of extended duration intravenous milrinone in patients hospitalized for advanced heart failure and the usefulness of uptitration of oral angiotensin-converting enzyme inhibitors.
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Chi-Square Distribution; Drug Admini | 1999 |
Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Blood Pressure; Cyclic Nucleotide Phosphodiesterases, Type 3; H | 2000 |
Milrinone for long-term pharmacologic support of the status 1 heart transplant candidates.
Topics: Adult; Aged; Cardiotonic Agents; Heart Failure; Heart Transplantation; Hemodynamics; Humans; Infusio | 2000 |
Tailored treatment for heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Cardiotonic Agents; Dose-Response Relationship | 2000 |
Pharmacokinetics of milrinone in patients with congestive heart failure during continuous venovenous hemofiltration.
Topics: Adult; Aged; Biological Availability; Female; Heart Failure; Hemodynamics; Hemofiltration; Humans; I | 2000 |
A group sequential test for survival trials: an alternative to rank-based procedures.
Topics: Biometry; Cardiotonic Agents; Heart Failure; Humans; Milrinone; Proportional Hazards Models; Randomi | 1999 |
Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: Hemodynamic efficacy, clinical outcome, and economic impact.
Topics: Cost-Benefit Analysis; Dobutamine; Dopamine; Drug Costs; Female; Heart Failure; Hemodynamics; Humans | 2001 |
Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; Card | 2001 |
Effects of milrinone for right ventricular failure after left ventricular assist device implantation.
Topics: Adolescent; Cardiotonic Agents; Heart Failure; Humans; Male; Middle Aged; Milrinone; Pacemaker, Arti | 2002 |
Treatment of acute heart failure: out with the old, in with the new.
Topics: Acute Disease; Atrial Natriuretic Factor; Cardiotonic Agents; Heart Failure; Humans; Milrinone; Natr | 2002 |
Positive inotropic drug infusions for patients with heart failure: current controversies and best practice.
Topics: Cardiotonic Agents; Chronic Disease; Dobutamine; Dopamine; Female; Heart Failure; Hemodynamics; Home | 2002 |
Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiotonic Agents; Carvedilol; Drug Therapy, Combination; | 2002 |
Cardiovascular pharmacology of the vasodilator-cardiotonic agent, 349U85.
Topics: Animals; Cardiotonic Agents; Cardiovascular System; Cricetinae; Dogs; Heart Failure; Heart Rate; In | 1992 |
Differential inotropic effects of flosequinan in ventricular muscle from normal ferrets versus patients with end-stage heart failure.
Topics: Animals; Calcium; Colforsin; Dose-Response Relationship, Drug; Ferrets; Heart Failure; Heart Ventric | 1992 |
Cardiovascular cyclic nucleotide phosphodiesterases and their role in regulating cardiovascular function.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Atrial Natriuretic Factor; Cyclic GMP; Heart Failure; Humans; | 1992 |
Autonomic nervous system dysfunction alters drug effects: implications for testing drugs for the treatment of heart failure.
Topics: Animals; Autonomic Nervous System; Cardiovascular Agents; Disease Models, Animal; Enalapril; Heart F | 1992 |
Intravenous milrinone in patients with severe congestive cardiac failure awaiting heart transplantation.
Topics: Adult; Heart Failure; Heart Transplantation; Humans; Infusions, Intravenous; Male; Middle Aged; Milr | 1992 |
Oral milrinone in severe chronic heart failure.
Topics: Administration, Oral; Animals; Cardiotonic Agents; Chronic Disease; Cricetinae; Heart Failure; Human | 1992 |
Preload-dependent hemodynamic effects of milrinone in moderate heart failure.
Topics: Administration, Oral; Aged; Blood Pressure; Cardiotonic Agents; Dose-Response Relationship, Drug; Fe | 1992 |
Acute effects of intravenous phosphodiesterase inhibition in chronic heart failure: simultaneous pre- and afterload reduction with a single agent.
Topics: Aged; Aged, 80 and over; Female; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Leg; M | 1992 |
[Additive effects of milrinone and dobutamine in severe heart failure].
Topics: Aged; Cardiotonic Agents; Dobutamine; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy | 1992 |
Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts.
Topics: Adult; Calcium; Chromatography, DEAE-Cellulose; Electric Stimulation; Female; Heart; Heart Failure; | 1991 |
Enoximone and milrinone--inotropic vasodilators for severe heart failure.
Topics: Cardiotonic Agents; Enoximone; Heart Failure; Humans; Imidazoles; Milrinone; Pyridones | 1991 |
Milrinone, a bridge to heart transplantation.
Topics: Cardiomyopathies; Cardiotonic Agents; Heart Failure; Heart Transplantation; Humans; Male; Middle Age | 1991 |
Intravenous milrinone: therapeutic responses in heart failure. Proceedings of a symposium. Stockholm, Sweden, September 19, 1990.
Topics: Heart Failure; Humans; Infusions, Intravenous; Milrinone; Phosphodiesterase Inhibitors; Pyridones | 1991 |
Intravenous milrinone: therapeutic responses in heart failure.
Topics: Cardiotonic Agents; Heart Failure; Humans; Infusions, Intravenous; Milrinone; Phosphodiesterase Inhi | 1991 |
Modulation of venous tone in heart failure.
Topics: Captopril; Felodipine; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Milrinone; Phosp | 1991 |
[Hemodynamics with dobutamine and milrinone in patients with severe heart failure in an intra-individual comparison].
Topics: Adult; Aged; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronary Disease; Dobutamine; Dose-Respons | 1991 |
Systolic time intervals as indicators for cardiac function in rat models for heart failure.
Topics: Age Factors; Animals; Blood Flow Velocity; Captopril; Cardiac Output; Cardiotonic Agents; Dobutamine | 1990 |
Beneficial hemodynamic effects of two weeks' milrinone treatment in conscious rats with heart failure.
Topics: Animals; Blood Pressure; Cardiac Output; Coronary Vessels; Heart Failure; Hemodynamics; Male; Milrin | 1990 |
Effect of milrinone on ventricular arrhythmias in congestive heart failure.
Topics: Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiotonic Agents; Female; Heart Failure; Hum | 1990 |
Antagonism of novel inotropic agents at A1 adenosine receptors and m-cholinoceptors in human myocardium.
Topics: Adult; Binding, Competitive; Cardiotonic Agents; Electric Stimulation; Guanylyl Imidodiphosphate; He | 1990 |
Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure.
Topics: 1-Methyl-3-isobutylxanthine; Caffeine; Calcium; Cardiotonic Agents; Colforsin; Cyclic AMP; Heart Fai | 1987 |
Effects of milrinone on systemic hemodynamics and regional circulations in dogs with congestive heart failure: comparison with dobutamine.
Topics: Animals; Cardiotonic Agents; Coronary Circulation; Dobutamine; Dogs; Heart Failure; Hemodynamics; Ma | 1987 |
Short-term assessment of left ventricular function, coronary hemodynamics, and catecholamine balance in severe congestive heart failure after a single oral dose of milrinone.
Topics: Aged; Angiocardiography; Cardiac Output; Cardiotonic Agents; Catecholamines; Coronary Circulation; F | 1988 |
Subsensitivity of the failing human heart to isoprenaline and milrinone is related to beta-adrenoceptor downregulation.
Topics: Aging; Cardiotonic Agents; Coronary Disease; Electric Stimulation; Heart Failure; Humans; In Vitro T | 1988 |
Positive inotropic and hemodynamic properties of flosequinan, a new vasodilator, and a sulfone metabolite.
Topics: Amrinone; Anesthesia; Animals; Ferrets; Heart Failure; Heart Rate; Hemodynamics; In Vitro Techniques | 1989 |
Effect of phosphodiesterase inhibition on myocardial oxygen consumption and coronary blood flow.
Topics: Amrinone; Animals; Coronary Circulation; Enoximone; Heart Failure; Humans; Imidazoles; Milrinone; My | 1989 |
Impaired chronotropic response to exercise in patients with congestive heart failure. Role of postsynaptic beta-adrenergic desensitization.
Topics: Adult; Exercise; Female; Heart Failure; Heart Rate; Humans; Isoproterenol; Male; Middle Aged; Milrin | 1989 |
Effects of milrinone treatment in cardiomyopathic hamsters (CHF 147) with severe congestive heart failure.
Topics: Animals; Body Weight; Calcium; Cardiomyopathy, Dilated; Cardiotonic Agents; Cricetinae; Disease Mode | 1989 |
Renal and hormonal effects of phosphodiesterase III inhibition in congestive heart failure.
Topics: Aldosterone; Arginine Vasopressin; Forearm; Glomerular Filtration Rate; Heart Failure; Hormones; Hum | 1989 |
Screening of positive inotropic agents in isolated cardiac preparations from different sources.
Topics: Animals; Atrial Function; Calcium; Cardiotonic Agents; Drug Evaluation, Preclinical; Heart; Heart Fa | 1989 |
Effect of milrinone on steady-state digoxin levels in congestive heart failure.
Topics: Cardiotonic Agents; Digoxin; Heart Failure; Humans; Male; Middle Aged; Milrinone; Pyridones | 1989 |
Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition.
Topics: Catecholamines; Dobutamine; Dose-Response Relationship, Drug; Heart Failure; Hemodynamics; Humans; M | 1988 |
Beneficial effects of milrinone and enalapril on long-term survival of rats with healed myocardial infarction.
Topics: Animals; Body Weight; Cardiomegaly; Cardiotonic Agents; Electrocardiography; Enalapril; Heart Failur | 1988 |
Enhancement of the effectiveness of milrinone to increase force of contraction by stimulation of cardiac beta-adrenoceptors in the failing human heart.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Aged; Cardiotonic Agents; Drug Synergism; Heart; Heart F | 1988 |
Alternatives to the digitalis glycosides for heart failure.
Topics: Adrenergic beta-Agonists; Aminopyridines; Amrinone; Cardiotonic Agents; Heart Failure; Humans; Milri | 1985 |
[Use of new inotropic agents in the treatment of acute cardiac failure].
Topics: Adrenergic Agonists; Amrinone; Calcium Channel Blockers; Cardiotonic Agents; Dobutamine; Dopamine; E | 1988 |
Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? III. Antagonist's viewpoint.
Topics: Adrenergic beta-Agonists; Animals; Cardiotonic Agents; Chronic Disease; Death, Sudden; Dobutamine; H | 1988 |
Observations on the intracoronary administration of milrinone and dobutamine to patients with congestive heart failure.
Topics: Coronary Circulation; Coronary Vessels; Dobutamine; Drug Therapy, Combination; Heart Failure; Hemody | 1989 |
Effects of phosphodiesterase inhibition on skeletal muscle vasculature.
Topics: Amrinone; Animals; Heart Failure; Humans; Milrinone; Muscles; Phosphodiesterase Inhibitors; Physical | 1989 |
Electrophysiology of phosphodiesterase inhibitors.
Topics: Amrinone; Arrhythmias, Cardiac; Cardiotonic Agents; Electrocardiography; Electrophysiology; Heart Co | 1989 |
Inotropic therapy for heart failure: paradise postponed.
Topics: Cardiotonic Agents; Heart Failure; Humans; Milrinone; Pyridones | 1989 |
General overview and update of positive inotropic therapy.
Topics: Amrinone; Blood Pressure; Cardiotonic Agents; Digitoxin; Dobutamine; Dopamine; Enoximone; Heart Fail | 1986 |
Survival in severe left ventricular failure treated with the new nonglycosidic, nonsympathomimetic oral inotropic agents.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Cardiotonic Agents; Death, Sudden; Drug Evaluati | 1987 |
Atrial natriuretic peptide during acute treatment of congestive heart failure.
Topics: Adult; Aged; Atrial Natriuretic Factor; Female; Heart Failure; Humans; Male; Middle Aged; Milrinone; | 1988 |
New positive inotropic drugs for the treatment of congestive heart failure.
Topics: Aminopyridines; Amrinone; Cardiac Output; Cardiotonic Agents; Dipeptides; Dobutamine; Enalapril; Hea | 1985 |
Acute and subacute hemodynamic effects of enalaprilat, milrinone and combination therapy in rats with chronic left ventricular dysfunction.
Topics: Animals; Antihypertensive Agents; Drug Therapy, Combination; Enalapril; Enalaprilat; Heart Failure; | 1987 |
Direct and indirect assessment of skeletal muscle blood flow in chronic congestive heart failure.
Topics: Captopril; Cardiac Output; Heart Failure; Humans; Lactates; Lactic Acid; Milrinone; Muscles; Phospho | 1988 |
Effects of amrinone on myocardial energetics in severe congestive heart failure.
Topics: Aminopyridines; Amrinone; Animals; Cardiotonic Agents; Coronary Circulation; Dogs; Enoximone; Heart; | 1985 |
Periodic breathing during exercise in severe heart failure. Reversal with milrinone or cardiac transplantation.
Topics: Cheyne-Stokes Respiration; Heart Failure; Heart Transplantation; Humans; Milrinone; Physical Exertio | 1987 |
[Central and regional vascular hemodynamics of milrinone in experimental heart failure: comparison with captopril and dobutamine].
Topics: Animals; Captopril; Dobutamine; Heart Failure; Hemodynamics; Male; Milrinone; Muscles; Myocardial In | 1987 |
Hemodynamic and regional blood flow response to milrinone in patients with severe congestive heart failure: a dose-ranging study.
Topics: Administration, Oral; Adult; Aged; Arm; Dose-Response Relationship, Drug; Female; Heart Failure; Hem | 1987 |
Effect of oral milrinone on end-systolic relations in patients with severe congestive heart failure.
Topics: Adult; Aged; Cardiotonic Agents; Heart Failure; Heart Function Tests; Hemodynamics; Humans; Methoxam | 1987 |
Evaluation of the vasodilator vs inotropic effect of milrinone using an animal model of left ventricular failure: reversal of disopyramide depression of the myocardium with milrinone.
Topics: Animals; Cardiac Output; Cardiotonic Agents; Depression, Chemical; Disease Models, Animal; Disopyram | 1987 |
Blood flow distribution within skeletal muscle during exercise in the presence of chronic heart failure: effect of milrinone.
Topics: Animals; Heart Failure; Hemodynamics; Male; Milrinone; Muscles; Myocardial Infarction; Physical Exer | 1987 |
Effect of a single oral dose of milrinone on left ventricular diastolic performance in the failing human heart.
Topics: Administration, Oral; Aged; Cardiac Output; Cardiotonic Agents; Catecholamines; Coronary Circulation | 1987 |
New inotropic drugs: amrinone and milrinone.
Topics: Amrinone; Heart Failure; Humans; Milrinone; Pyridones | 1987 |
Role of reflex sympathetic withdrawal in the hemodynamic response to an increased inotropic state in patients with severe heart failure.
Topics: Drug Administration Schedule; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Milrin | 1986 |
New positive inotropic agents for congestive heart failure.
Topics: Aminopyridines; Amrinone; Animals; Cardiotonic Agents; Drug Evaluation; Heart Failure; Humans; Milri | 1986 |
Additive positive inotropic effects of milrinone, ouabain and calcium in diseased human ventricular myocardium.
Topics: Adult; Calcium; Cardiomyopathies; Cardiotonic Agents; Female; Heart Failure; Humans; Male; Middle Ag | 1986 |
Myocardial and vascular effects of intracoronary versus intravenous milrinone.
Topics: Blood Pressure; Cardiac Catheterization; Cardiac Output; Cardiotonic Agents; Female; Heart; Heart Fa | 1985 |
Systemic and regional hemodynamic effects of captopril and milrinone administered alone and concomitantly in patients with heart failure.
Topics: Adult; Aged; Captopril; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Inje | 1985 |
Alternatives to the digitalis glycosides for heart failure.
Topics: Digitalis Glycosides; Heart Failure; Humans; Milrinone; Pyridones | 1985 |
Identification of the direct vasodilator effect of milrinone with an isolated limb preparation in patients with chronic congestive heart failure.
Topics: Adult; Aged; Cardiotonic Agents; Chronic Disease; Female; Forearm; Heart Failure; Hemodynamics; Huma | 1986 |
Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique.
Topics: Adult; Aged; Blood Pressure; Cardiotonic Agents; Coronary Vessels; Female; Heart; Heart Failure; Hea | 1986 |
The effects of two new inotropic agents on microsomal liver function in patients with congestive heart failure.
Topics: Adult; Aged; Aminopyridines; Aminopyrine; Amrinone; Breath Tests; Cardiac Output; Cardiotonic Agents | 1986 |
Analysis of milrinone in plasma using solid-phase extraction and high-performance liquid chromatography.
Topics: Cardiotonic Agents; Chromatography, High Pressure Liquid; Heart Failure; Hemodynamics; Humans; Male; | 1986 |
Survival of patients with severe congestive heart failure treated with oral milrinone.
Topics: Administration, Oral; Adult; Aged; Cardiotonic Agents; Electrocardiography; Female; Heart Failure; H | 1986 |
Occurrence of ventricular arrhythmias in patients receiving acute and chronic infusions of milrinone.
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiotonic Agents; Drug Administration Schedule; Female; Heart F | 1986 |
Electrophysiologic effects of milrinone in patients with congestive heart failure.
Topics: Adult; Aged; Electrophysiology; Female; Heart Failure; Heart Function Tests; Hemodynamics; Humans; M | 1986 |
Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure.
Topics: Aged; Coronary Circulation; Dobutamine; Female; Heart; Heart Failure; Hemodynamics; Humans; Male; Mi | 1986 |
Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.
Topics: Adult; Aged; Cardiotonic Agents; Dose-Response Relationship, Drug; Female; Heart Failure; Hemodynami | 1985 |
Acute dose range study of milrinone in congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Cardiotonic Agents; Chronic Disease; Dose-Response Relationship, | 1985 |
Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure.
Topics: Blood Pressure; Cardiotonic Agents; Coronary Circulation; Energy Metabolism; Heart Failure; Heart Ra | 1985 |
Milrinone in heart failure. Acute effects on left ventricular systolic function and myocardial metabolism.
Topics: Adult; Aged; Cardiotonic Agents; Female; Heart Failure; Heart Ventricles; Hemodynamics; Humans; Lact | 1985 |
Milrinone in heart failure. Effects on exercise haemodynamics during short term treatment.
Topics: Adult; Analysis of Variance; Cardiotonic Agents; Exercise Test; Female; Heart Failure; Hemodynamics; | 1985 |
Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation.
Topics: Actuarial Analysis; Administration, Oral; Adult; Aged; Cardiotonic Agents; Female; Follow-Up Studies | 1985 |
Echocardiographic and clinical effects of milrinone in dogs with myocardial failure.
Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Echocardiography; Heart Failure; Heart Ventricles; | 1985 |
Milrinone in congestive heart failure: observations on ambulatory ventricular arrhythmias.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Arrhythmias, Cardiac; Cardiotonic Agents; Electr | 1985 |
Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure.
Topics: Adult; Aged; Cardiotonic Agents; Dose-Response Relationship, Drug; Female; Half-Life; Heart Failure; | 1985 |
A new model of congestive heart failure in anesthetized dogs.
Topics: Animals; Disease Models, Animal; Dogs; Heart Failure; Hemodynamics; Milrinone; Pyridones | 1985 |